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Magna opera DoMini, exquirenDa oMnibus, qui cupiunt ea.
“Machtig zijn de werken van de heer, wie ze liefheeft, onderzoekt ze.”




Mast cells in rheumatic diseases
Mast cell depletion in the pre-clinical phase of collagen 
induced arthritis reduces clinical outcome by lowering the 
inflammatory cytokine profile
Presence of Anti-Citrullinated Protein Antibodies (ACPA) in 
cardiovascular patients without RA
Circulating immunoglobulins are not associated with 
intraplaque mast cell number and other vulnerable plaque 
characteristics in patients with carotid artery stenosis
ApoE deficient inducible mast cell knockout mice: 
A new model to study the role of mast cells in atherosclerosis
Depletion of mast cells in established experimental 
atherosclerosis increases plaque stability and reduces the pro-
inflammatory phenotype
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The immune system is constantly challenged by a multitude of environmental agents 
that attempt to break through anatomical barriers such as the skin and intestinal tract to 
reach the interior of the human body. In the defense towards these invading pathogenic 
agents, mammals are equipped with a powerful immune system that comprises non-
cellular effector mechanisms as well as immune cells. The immune system can roughly 
be dived into two parts: the innate and the adaptive arm of immunity. Hallmark of innate 
immunity is the rapid activation in a “non-specific” manner without the development 
of immunological memory. Cells of the innate immune system can found in various 
tissues, especially at sites that are in close proximity to the external environment. Tissue 
resident dendritic cells and mast cells are the first immune cells to encounter these 
invading pathogens. Together with other types of immune cells such as natural killer cells, 
neutrophils and macrophages these cells belong to the innate arm of the immune system. 
Adaptive immunity takes longer to establish but it is highly specific and very potent and 
has memory. Key players in adaptive immunity are dendritic cells, T and B cells, responsible 
for cellular and humoral immunity respectively.
Mast cell biology
The history of mast cell biology starts with Paul Erhlich’s thesis in June 1878. In his thesis 
he describes a cell type that is clearly visible and distinguishable from other cells with 
his new aniline dye. The “well-fed appearance” of the cell led him to designate these cells 
as ‘Mastzelle’ [1]. He described the presence of large cytoplasmic granules inside the 
cell, which he thought to have a nutritional function. Currently, it is known that these 
granules contain large amounts of preformed mediators such as proteases, cytokines 
and other mediators. Mast cells reside in many different tissues throughout the body 
but predominantly at sites near the body surface, such as  the skin, the airways, and  the 
intestinal tract, but also close to the vasculature and joints [2].
Nowadays, mast cells are regarded as critical effector cells in the acute phase of bacterial 
and viral infections as well as in the immune response towards parasites. Besides the 
critical role in host defense, mast cells are also implicated in a number immune driven 
disorders such as rheumatoid arthritis and cardiovascular diseases.
Mast cell development and heterogeneity.
Mast cells originate from multipotent hematopoietic stem cells in the bone marrow. Mast 
cell progenitors (MCP) circulate as immature precursors derived from the bone marrow 
via the vascular system into peripheral tissues. In connective or mucosal tissues, the MCPs 
mature into tissue resident mast cells under influence of several growth factors [3]. The 
micro-environment is essential for mast cell development. Especially stem cell factor 
(SCF), produced by stromal cells, is an essential growth, differentiation, proliferation and 
survival factor for both murine and human mast cells [4,5]. 
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Binding of SCF to its receptor c-Kit (CD117) leads to the activation of its intrinsic 
kinase activity that controls the transcription of different mast cell-specific genes. All 
hematopoietic progenitor cells express c-Kit, but downregulate it upon differentiation 
into all leukocyte lineages except for mast cells, which express c-Kit throughout their 
lifespan, thus remaining responsive to SCF. Mice with mutations in the c-Kit receptor 
locus, Kit W/W-v and KitWsh/Wsh, lack mast cells [4,6]. 
Other key factors that influence mast cell development and survival are Interleukin (IL)-
3, IL-4, IL-5, IL-6, IL-9, IL-10, Interferon γ (IFNγ), Nerve Growth Factor (NGF), Transforming 
Growth Factor- β (TGF-β), Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) 
and thrombopoietin (TPO) [7]. The lifespan of a mast cell is believed to be relatively long, 
as radioactively labeled mast cells were still detectable at 84 days after injection of the 
radioactive marker [8].
The phenotype of the mast cell differs between the various tissues in which they reside. 
This is mostly due to the micro-environment and the presence or absence of the above-
mentioned growth factors at the site were the MCP differentiate into mast cells [7].
Human mast cells can be divided into MCT (tryptase-positive, chymase-negative) and MCTC 
(tryptase-positive, chymase-positive) mast cells [9,10]. The MCTC subset can be found in 
connective tissue such as skin, submucosa, usually in intimate contact with microvascular 
and neuronal networks. The MCT subset is mainly found at mucosal and epithelial surfaces 
within the gut and lung [11]. However, the distribution of the subsets in humans is not as 
clear as in mice and is altered in diseases such as rheumatoid arthritis were both subsets 
are present within the synovium [12]. 
In mice and rats, two major types of mast cells are described; the mucosal (MMC) and 
connective tissue type (CTMC) mast cell. This distinction is based on the location, cell 
size, cellular content and staining characteristics. The human MCT share characteristics 
with the murine MMC mast cells, while the human MCTC share characteristics with the 
murine CTMC mast cells [11]. The MMC is located predominantly in the epithelium of the 
intestinal and respiratory tract. MMCs are smaller and contain fewer granules compared 
with CTMC, and they express mouse mast cell chymase (mMCP)-1 and -2 but not tryptase 
[13]. Interestingly, the MMC population, but not the CTMC population, expands upon T 
cell-dependent responses towards intestinal parasites indicating that MMC are dependent 
on T cells for their survival [13,14]. The CTMC type can be found throughout the body in 
various tissues such as the skin and peritoneal cavity, and they express mMCP-4, -5, -6 and 
carboxypeptidase A. The phenotype of mast cells has been shown to be dynamic, since 
MMC can differentiate into CTMC but also vice versa [15]. 
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Receptors expressed by mast cells
In order to respond to stimuli such as pathogens, mast cells express a variety of receptors 
such as Fc-receptors, pattern-recognition receptors and complement receptors.
Fc-receptors
Antibodies are a crucial part of the adaptive immune system. They bind to antigens via 
the variable part of the Fab fragment leading to the formation of immune complexes. 
The constant region of the antibody, the Fc part, can bind to C1q and Fc-receptors. The 
Fc-receptors are widely expressed by many (non)-immune cells, but in particular by innate 
immune cells. Each immunoglobulin isotype (IgA, IgM, IgE and IgG) binds to a specific Fc-
receptor: IgA binds to FcαR, IgM to FcμR, IgE to FcεR and IgG to FcγR [16]. These receptors 
combine the specificity of adaptive immunity with the powerful effector functions 
of innate cells. Mast cells express receptors for IgE (FcεRI) and IgG (FcγR), which will be 
discussed below.
FcεRI receptor
A main characteristic of human and murine mast cells is the expression of the high affinity 
receptor for immunoglobulin E (IgE), the FcεRI. It is composed of an α-chain, which is 
responsible for binding IgE, a β-chain, important for the amplification of the intracellular 
signaling, and a disulphide linked y-chain, needed for the initiation of the intracellular 
signaling cascade [17]. The FcεRI binds IgE with a very high affinity in the absence of 
antigens. As a result, mast cells are coated or sensitized with IgE molecules that can bind 
to specific antigens. To activate mast cells via the FcεRI a certain antigen needs to bind 
to the IgE molecule and crosslink at least two IgE molecules bond to their receptors. This 
causes the activation of an internal signaling cascade which includes activation of tyrosine 
kinases, such as Syk, Lyn, Fyn, and BTK and phosphorylation of numerous adaptor proteins 
[18,19]. Finally, this cascade leads to cytoskeletal rearrangements resulting in the release 
of the preformed mediators stored in the granules inside the cells, a process referred to 
as degranulation. This is the most powerful and fastest way of activating mast cells and 
within seconds they are able to release their mediators into the environment.
Fcy Receptors
Receptors for the Fc part of IgG antibodies, FcyRs, bind extracellular monomeric IgG’s or 
immune complexes. To date, six FcyRs are described in humans; FcyRI, FcyRIIA, FcyRIIB, 
FcyRIIC, FcyRIIIA and FcyRIIIB [20] (Table 1). In mice, four different classes of FcyRs have 
been described; FcyRI, FcyRIIB, FcyRIII and FcyRIV (Table 1). High affinity receptors like FcyRI 
can bind IgGs with and without antigens, while low affinity receptors like FcyRII/III only 
bind antibodies that have formed immune complexes. Also the different IgG subclasses 
(human: IgG1-IgG4, mice: IgG1,2a, 2b, 3) bind with varying affinity and specificity to 
the different FcyRs [21,22]. Stimulation of FcyRs will trigger an intracellular signaling 
12 | CHAPTER 1
pathway that leads to activation and/or inhibitory signals. The signal outcome depends 
on the intracellular motifs of the receptor. Receptors with an immunoreceptor tyrosine-
based activation motif (ITAM) will initiate an activating signaling pathway upon receptor 
aggregation, while immunoreceptor tyrosine-based inhibition motifs (ITIM) are coupled 
to inhibitory receptors. Upon activation by immune complexes, ITIM is phosphorylated 
and initiates the recruitment of inhibitory molecules e.g. SHIP [23]. In general, the FcyRs 
are activating, with the FcyRIIB receptor as the exception of being an inhibitory receptor 
[24].
The low affinity receptor FcyRIIA is expressed in cultured and isolated human mast cells 
[25–27]. Cultured human mast cells also express the inhibitory receptor FcyRIIB [26]. 
Expression of the high affinity receptor FcyRI can be induced by IFNy on human but not on 
mouse mast cells [28,29]. Murine mast cells constitutively express FcyRIIB and FcyRIIIA [30]. 
Since FcyRIII expresses the same subunits as the FcεRI, they can trigger a similar response 
upon activation [31]. Stimulation of freshly isolated peritoneal mast cells or cultured mast 
cells via either the FcεRI or FcyRIII results in a comparable β-hexosaminidase activity in 
the releasate, which is an indicator for degranulation [32]. Stimulation of cultured human 
mast cells with oxLDL-immune complexes, which activate via FcγR, results in release of 
histamine and tryptase [33]. These data indicate that both human and murine mast cells 
can also be activated via their activating FcγRs, which is comparable to IgE mediated 
activation in terms of released mediators.
Table 1: FcR expressed by human and mouse mast cells.
Receptor Ligand Action Ref.
Human
FcεRI Monomeric IgE Activating
FcγRI (IFNγ in-
duced)
Monomeric IgG Activating [28,29]
FcγRIIA IgG Immune complex Activating [25–27]
FcγRIIB IgG Immune complex Inhibitory [26]
Mouse
FcεRI Monomeric IgE Activating
FcγRIIIA IgG Immune complex Activating [30]
FcγRIIB IgG Immune complex Inhibitory [30]
1
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Pattern-recognition receptors
Cells of the innate immune system detect pathogens via several pattern-recognition 
receptors (PRRs). These PRRs detect components of microorganisms, known as pathogen 
associated molecular patterns (PAMPs). Each PRR reacts with specific PAMPs, thereby 
activating specific signaling pathways, each leading to a specific antipathogenic outcome 
[34]. Several PPRs have been described, such as the nucleotide oligomerization domain 
(NOD)-like receptors (NLRs), C-type lectins and Toll-like receptors (TLRs). On mast cells, the 
TLR family is studied mostly. To date, 10 members of the TLRs have been described in the 
human genome, and 13 are found in the murine genome [35]. Human mast cells express 
TLR1-7 and 9-10, whereas murine mast cells express TLR1-4 and 6-9 [36]. In general, 
stimulation of mast cells with TLR agonists results in the production and secretion of 
cytokines and chemokines, but not in degranulation. However, some reports show that 
TLR2, but not TLR4 agonists can induce degranulation of both human and murine mast 
cells, establishing that stimulation of mast cells via individual TLRs results in a very specific 
receptor-dependent response [37,38].
Complement receptors
The complement system is a highly efficient part of the innate immune system and is 
characterized by a biochemical cascade that consists of around 30 plasma proteins. 
Complement activation via one of the three pathways leads to cleavage of C3 and C5. The 
splice products C3a and C5a are potent inflammatory proteins. Complement receptors 
are membrane-bound proteins expressed by many (non)-immune cells [39]. Human and 
murine mast cells express receptors for complement component C3a (C3aR) and C5a 
(C5aR) [40,41] and binding of complement factors leads to cellular activation and to the 
secretion of cytokines (C3aR) or degranulation of mast cells (C5aR) [41].
Mediators released by mast cells
Upon activation, mast cells are able to secrete a wide range of mediators. There are two 
major ways how mast cells release their mediators into the environment. The first process 
is the release of pre-formed mediators that are stored inside the granules of the mast cells, 
which is the process referred to as degranulation. Secondly, mast cells can, upon receptor-
mediated activation, start to express, produce and secrete chemokines, lipid mediators 
and cytokines. The release pathway initiated upon mast cell activation is dependent on the 
type of triggered surface receptor, e.g. activation via the FcεRI will cause degranulation, 
whereas TLR stimulation will result in the release of de novo produced mediators.
Degranulation
Mast cell degranulation is the active release of granules, which are filled with a large panel 
of preformed mediators. Several external stimuli can induce mast cell degranulation, 
of which IgE crosslinking on the FcεRI by a certain antigen is most commonly known. 
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However, degranulation can also occur after binding of complement factors like C5a, 
neuropeptides such as substance P and Neuropeptide Y, or by IgG-immune complexes 
to their specific receptors. Upon activation mast cells will actively release granules into 
the extracellular environment, which can have a strong local effect, but can also induce 
systemic events such as anaphylaxis. A large number of (mast cell specific) mediators can 
be found inside mast cell granules, which are summarized in table 2. 
Many of the mast cell effector functions are closely related to the biological action of the 
mediators present in the granules. For example, proteases like tryptase, chymase and 
carboxypeptidase have been implicated in tissue remodeling and recruitment of other 
immune cells [42,43]. The presence of histamine and serotonin is a key characteristic of 
mast cell granules. They have a potent effect on vascular permeability and contribute to 
the symptoms of allergic diseases [44]. In addition to several enzymes, mast cell granules 
also contain preformed cytokines such as TNFα. To date, murine mast cells but not 
human mast cells are the only immune cells that have preformed TNFα and therefore are 
an important source of TNFα during acute phase reactions [45]. Furthermore, mast cell 
derived TNFα is shown to drive both the hypertrophy of the draining lymph nodes and 
recruitment T cells to the site of infection [46].
Table 2: Content of mast cell granules.
Mediator Mediator class Function Ref.
Tryptase Serine proteases Protective (parasitic infections) or damaging func-
tions (autoimmunity)
[48]





Metalloproteinase Degradation of toxins derived from snake venom [50,51]
Histamine Vasodilator Increases vascular permeability [52]
Serotonin Neurotransmitter Role in mast cell mediated signaling to nerve 
endings
[53]
Dopamine Neurotransmitter Role mast cell mediated signaling to nerve end-
ings
[54]
Cathepsin B/C/L/D/E Proteases Processing of pro-chymases/tryptases/pro-cpa3 
to functional proteases. 
[55]
TNFα Cytokine Pro-inflammatory activities in acute phases [45]
IL-4 Cytokine Mast cell driven Th2 T cell polarization [56]
β-Hexosaminidase Lysosomal en-
zyme
Degradation of bacterial cell wall peptidoglycan 
as a bactericidal mechanism
[57,58]
(adapted and modified from Wernersson and Pejler Nat. Rev. Immunol 2014 [47])
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Cytokine/chemokine release
Besides the release of the above mentioned mediators stored in the granules, mast 
cell activation also leads to the de novo production and secretion of many different 
mediators like lipid mediators as well as a wide range of cytokines and chemokines. Table 
3 summarizes the majority of mast cell mediators that can be released upon stimulation. 
Cytokines that are produced by mast cells can be divided into pro-inflammatory and 
immunomodulatory. The array of mediators released by mast cells depends on the 
specific activation pathway, which enables mast cells to initiate and modulate the immune 
response in a manner appropriate for the pathogen.
Table 3: Mediators produced and secreted by mast cells. 
Mediator Function Ref.
Lipid-derived
LTC4, LTB4, PGD2 and PGE2 Recruit effector cells, regulation immune response, pro-
mote angiogenesis, edema and bronchoconstriction.
[60–64]
Platelet-activating factor Activates immune effector cells, enhances angiogenesis 
and induces physiological inflammation
[64]
Cytokine
TNFα, IL-1α, IL-1β, IL-6, IL-18, GM-
CSF, LIF, IFNα and IFNβ
Induce inflammation [45,65–69]
IL-3, IL-4, IL-5, IL-9, IL-13, IL-15 and 
IL-16
Induction of a T helper 2 like immunological phenotype [70,71]
IL-12 and IFNg Induction of a T helper 1 immunological phenotype [72,73]
IL-10, TGF-β and VEGF Regulate inflammation and angiogenesis [74,75]
Chemokine
CCL2, CCL3, CCL4, CCL5, CCL11 
and CCL20
Recruit effector cells like monocytes and DCs and 
regulate immune responses
[76–80]
CXCL1, CXCL2, CXCL8, CXCL9, 
CXCL10 and CXCL11




Nitric oxide and superoxide 
radicals
Bactericidal [83–85]
Antimicrobial peptides Bactericidal [86]
(Adapted and modified from Marschall, Nat. Rev. Immunol. 2004 [59])
Physiological and pathophysiological role of mast cells
In a physiological state, mast cells and basophils act as the first line of defense against 
parasites such as worms and protozoa. Parasites can establish a long lasting, persistent 
infection in the host and are very efficient in escaping the immune system. Frequently, 
parasite infections cannot be controlled by cellular and molecular mechanisms alone. 
Therefore, an IgE mediated response is elucidated that will activate both basophils and 
mast cells upon encountering the parasite. The release of the described mediators will 
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create an environment that allows a quick elimination of the parasite. 
Nowadays in most industrialized countries a parasitic infection is rare, while hypersensitivity 
reactions towards antigens like pollen are common. Most of these responses are 
IgE mediated and are referred to as type I hypersensitivity reactions. Hallmark of a 
hypersensitivity reaction or allergy is the production of IgE antibodies towards a harmless 
antigen. Upon contact with the targeted antigen, this will initiate a mast cell mediated 
immune response, which is similar to the response upon parasite infection. 
Next to its contribution to host defense and allergy, mast cells have also been implicated 
in many immune driven disorders such as asthma, multiple sclerosis (MS), atherosclerosis 
and arthritis [87–90]. Asthma is characterized by airway obstruction, hyper responsiveness 
and inflammation. Most of the asthmatic patients exhibit hypersensitivity towards defined 
environmental allergens, like house dust mite [91]. As in other hypersensitivity type I 
reactions, IgE is the main immunoglobulin isotype in asthma [92]. Inhalation of allergens 
will activate IgE sensitized mast cells and induce the subsequent release of mediators like 
histamine and lipid mediators, which act as bronchoconstrictors [91]. Cytokines like IL-4, 
IL-5 and IL-13, produced by mast cells, will induce immunoglobulin class switching of B 
cells to produce IgE. Blockage of IgE by the monoclonal antibody omalizumab reduces 
both the response to allergens and airway inflammation in asthmatic patients [93].
Mast cells were first observed over 100 years ago in central nervous system (CNS) lesions 
of MS patients [94]. The expression of mast cell specific proteases is increased during the 
chronic phase of MS, as measured by microarray analysis. and elevated levels of tryptase 
are found in the cerebrospinal fluid of MS patients [95,96]. Hallmark of MS is the loss of the 
myelin sheath around the neurons and mast cell derived proteases are able to degrade 
myelin sheath proteins [97], indicative of an active contribution of mast cells to the 
pathology of MS.
Mast cells have also been implicated in a number of other (autoimmune) diseases, such 
as systemic lupus erythematosus, osteoarthritis and Sjögren’s syndrome [98–100]. Most 
of the data that connect mast cells to these conditions are obtained from observational 
studies showing mast cell activation during disease. 
Mouse models for mast cell deficiency 
Over the past decades, the contribution of mast cells to physiological and 
pathophysiological processes has been studied in mast cell deficient mouse strains. Three 
frequently used mast cell deficient mouse strains are the WCB6F1 KitlSl/KitlSl-d (Sl/Sld) 
mice, the WBB6F1-KitWKitW-v (W/Wv) mice and the KitW-Sh/KitW-Sh (sash) mice, which all have 
defects in the SCF signaling pathway. WCB6F1 KitlSl/KitlSl-d (Sl/Sld) mice lack SCF due to a 
loss of function mutation in the SCF gene [4]. The KitWKitW-v (W/Wv) mice have a deletion 
mutation, resulting in a non-functional Kit-protein lacking the transmembrane domain 
and is therefore not expressed, and a point mutation in the Kit signaling pathway that 
markedly decreases the activity of the receptor [101]. KitW-Sh/KitW-Sh (sash) mice contain 
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a large genetic inversion affecting the transcriptional regulatory elements upstream of 
the Kit transcription start site on chromosome five [102]. Bone marrow-derived mast cells 
from wild-type or specific knockouts can be used to reconstitute the mast cell population 
in these mouse models, therefore are also referred to as mast cell knockin models. 
Because c-Kit is not only expressed by mast cells, mutations of c-Kit affect other cells of 
hematopoietic and non-immune origin. The W/Wv mice suffer from basal neutropenia, 
anemia, sterility and lack of melanocytes [6]. KitW-Sh/KitW-Sh mice are fertile and lack anemia, 
but suffer from other hematopoietic abnormalities, such as expanded myeloid and 
megakaryocyte populations [103,104]. Therefore, new models of mast cell deficiency have 
been developed, which are independent of c-Kit mutations. 
Cell type-specific knockout mice can be generated by the use of site-specific recombination 
systems. For example, the Cre/loxP recombination system has been shown to be very 
efficient and is used frequently to study individual cell types in vivo [105]. This system 
is based on the ability of the enzyme Cre recombinase (Cre) to catalyze recombination 
between two DNA recognition sites, i.e. the loxP sites. Cre deletes sequences between 
these sites resulting in a single LoxP sequence, subsequently leading to depletion of the 
gene of interest. The expression of Cre is usually under control of a cell specific protein, 
leading to depletion of cells specifically controlled by that protein. To create mast cell-
specific knockouts several proteins/receptors have been used, e.g. FcεRIβ, MCPT5 or Cpa3 
[106–108]. To specific establish mast cell deficiency, these Cre mice can be crossed with 
mice that express the diphtheria toxin (DT) under control of a loxP-flanked stop cassette. 
Expression of Cre activates the expression of DT resulting in cell death [109]. Another 
possibility is the crossing of Cre-expressing mice with mice that have a floxed allele of an 
anti-apoptotic gene e.g. Mcl1 [108].
Recently a new inducible mast cell knockout mouse model was presented, in which mast 
cells can be selectively depleted. In this the so-called RMB (red mast cell and basophil) 
mouse, the 3’-UTR of the gene encoding the FcεRI β chain contains the human DT receptor 
(FcεRIβ-DTR), resulting in depletion of mast cells and basophils upon treatment with DT 
[106]. At 12 days after the DT injection, basophils are completely repopulated, whereas 
mast cells remain depleted up to at least 2 months [106]. Therefore, this model can be 
used to study the effects of mast cell depletion when mice display clinical manifestations 
of diseases such as arthritis and atherosclerosis, which may provide more insight into the 
active contribution of mast cells in progression of several diseases. 
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Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a common autoimmune disorder that affects around 0,5 – 1% 
of the adult population in industrialized countries [110]. A healthy joint is composed of two 
bone ends covert by a layer of cartilage, which is essential for distribution of pressure on 
the bones. Furthermore, the cavity inside the joint is filled with synovial fluid that ensures 
optimal sliding between the joints and is produced by a single layer of synoviocytes that 
forms the synovial membrane (Fig. 1a). RA is characterized by persistent inflammation of 
the synovial membrane (synovitis) in the joints. RA starts with the influx of leukocytes, 
such as monocytes and neutrophils, into the synovial layer leading to thickening of 
the membrane. The release of mediators by the leukocytes leads to the destruction of 
cartilage and bone of the joint, which is the hallmark of RA (Fig. 1b). Although all joints 
in the body can be affected by RA, it affects most commonly the hands, feet and knees 
[111]. The prevalence of RA differs between different populations. While a very high RA 
prevalence is found in native American populations, a very low prevalence is reported in 
South-East Asian populations [112,113]. The incidence of RA is approximately two times 
higher in women than in men and the prevalence increases with age [114]. RA is a systemic 
inflammatory disease, which frequently coincides with symptoms like weight loss, fever, 
increased cardiovascular risk as well as disorders in the vascular system. 
The persistent inflammation causes a significant increase in the mortality, morbidity and 
disability rate in RA patients [110,115,116]. Genetic as well as environmental risk factors 
have been described for the development of RA. The most important genetic factor is the 
HLA class II locus. While the presence of the HLA-DRB1*04 gene strongly predisposes to 
RA, the presence of the HLA-DRB1*13 allele is protective for development of RA [117,118]. 
It is reported that these alleles are involved in the development or protection of Anti-
Citrullinated Protein Antibodies (ACPA)+-RA [119]. Environmental risk factors for RA are 
alcohol intake, low vitamin D levels, low socioeconomic status and smoking [120], and of 
these, smoking is the most dominant one, which doubles the risk of developing RA [121].
Patients with RA are treated with disease-modifying anti-rheumatic drugs (DMARDs), which 
reduce the inflammatory response both locally and systemically, prevent progression of 
joint destruction and improve the function of the affected joints [122]. DMARDs form a 
heterogeneous collection of drugs of which the mechanisms of action are not completely 
understood. Nowadays, the most frequently used DMARD is methotrexate, which can 
be combined with other similar drugs such as sulfasalazine, hydroxychloroquine and 
leflunomide [123]. Since the immune system plays a dominant role in RA several biological 
agents have been developed to target specific components of the immune system, such 
as anti-TNF (infliximab), CD80/86 blockade (Abatacept), anti-CD20 (Rituximab) and IL-6R 
blockage (Tocilizumab) [110]. These biologicals have proven to be very effective and lead 
to a therapeutic improvement for RA patients [110]. Current treatment aims to achieve 
the lowest possible disease activity and ultimately remission. Nevertheless, RA remains to 
be a major autoimmune disease leading to (partial) disability and loss of productivity, and 
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eventually to high costs in healthcare [124].
The immune system in Rheumatoid Arthritis
Despite the fact that RA is a considerable health problem for society, relatively little is 
known about the exact pathology and etiology of the disease. Unquestionably, the 
immune system plays a very dominant role in the pathogenesis of RA. Leukocytes such as 
macrophages, neutrophils, mast cells and lymphocytes accumulate during the progression 
of RA within the synovial tissue and fluid. The active interplay between the innate and 
adaptive immune system leads to the development of auto-reactive T cells, production of 
auto-antibodies by B cells and secretion of a variety of inflammatory mediators by innate 
cells like macrophages, neutrophils and mast cells [125,126]. 
Hallmark of autoimmunity is the development of a strong immune response toward self-
antigens. RA is characterized by the presence of a variety of antibodies targeting (modified) 
self-antigens like collagen type II, rheumatoid factor, citrullinated (Anti-Citrullinated 
Protein Antibodies or ACPA) and carbamylated proteins (anti-CarP) [127,128]. Of these 
Figure 1. (A) A healthy joint is composed of two adjacent bony ends each covered with a layer of 
cartilage, separated by a joint space and surrounded by the synovial membrane and joint capsule. 
(B) Hallmark of Rheumatoid Arthritis (RA) is the inflammatory response of the synovial membrane 
that is characterized by an influx and local activation of a variety of mononuclear cells, such as T 
cells, B cells, plasma cells, dendritic cells, macrophages, mast cells, as well as by new vessel forma-
tion. Hallmark of RA is bone destruction caused by activated osteoclasts. Bone repair by osteoblasts 
usually does not occur in active RA. Within the synovial fluid many neutrophils can be found, as well 
as mediators released by many activated immune cell like neutrophils, plasma cells and mast cells 
leading to cartilage destruction.
Adapted and modified from Smolen and Steiner Nature Reviews Drug Discovery 2003; 473:488 [121]
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antibodies, ACPA are of great interest because they have been shown to be very specific 
for RA. Only a low frequency of ACPA has been detected in non-RA diseases like systemic 
lupus erythematosus (5,5%), primary Sjögren’s syndrome (13,3%), psoriatic arthritis (9,4%), 
juvenile idiopathic arthritis (5%) [129–132]. In early RA patients, ACPA can be detected in 
50-70% of the cases, which renders ACPA an important clinical biomarker for RA. Target 
of ACPA are citrullinated proteins, hence their name anti-citrullinated protein antibodies. 
Citrullination or peptidylarginine deimination is a physiological process catalyzed by a 
family of enzymes called peptidyl arginine deiminases (PAD-1-4). These enzymes convert 
the positively charged amino acid arginine to an uncharged amino acid citrulline in the 
presence of relatively high calcium concentrations [133]. The antigens targeted by ACPA 
are highly diverse as they show reactivity towards many different citrullinated proteins, 
such as collagen, vimentin, fibrinogen, enolase, fibronectin, vinculin and histones 
[134–137]. These citrullinated proteins that have been identified within the synovial 
compartment and are targets of ACPA. The presence of both a wide array of antigens and 
high levels of ACPA within the synovial fluid indicates a direct pathogenic role for ACPA 
in the process of synovial inflammation via e.g. the formation of immune complexes or 
complement activation [138,139]. Interestingly, ACPA can be detected in the serum for up 
to 10 years before onset of RA, without any clinical signs of arthritis [140,141]. 
To date, it is largely unknown how the tolerance of T and B cells is breached in the early 
phase of RA. Many studies have shown that there is a correlation with the HLA-locus 
expressed by antigen presenting cells and the development of RA, suggesting a role for T 
cells in the pathogenesis of RA [119]. Furthermore, high numbers of T cells can be detected 
in the inflamed synovium and T cells are required in experimental arthritis models [142]. 
Recently, it was shown that a peptide sequence present in citrullinated vinculin and many 
microbes, DERAA, can bind to and is presented to T cells via HLA-molecules associated 
with RA-susceptibility [143]. Nevertheless, direct targeting of T cells by depleting CD4-
specific or CD52-specific antibodies has been unsuccessful [144], possibly due to the fact 
that besides the depletion of pathogenic effector T cells also regulatory T cells (Treg) are 
depleted. In the rheumatoid synovial joint both Th1 and Th17 cells as well as regulatory T 
cells have been detected [145]. Especially Th17 cells, producers of IL-17A, have shown to 
enhance the secretion of inflammatory cytokines by several joint cells like fibroblasts and 
chondrocytes [146]. Although regulatory T cells have been detected in tissues from RA 
patients, their functional capacity is described to be limited due to the suppressive effects 
of TNFα [147]. 
As mentioned, humoral immunity plays a dominant role in RA and experimental models 
of arthritis. Throughout the synovium B cells, plasmablasts and plasma cells can be found. 
Depletion of B cells by the anti-CD20 antibody rituximab has been proven to be effective 
in RA, as it reduces the level of ACPA antibodies and inflammatory cytokines like IL-6 and 
TNF, which are amongst others produced by B cells [148].
Innate effector cells, including macrophages, neutrophils, natural killer cells and mast cells 
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have been implicated in the pathogenesis of RA. Macrophages are central effector cells 
during synovitis, and they act through the release of a range mediators like cytokines 
(TNFα, IL-1, IL-6, IL-12, IL-15, IL-18, IL-23), chemokines (MCP-1, IL-8), reactive oxygen 
intermediates, nitrogen intermediates, matrix degrading enzymes and the expression of 
MHC class II [149]. These macrophages display an M1-like phenotype and can be activated 
via many pathways, such as via TLRs, cytokines, immune complexes and lipid mediators. 
Neutrophils are found in large numbers predominantly within the synovial fluid but also in 
the pannus region of the inflammation. Upon activation via e.g. immune complexes, they 
secrete potent effectors of cartilage destruction, such as serine and metalloproteases, 
but also RANKL and BAFF, which are known to activate osteoclasts and B cells [150]. Over 
time, mast cells also accumulate within the synovial tissue and produce large numbers of 
cytokines and chemokines upon activation via one of the many receptors they express. 
The contribution of mast cells in RA will be discussed in more detail in chapter 2.
To conclude, activated innate effector cells are present in high numbers within the inflamed 
synovium and are thought to have a great impact on the process of joint destruction. 
More insight in the contribution of innate immune cells to RA progression could lead to 
new therapeutic targets that positively modulate the immune response.
Arthritis mouse models
A cornerstone of experimental biomedical research is the use of animal models to explore 
basic pathophysiological mechanisms. Much of the current knowledge regarding the 
pathogenesis of rheumatoid arthritis has been obtained using models of experimental 
arthritis. These models have given much insight into the contribution of the immune 
system to RA pathology. Nonetheless, none of the available animal models exactly 
resemble the pathology of human RA, which is the reason that these models are referred 
to as “arthritis” models instead of RA models. Roughly, the models of experimental arthritis 
can be divided in either actively (immunization based) – or passively (antibody-infusion 
based) – induced arthritis.
Collagen induced arthritis (CIA)
This frequently used model for arthritis was discovered in the mid-1970s by Kang et al 
[151]. In an attempt to raise antibodies towards collagen type II, the authors unexpectedly 
found that 40% of the immunized rats developed inflammatory arthritis. Subsequent 
studies have shown that immunization of mice with collagen type II (in the presence of 
complete Freund’s adjuvant) also resulted in the development of arthritis [152]. Since 
cartilage destruction is largely mediated through autoantibodies against collagen type II, 
this model resembles rheumatoid arthritis in several aspects [153,154].
The pathogenesis of CIA is rather complex, involving both cellular and humoral immunity. 
Chronic inflammation in CIA is thought to be mediated by anti-collagen autoantibodies 
and Th17 cells. After initiation of the autoreactive response, effector mechanisms include 
complement and Fc receptor activation, production of IL-1β and TNFα [155–157].
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The onset of clinical symptoms occurs around 14 to 21 post immunization, characterized 
by gradually increasing inflammation of joints in the paws. At the end stage, inflammation 
becomes less intense and the swelling disappears followed by ankylosis of the affected 
joints.
Antibody-induced arthritis
The basis for this model are autoantibodies directed to glucose-6-phosphate (GPI), which 
originate from crossing mice expressing a T cell receptor reacting to self-antigens (KRN-
C57BL/6 mice) with autoimmune-prone NOD mice leading to systemic T cell activation 
towards GPI [158]. Serum of these K/BxN mice can be used to passively induce arthritis 
in wild-type mice. Anti-GPI antibodies home to distal joints within minutes, where they 
activate the complement system and subsequently form immune complexes, thereby 
inducing the development of arthritis. These autoantibodies activate the inflammatory 
response via complement receptors, Fc receptors and depend on production of TNFα and 
IL-1. The recipient mice will develop arthritis in 6 to 7 days after injection. However, this is 
a more transient arthritis that often resolves after 15 to 30 days and repeated injections 
of serum are required to maintain the disease. Furthermore, it has been established 
that transfer of GPI antibodies or anti-collagen type II antibodies from K/BxN mice into 
recipient mice is sufficient to induce disease. The K/BxN mouse model resembles human 
RA in terms of leukocyte infiltration, synoviocyte proliferation as well as cartilage and 
bone erosion
Additional arthritis models
Besides the CIA and the K/BxN mouse models of arthritis, a number of other inducible 
arthritis mouse models have been developed. The models include antigen-induced 
arthritis, adjuvant-induced arthritis, oil-induced arthritis and proteoglycan-induced 
arthritis. However, these models are not as frequently used as CIA or K/BxN mice and 
display a relatively slow onset of RA.
The IL-1β/mBSA induced arthritis model has been published in 1990, but the precise 
mechanism is to date unknown [159]. The model is based on an intra-articular injection 
of methylated bovine serum albumin (mBSA) into the knee joint together with a 
subcutaneous injection of recombinant IL-1β in the rear footpath of the mouse. Additional 
injections of IL-1β are necessary to fully induce arthritis. This procedure results in an acute 
arthritis starting 4–7 days after the first injection, which resolves around day 28. Monocytes 
and neutrophils are present in the affected joints suggesting the involvement of innate 
immunity in the development of the IL-1β/mBSA induced arthritis, but also T cells seem 
to contribute to its initiation and progression [160]. Since the arthritis develops rather 
quickly, this model can be used to study acute inflammatory responses. In addition, this 
model is not dependent on a certain MCH haplotype such as in the CIA model, therefore 
it can be used in e.g. C57BL/6 mice.
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Several of these mouse models have been used to study the role of mast cells in 
experimental arthritis. The outcome of these studies are rather contradictory and are 
discussed in more detail in chapter 2. 
Atherosclerosis
Cardiovascular diseases (CVD), such as coronary heart disease and cerebrovascular disease, 
are the leading cause of death worldwide [161]. Environmental risk factors for CVD are 
a high-fat diet, smoking, sedentary lifestyle, stress, hypertension, [162]. Atherosclerosis, 
which is the main underlying cause of CVD, can be considered as a chronic, systemic, 
lipid-driven autoimmune-like disease that affects the large- and medium-sized arteries. 
Originally, it was thought that atherosclerosis was the result of passive accumulation of 
lipids in the wall of the blood vessels. Over time, this lesion will expand and eventually 
occlude blood vessel, which will trigger clinical symptoms of ischemia. However, it is now 
widely accepted that atherosclerosis is, besides lipid-driven, also a chronic inflammatory 
condition were both the innate and adaptive arm of immunity contribute significantly 
to the initiation and progression of the atherosclerotic plaque [163]. Current therapeutic 
options are the use of lipid lowering drugs like statins and anti-hypertensive drugs. Often 
these drugs are combined with recommendations to change lifestyle such as a reduction 
in dietary (cholesterol) intake, to quit smoking and to increase physical exercise. However, 
statins are not always effective and the recommended changes in lifestyle are often 
ignored. This underscores the importance of new therapeutic targets that are able to 
modulate the initiation and progression of atherosclerosis or even induce regression of 
the atherosclerotic plaque.
Pathology and etiology of atherosclerosis
Early lesion development: Endothelial dysfunction
In physiological conditions, the innermost layer of the artery is responsible for regulating 
the vascular tone and has an anti-coagulant and anti-inflammatory function (Fig. 2a). In 
response to damage as induced by hypertension, hypercholesterolemia or smoking, the 
endothelium of the artery becomes dysfunctional, as indicated by increased expression 
of pro-inflammatory cytokines and cellular adhesion molecules such as VCAM-1 [164]. 
This is accompanied by an increased permeability of the endothelium, which allows 
an influx of inflammatory leukocytes and lipids into the vessel wall. The early phase of 
atherosclerosis is characterized by the accumulation of low-density lipoprotein (LDL) and 
monocytes in the sub-endothelial layer. Here, the LDL undergoes modification such as 
lipolysis, proteolysis and oxidation [165]. Of these LDL modifications, the oxidized form 
of LDL or oxidized LDL (oxLDL) is believed to be a major auto-antigen in atherogenesis 
[166]. The microenvironment inside the early lesion induces maturation of monocytes to 
inflammatory macrophages, which will secrete inflammatory cytokines like TNFα and IL-6 
[167]. Moreover, macrophages express scavenger receptors that enables them to take up 
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oxidation specific molecules such as oxLDL and cellular debris [168]. As a result cholesterol 
esters accumulate within the cell. This transforms the macrophage into a lipid rich ‘foam 
cell’ because of the lipid droplets that provide the cell a foamy appearance. In this initial 
phase the lesion is referred to as early lesion or fatty streak, which can either disappear or 
progress to an advanced atherosclerotic lesion (Fig. 2b) [169].
Lesion progression and destabilization
Under the influence of cytokines and growth factors secreted by local macrophages and 
foam cells, smooth muscle cells (SMCs) migrate from the media into the intimal layer of 
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Figure 2. (A) A healthy artery is composed of multiple layers, which are from inner to outer layer 
the endothelial, intima, media and adventitia. (B) Increased endothelial permeability enables LDL 
to cross into the vessel wall where it is quickly modified into immunogenic oxidized LDL. Further-
more, endothelial activation leads to upregulation of cellular adhesion molecules on the surface of 
endothelial cells, which causes adhesion and migration of immune cells like monocytes and T cells. 
The inflammatory milieu causes differentiation of monocytes into macrophages who turn into foam 
cells, which accumulate and form a ‘fatty streak’. 
Adapted and modified from Libby et al. Nature 2011; 473:317. [170]
the vessel. In the intima they start to produce collagen and other extra cellular matrix 
components, which results in the formation of a fibrous cap (Fig. 3a). Other inflammatory 
cells like Th1 cells, dendritic cells and mast cells infiltrate the lesion and cytokines, IFNγ and 
IL-1β, produced by these cells may further enhance the foam cell formation [171–173]. A 
combination of relative hypoxia, the inflammatory milieu, increased oxidative stress and 
excessive protease activity in the plaque will cause apoptosis of lipid loaded macrophages 
and foam cells. This leads to the deposition of lipids within the plaque and causes the 
formation of a necrotic core underneath the fibrous cap. Neovascularization takes place in 
the lesion, which upon leakiness may result in intraplaque hemorrhage and accumulation 
of even more inflammatory cells [174].
The composition of the atherosclerotic lesion is essential for maintaining lesion stability. 
Changes in the morphology of a lesion can negatively influence plaque stability resulting 
in an unfavorable clinical outcome. An unstable lesion is characterized by a large necrotic 
core, that is covered by a thin fibrous cap. Fibrous cap erosion is caused by smooth muscle 
cell apoptosis and collagen degradation, which is mediated by inflammatory cells e.g. 
macrophages that secrete matrix metalloproteinases [175]. Other mediators secreted from 
immune cells can also contribute to the degradation of lesion components. For example, 
IgE mediated mast cell activation results in the secretion of many proteases like chymase 
that inhibit expression and growth of collagen and induces apoptosis of SMCs [176,177]. 
At a certain point this thinning of the fibrous cap causes rupture of the plaque, exposing 
its thrombogenic content to the blood, resulting in acute thrombosis and potentially an 
acute cardiovascular event (Fig 3b).
26 | CHAPTER 1
Figure 3. Both foam cell formation and smooth muscle proliferation cause a thickening of the vessel 
and the formation of a fibrous cap that covers a necrotic core (A). As the plaque enlarges, it causes 
narrowing of the lumen but also thinning of the fibrous cap. Finally, the plaque ruptures, which can 
lead to thrombosis and clinical events (B). 
Adapted and modified from Libby et al. Nature 2011; 473:317. [170]
Mouse models of atherosclerosis
Atherosclerosis is a complex multifactorial disease were both dyslipidemia and immunity 
interact to induce an atherogenic response. The use of laboratory animals is crucial to 
evaluate the complex cell-cell interaction in atherosclerosis. The mouse has become 
the most commonly used animal for biomedical research due to ability of genetic 
modification. Nonetheless, mice are highly resistant to atherosclerosis and C57BL/6 mice 
only develop small fatty streak lesions when put on a high fat and high cholesterol diet for 
a long period [178]. Mice with deficiencies in the lipid metabolism have been created to 
induce lesion development. In atherosclerosis studies, apoE KO, apoE*3-Leiden transgenic 
and LDLr knockout mice as well apoE/LDLr double knockout mice are frequently used 
[179–182]. In mice, apolipoprotein E and the LDL receptor are essential in the clearance of 
chylomicrons and VLDL from the circulation. Therefore mice deficient in apoE and LDLr or 
both have increased levels of cholesterol and triglyceride-rich lipoproteins when placed 
on a high fat and cholesterol diet, which results in lesion development regions with shear 
stress like the aortic root. 
Recently, a new murine atherosclerosis models has been proposed, which is based on 
Adenovirus mediated overexpression of Proprotein convertase subtilisin kexin 9 (PCSK9) 
[183]. Overexpression of PCSK9 resulted in elevated plasma total cholesterol and LDL, 
which is nearly identical to that of LDLR knockout mice. Likewise, mice injected with 
this PCSK9-encoding virus developed atherosclerosis, which was comparable with LDLr 
knockout mice based on lipid profile and histological analysis of the aortic root [184].
The immune system in atherosclerosis
In combination with dyslipidemia, the immune system plays an essential role in the 
initiation, progression and destabilization of the atherosclerotic plaque. Cells of both arms 
of the immune system are involved in the process of atherogenesis [185].
Monocytes and macrophages
In the early stages of atherosclerosis monocytes are recruited to the arterial wall under 
influence of chemokines CCL2 (MCP-1) ligands for CCR2 and CXCR3 and CCL7 [186,187]. 
Both in mice and in humans, different populations of monocytes have been described. In 
general, circulating murine monocytes (CD11b+CD115+F4/80lowLy6G-) can be differentiated 
on basis of the expression of Ly6C. Monocytes that are Ly6Chi are comparable with the 
human classical monocytes (CD14+CD16-) based on gene expression profiles, while the Ly6C- 
monocytes share properties with the human non-classical monocytes (CD14dimCD16+). Of 
these two subsets, the Ly6Chi subset of monocytes infiltrates the vessel wall [188]. In the 
intima, the monocytes differentiate into macrophages in the presence of macrophage 
colony-stimulating factor, which is produced by local cells like endothelial and smooth 
muscle cells. The macrophage plays a dominant role in all phases of atherosclerosis and 
outnumbers all other immune cells. Via scavenger receptors such as SR-A1 and CD36, 
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macrophages take up modified lipoproteins such as oxLDL and cellular debris, which are 
digested in lysosomes [189]. The accumulation of lipids in the macrophages will activate 
the pro-inflammatory signaling pathway resulting in the secretion of pro-inflammatory 
cytokines like IL-6 and TNFα. Also, local endogenous ligands like HSP60 or oxLDL, which 
bind to TLRs, induce cytokine production and accelerate foam cell formation [190]. In 
advanced atherosclerotic lesions, the macrophages are unable to efflux the absorbed 
cholesterol, which results in apoptosis of the cell and expansion of the necrotic core.
Neutrophils
Neutrophils are the most abundant cell type in the circulation and upon activation 
they release various mediators like MMPs that can influence plaque stability. They have 
been detected in early atherosclerotic lesions of apoE-/- mice, but also in human carotid 
atherosclerotic plaques [191,192]. Via chemotactic molecules (C5a, C3a, fMLP) and 
chemokines (IL-8) they are recruited into peripheral tissues. Interestingly, it has been 
shown that systemic IgE-mediated mast cell activation in mice leads to the recruitment 
of neutrophils into the atherosclerotic lesion [193]. However, the role of neutrophils in 
atherosclerosis is not completely confirmed yet, which is probably due to the short life 
span of the cell.
Mast cells
In physiological conditions, mast cells are located around the blood vessels and during 
atherogenesis their amount increases with the highest number in rupture prone plaques 
[194,195]. Analysis of human plaques obtained after carotid endarterectomy showed that 
intraplaque mast cell number correlated with atherosclerotic plaque progression and 
micro vessel density, but also with the incidence of future cardiovascular events [196]. 
The causality between mast cells and plaque progression and destabilization is shown 
in a study where systemic mast cell activation led to increased plaque growth, which 
was inhibited by administration of the mast cell stabilizer cromolyn [197]. Inhibition of 
chymase by a chemical inhibitor resulted in reduced lesion size and increased stability 
in apoE-/- mice [198]. Atherosclerosis-related stimuli like Substance P, C5a, neuropeptide 
Y, oxLDL-immune complexes and endogenous TLR ligands have been shown to activate 
mast cells [33,190,199–201]. These activation pathways often result in the secretion of 
proatherogenic cytokines such as TNFα, IL-6 and IL-8. Combined, these data clearly establish 
that mast cells actively contribute to atherosclerosis by the recruitment of leukocytes 
like neutrophils, by the induction of intraplaque apoptosis and to destabilization of the 
plaque via the release of proteases.
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Dendritic cells
Dendritic cells (DCs) are professional antigen-presenting cells that are required for the 
stimulation and differentiation of naïve T cells and the development of antigen specific T 
cell-mediated immune responses. In atherosclerosis, DCs are responsible for the initiation 
of an adaptive immune response; they take up antigens, e.g. oxLDL, and present them in 
secondary lymph nodes to naïve T cells [185]. During the progression of atherosclerosis 
the number of DCs increases in apoE-/- mice [202]. Modulation of the immune response by 
both oxLDL-pulsed mature DCs and oxLDL-induced apoptotic DCs resulted in a decrease 
in lesion development [203,204]. 
T cells
In the lymphoid organs DCs present antigens via MHCII to the T cell receptor (TCR) on 
naive CD4+ T cells. For optimal T cell activation two additional signals are required from 
the DC: co-stimulation and the secretion of cytokines. Co-stimulation via molecules like 
CD80/86 will activate the T cell and the presence of cytokines secreted by the DC will 
skew the T cell towards a certain subset. Key T cells subsets in atherosclerosis are Th1, Th2, 
Th17 and Tregs. Th1 T cells are the predominant type of CD4+ T cells in human and murine 
atherosclerosis they secrete a range of proatherogenic cytokines like IFNγ, TNFα, IL-2 
and IL-12 [205,206]. Especially IFNγ, a hallmark cytokine of Th1 T cells, influences lesion 
progression and destabilization both by accelerating the ongoing inflammatory response 
through macrophage activation and inhibiting the production of collagen by smooth 
muscle cells [207]. LDLr-/- mice also deficient for IFNγ develop smaller atherosclerotic 
lesions in the aortic arch and descending aorta compared to control mice [208]. Th2 T 
cells are present in low numbers in the atherosclerotic lesion and they produce cytokines 
like IL-4, IL-5, IL-10 and IL-13 [206]. These cytokines influence the maturation of B cells 
into antibody producing plasma cells and downregulate the production of IFNγ thereby 
inhibiting Th1 responses. The role of Th2 T cells is rather controversial: on one hand IL-4 
deficiency reduces atherosclerosis, while on the other hand the Th2 cytokines IL-5 and 
IL-13 have been shown to be important for the activation of atheroprotective B-1 B cells, 
which produce athero-protective IgM antibodies [209,210]. Another potent inflammatory 
CD4+ T cell subset is the Th17 T cell, which produces large amounts of IL-17, IL-21 and 
IL-22. Key cytokines in Th17 T cell biology are IL-6 and TGF-β for induction, IL-21 for the 
proliferation and IL-23 for the maintenance of Th17 T cells [211]. Although Th17 T cells have 
been implicated in many other immune-driven disorders, their role in atherosclerosis is 
still under debate. Blockade of IL-17A in apoE-/- mice and IL-17A-/- apoE-/- mice showed 
reduced lesion development compared to control mice [212,213]. However, other studies 
showed that IL-17 deficiency had either no effect or resulted in a significant increase 
in lesion size [214,215]. The main function of regulatory T cells (Tregs) is the regulation 
of immune responses via the suppression of immune cell proliferation and cytokine 
production. In mice, Tregs express surface molecules CD4 and CD25, and the transcription 
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factor Forkhead box protein P3 (FoxP3). Furthermore, Tregs secrete large amounts of 
anti-inflammatory IL-10 and TGF-β, which is beneficial for dampening inflammation in 
atherosclerosis. Similarly, depletion of CD4+FoxP3+ cells in apoE-/- mice results in increased 
lesion formation [216]. 
CD8+ T cells recognize antigens via the MHC class I molecule, which is expressed on all 
nucleated cells. Upon activation cytotoxic CD8+ T cells secrete the cytotoxin perforin and 
granzymes that will induce apoptosis of the targeted cell. Furthermore, activated CD8+ T 
cells secrete large amounts of the proatherogenic IFNγ. CD8+ T cells are present in both 
human and murine atherosclerotic lesions but their role is still under debate [211,217,218].
B cells
Next to a powerful innate and cellular immune response in atherosclerosis, there is also a 
humoral response. B cells and plasma cells are key players in this response and produce 
antibodies towards modified self-antigens, such as oxLDL [210,219]. Both in human and 
murine serum samples IgG antibodies have been detected towards oxLDL, of which the 
amount correlates with the severity of the disease [219]. In mice, several B cell subsets have 
been identified; B1, B2 and B10 cells. B1 cells are known to produce natural IgM antibodies 
independent of T cell help. In atherosclerosis, these B1 cell produce oxLDL-specific IgM 
that is protective since it prevents foam cell formation and other inflammatory reactions 
towards oxLDL [220]. B2 B cells are the conventional B cells that are able to produce high 
titers of immunoglobulins reactive against several antigens like modified lipoproteins, 
which accelerate the immune response in atherosclerosis [210]. Depletion of B2 cells, but 
not B1 cells with an CD20 monoclonal antibody in atherosclerosis-prone apoE-/- and LDLr-
/- mice, resulted in a significant reduction of atherosclerosis [221,222], indicating that B2 
cells are atherogenic whereas B1 cells are atheroprotective in atherosclerosis. Of interest 
are B10 B cells that are able to produce IL-10 upon stimulation. A study that created 
chimeric LDLr-/- mice with a B cell specific deficiency in IL-10 showed that B cell derived 
IL-10 does not alter atherosclerosis in mice [223], but  more research is needed to unravel 
the role of this B cell subset.
CVD risk in RA patients
Since the introduction of immune targeting therapies in combination with DMARDs, 
the therapeutic efficiency in RA treatment has significantly increased [224]. Despite 
this important therapeutic progress, RA is still associated with elevated mortality rates, 
which are mainly caused by cardiovascular diseases like acute myocardial infarction, 
cerebrovascular accidents and congestive heart failure [225]. RA patients have accelerated 
progression of subclinical atherosclerosis compared to healthy age-matched controls 
that may precede the mentioned clinical events [226,227]. Analysis of carotid plaques 
in active RA patients showed a more unstable, rupture-prone plaque phenotype [228]. 
This atherosclerosis-prone phenotype in RA patients can only be partly be explained by 
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traditional risk factors like dyslipidemia, smoking, diabetes mellitus, hypertension and 
increased BMI [229].
The main common characteristic in both RA and atherosclerosis is the persistent systemic 
inflammation and immune dysregulation, which leads to synovial inflammation and 
destabilization of atherosclerotic lesions. In fact, both diseases share many inflammatory 
pathways like acute phase cytokines (TNFα, IL-6 and IL-1β) and the production of disease 
associated autoantibodies such as ACPA or anti-oxLDL-IgGs, which are implicated in the 
pathogenesis of both RA and atherosclerosis [219,230–232].
Presence or absence of ACPA not only influences the clinical progression and response 
to treatment, it also affects the extra-articular diseases like the cardiovascular risk in 
RA patients. Even though both ACPA negative and ACPA positive RA patients have a 
comparable clinical manifestation in the early phases of RA, the sero-positive patient group 
is associated with a more progressive disease in the established phase of RA. Furthermore, 
ACPA positivity is also associated with an increased risk in cardiovascular diseases like 
ischemic heart disease in RA patients [233]. ACPA may influence plaque progression and 
destabilization in RA patients, as it is known that ACPAs are able to recognize different 
citrullinated proteins and are cross-reactive [234], while it is also reported that citrullinated 
proteins are present within the atherosclerotic lesions as well as PAD3 enzymes that drive 
the citrullination [235–237]. Additional research should focus on the precise mechanisms 
how dysregulated (immune) pathways in RA contribute to the accelerated atherogenesis 
in RA patients. 
Aim of thesis
Rheumatoid arthritis and atherosclerosis are disorders affecting a large proportion of 
the world population. Although not completely understood, it is well accepted that the 
immune system plays a dominant role in the pathology and etiology of both diseases. As 
members of the innate immunity, mast cells are strategically located at surfaces that are in 
close contact with the external environment. Therefore they are one the first immune cells 
that respond to invading pathogens by the release of (preformed) mediators. Mast cells 
can also be found around blood vessels and in the joint in the synovial layer. Here, they 
can influence the micro-environment by the release of immune regulatory mediators that 
influence other local (immune) cells.
This thesis aims to obtain more insight in the role of mast cells in the immune driven 
disorders rheumatoid arthritis and atherosclerosis, as well as the potential contribution 
of mast cell activators like immunoglobulins to these diseases. The role of mast cells in 
rheumatic diseases is reviewed in chapter 2. Here we summarize the current physiological 
and pathophysiological role of mast cells in human arthritis and in mouse models of 
arthritis. Like in human RA, mouse models of arthritis are composed of a pre-clinical and 
a clinical phase of arthritis. In both phases it is thought that mast cells could play a role. In 
chapter 3 we took advantage of the mast cell inducible knockout mouse model to deplete 
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mast cells in either the pre-clinical or clinical phase of collagen induced arthritis. Depletion 
of mast cells in the pre-clinical phase, but not the clinical phase, significantly reduced the 
clinical score of the mice. Furthermore, the T cell phenotype in mast cell depleted mice 
show a marked reduction in arthritogenic Th17 T cells and an increase in protective FoxP3+ 
T cells, which coincided with a altered cytokine response towards collagen. Despite the 
fact that ACPA is highly specific for RA, we were able to detect ACPA in two cohorts of non-
RA cardiovascular patients. As described in chapter 4 we determined the CCP3 reactivity 
of sera from three cardiovascular cohorts (AtheroExpress, Mission and Circulating Cells). 
We found that a small proportion of non-RA cardiovascular patients were positive for CCP3. 
Clinical analysis showed a correlation with long-term mortality and CCP3 positivity in the 
MISSION! cohort.  Mast cells are implicated in both in human atherosclerotic lesion and in 
mouse models of atherosclerosis. There are a number of endogenous ligands described 
that could activate mast cells in the atherosclerotic plaque. In the study described in 
chapter 5 we aimed to find a correlation between either the number of mast cells or 
their activation status and circulating serum immunoglobulins. We were unable to detect 
a significant correlation with serum immunoglobulin levels and plaque characteristics, 
indicating that other (endogenous) ligands, besides immunoglobulins, might also activate 
mast cells in the atherosclerotic lesion. The study in chapter 6 presents a new mouse 
model is characterized to study the role of mast cell in atherosclerotic lesion development. 
We depleted mast cells before the induction of atherosclerotic lesions in this RMB-apoE-/- 
mouse model and detected a significant reduction in lesion size compared to mast cell 
competent mice. Furthermore, the mast cell depleted lesions were characterized by an 
increased collagen content and a reduced necrotic core size, suggesting that absence of 
mast cells in the early phases of atherosclerosis increases plaque stability. The involvement 
of mast cells in lesion progression is described in chapter 7. Using RMB-LDLr-/- mice we 
studied the effect of mast cell depletion on established lesions. While depletion of mast 
cells had no effect on lesion size, the phenotype of the plaque significantly changed 
towards a more stable plaque. We observed a reduced total macrophage area and an 
increased collagen content in lesions in mast cell depleted mice. Further analysis of 
circulating blood leukocytes showed a significant reduction in inflammatory monocytes 
and in serum we detected reduced levels of pro-atherogenic cytokines. Finally, all the 
results described in this thesis and future perspectives are summarized and discussed in 
chapter 8.
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Abstract
Rheumatoid Arthritis is a chronic autoimmune disease with a complex disease 
pathogenesis leading to inflammation and destruction of synovial tissue in the joint. 
Several molecules lead to activation of immune pathways, including autoantibodies, Toll-
Like Receptor ligands and cytokines. These pathways can cooperate to create the pro-
inflammatory environment that results in tissue destruction. Each of these pathways can 
activate mast cells, inducing the release of a variety of inflammatory mediators, and in 
combination can markedly enhance mast cell responses. 
Mast cell-derived cytokines, chemokines, and proteases have the potential to induce 
recruitment of other leukocytes able to evoke tissue remodeling or destruction. Likewise, 
mast cells can secrete a plethora of factors that can contribute to tissue remodeling and 
fibroblast activation. 
Although the functional role of mast cells in arthritis pathogenesis in mice is not yet 
elucidated, the increased numbers of mast cells and mast cell-specific mediators in 
synovial tissue of rheumatoid arthritis patients suggest that mast cell activation in 
rheumatoid arthritis may contribute to its pathogenesis.
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Pathogenic pathways in rheumatoid arthritis
Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic 
inflammation of the synovial lining of the joint, and is one of the most common autoimmune 
diseases affecting approximately 1% of the general population (Gabriel, 2001). Synovitis, 
inflammation of the synovial tissue, is mediated through leukocyte infiltration of the 
tissue, and leads to hyperplasia of fibroblast-like synoviocytes and tissue remodeling. 
Likewise, synovitis can induce cartilage destruction and bone erosion, ultimately leading 
to destruction of the joint. Clinically, synovitis induces pain and swelling of the involved 
joints, and the tissue destruction evoked can lead to disabilities if left untreated. 
It is currently believed that different cells of the immune system play a role in the 
pathogenesis of rheumatoid arthritis. However, the exact cause of rheumatoid arthritis is 
not known. Genetic risk factors (such as HLA) underlying disease susceptibility are often 
involved in T and B cell responses and the presence of activated B cells and T cells in the 
inflamed synovium of rheumatoid arthritis patients indicate that adaptive immunity plays 
a prominent role. Furthermore, the presence of autoantibodies in the majority of patients 
points towards an important role for B cells in rheumatoid arthritis. However, besides 
the role of adaptive immune cells in initiation of autoreactive responses, innate immune 
cells are thought to play an important role during the effector phase by sustaining 
inflammation.
Treatment is usually aimed at lowering disease activity via immunosuppression, which 
can be achieved in various ways including through the interference with B cell-mediated 
immunity, co-stimulatory pathways, and inhibition of proinflammatory cytokines, 
suggesting that these pathways play an important role in disease pathogenesis.
Autoantibodies
A major effector function thought to contribute to pathogenesis in rheumatoid 
arthritis is mediated by autoantibodies. The classical autoantibody system associated 
with rheumatoid arthritis is rheumatoid factor, which recognizes the Fc portion of IgG. 
However, rheumatoid factor is not specific for rheumatoid arthritis patients, as it is also 
produced in a number of other inflammatory conditions, therefore its role in disease 
pathogenesis is often questioned. An important group of autoantibodies in rheumatoid 
arthritis targets modified proteins, with anti-citrullinated protein antibodies (ACPA) being 
the most well-characterized. These antibodies recognize a variety of proteins or peptides 
in which the amino acid arginine is modified into a citrulline through a posttranslational 
modification process mediated by Peptidyl Arginine Deiminase (PAD) enzymes. PAD 
enzymes are normally present inside cells and can be activated by high calcium levels 
when cells, such as neutrophils, undergo apoptosis, an event readily occurring during 
inflammation (Gyorgy et al., 2006). PAD enzymes that are transported to the outside 
of cells can citrullinate the extracellular matrix and in doing so can create targets for 
ACPA. Citrullinated proteins can be found in a variety of inflamed tissues, including the 
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synovial tissue of rheumatoid arthritis patients (Baeten et al., 2001; Makrygiannakis et al., 
2006). ACPA can recognize many citrullinated proteins such as vimentin, filaggrin, and 
fibrinogen. Because fibrinogen and vimentin are also present in the extracellular matrix of 
the synovium, these proteins are often considered as important target antigens for ACPA 
(Klareskog et al., 2008).
ACPA show a very high specificity for rheumatoid arthritis, and are present in the 
majority (~70%) of rheumatoid arthritis patients (Nishimura et al., 2007; Schellekens et 
al., 2000). Since their discovery ACPA are mainly used as diagnostic marker. However, it 
is now becoming increasingly clear that ACPA might also play a functional role in the 
pathology of rheumatoid arthritis. Several observations underlie this notion. ACPA can 
be observed already years before the onset of symptoms, and rarely develop after onset 
of clinical manifestation of rheumatoid arthritis (Rantapaa-Dahlqvist et al., 2003; Ronnelid 
et al., 2005). The latter indicates that it is not likely that ACPA are a consequence of the 
inflammation present in rheumatoid arthritis patients. ACPA+ and ACPA- patients differ 
considerably with respect to the underlying genetic and environmental risk factors, 
suggesting that rheumatoid arthritis consists of two different disease entities: ACPA+ 
and ACPA- rheumatoid arthritis (Huizinga et al., 2005; Klareskog et al., 2006; Pedersen et 
al., 2007; van der Helm-van Mil et al., 2006). Furthermore, ACPA+ and ACPA- rheumatoid 
arthritis patients have a different disease course with ACPA+ patients having a more 
progressive disease, characterized by increased radiological joint damage and worse 
disease activity scores (Meyer et al., 2003; Ronnelid et al., 2005). These findings suggest 
that ACPA contribute to disease pathogenesis.
When ACPA antibodies are adoptively transferred into mice with a low-level synovial 
inflammation caused by anti-collagen antibodies, ACPA (reactive with citrullinated 
fibrinogen or collagen II) could enhance arthritis, implicating their direct involvement in 
the inflammatory process (Kuhn et al., 2006; Uysal et al., 2009).
Other autoantibodies present in rheumatoid arthritis patients include antibodies 
directed against carbamylated proteins, or anti-Carbamylated Protein Antibodies (anti-
CarP), another autoantibody directed towards modified proteins. Like ACPA, Anti-CarP 
are present before disease onset and associate with disease severity in (ACPA-negative) 
rheumatoid arthritis patients, and could potentially contribute to disease pathogenesis 
(Shi et al., 2011).
Toll Like Receptor ligands
Toll Like Receptor (TLR) activation is another important pathway for immune activation 
in rheumatoid arthritis. Although TLR are particularly known for their role in protection 
against pathogens, through their recognition of pathogen associated molecular patterns, 
endogenous ligands have been reported to trigger these receptors as well. Such 
endogenous ligands are present in conditions of stress or tissue damage, and often are 
intracellular molecules that can be either passively or actively released upon cell death. As 
52 | CHAPTER 2
rheumatoid arthritis, like other inflammatory conditions, is related to tissue destruction, 
cell death and the associated presence of endogenous TLR ligands is a common feature 
in synovium of patients. Several examples have been described of damage associated 
endogenous TLR ligands present in synovium, including HMGB1, heat shock proteins, 
tenascin c, and fibronectin (Gondokaryono et al., 2007; Martin et al., 2003; Midwood et al., 
2009; Pullerits et al., 2003; Taniguchi et al., 2003).
These endogenous ligands are thought to contribute to the chronicity of inflammation, 
as they can activate TLRs, inducing an inflammatory response, further tissue and cellular 
damage, and thereby the sustained release of damage associated TLR ligands. 
Next to damage-associated TLR ligands, cell death can also lead to release of PAD enzymes 
into the extracellular environment, leading to generation of citrullinated proteins, 
including fibrinogen. Citrullinated fibrinogen, one of the antigens recognized by ACPA, 
was shown to trigger TLR4 (Sokolove et al., 2011). Therefore, chronic inflammation is often 
related to release or generation of TLR ligands, leading to a self-amplifying inflammatory 
loop (Fig. 1).













Release of TLR 
ligands
Figure 1. Damage associated molecular patterns (DAMPs), cytokines and citrullinated proteins are 
all implicated in rheumatoid arthritis pathogenesis and are released upon inflammation, in particu-
lar in association with cell death. Both have been shown to activate mast cells: citrullinated proteins 
can form immune complexes with ACPA autoantibodies, and activate mast cells through Fc γ recep-
tors; DAMPs can activate mast cells through Toll Like Receptors (TLRs); various cytokines can activate 
mast cells. In the environment of the inflamed joint, all of these triggers are present at the same 
time, and together lead to synergy in mast cell activation. This synergy leads to enhanced tissue 
inflammation, in particular neutrophil influx, leading to cell death in the tissue. This cell death can 
lead to an amplification loop by generating more endogenous ligands and citrullinated proteins.
2
T helper cells
The strong genetic association of the HLA region with disease susceptibility suggests 
the involvement of T helper cells in the etiology of rheumatoid arthritis. The association 
to HLA-DR alleles is not completely understood, but is specifically related to the ACPA 
response and could therefore be attributed to the helper function of T cells by which they 
can drive autoantibody responses by B cells (van der Helm-van Mil et al., 2006).
However, T cells themselves may also exert pathogenic effects, for example through their 
production of cytokines. Initially, Th1 cells, producing IFNγ and TNFα were thought to drive 
the immune response in rheumatoid arthritis. Since discovery of a wide variety of T helper 
cell subsets, Th17 cells (producing IL-17) have been proposed as the most relevant subset 
of T cells in relation to arthritis, although their putative role in- or contribution to the 
pathogenesis of rheumatoid arthritis in humans is unclear (Benedetti and Miossec, 2014). 
Cytokines & chemokines: inflammatory mediators
The importance of proinflammatory cytokines in the pathogenesis of rheumatoid arthritis 
is well established. The development of biologic agents that target various immune 
mediators has dramatically improved the patient prognosis in the past decades, and most 
of these biologicals target cytokines or cytokine receptors. Established and approved 
therapies for rheumatoid arthritis block cytokine responses to TNFα and IL-6 (Smolen et 
al., 2007). Cytokines are produced in response to immune cell activation, and can activate 
cells in an autocrine, paracrine or systemic manner, leading to gene transcription of 
other cytokines, MMPs and other proinflammatory molecules. Thereby they contribute 
to the self-amplifying loop of immune activation. The cytokines mentioned above have a 
variety of target cells and functions, thereby able to trigger tissue inflammation, cartilage 
destruction, bone erosion and angiogenesis.
Activation of mast cells in rheumatoid arthritis
The mast cell is a potent immune cell from the myeloid lineage and is well-known for 
its granules containing inflammatory mediators which can be rapidly released upon 
activation. Mast cells reside at interfaces with the external environment, where they act as 
first line of defense against invading pathogens, such as parasites and bacteria. In addition, 
mast cells play an important role in allergic diseases (Sayed et al., 2008). As there is overlap 
in the mechanisms involved in hypersensitivity in allergy and autoimmune diseases, a role 
for mast cells in autoimmune disease has long been postulated. Several clinical findings 
support an active role of mast cells in rheumatoid arthritis pathogenesis, and suggest that 
mast cells are activated in the synovium of rheumatoid arthritis patients. 
Mast cell hyperplasia in synovium
It has been shown that increased numbers of mast cells are present in synovium of 
rheumatoid arthritis patients, with numbers up to 5% of the total cell number in synovium 
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(Crisp et al., 1984; Malone et al., 1986). Increased mast cell numbers, or so-called mast cell 
hyperplasia, is a hallmark of multiple autoimmune diseases.
Growth factors and cytokines in synovial tissue, such as stem cell factor, the critical 
growth factor for mast cell survival, as well as IL-3 and IL-4 are present in synovial tissue 
of rheumatoid arthritis patients. These mediators can induce proliferation of mast cells, 
whereas in addition, stem cell factor and TGFβ have been shown to induce recruitment of 
mast cells, (Olsson et al., 2001) suggesting that the accumulation of mast cells in synovium 
may be the consequence of an ongoing inflammatory response mediating mast cell 
expansion through increased recruitment and proliferation.
In addition to the accumulation of mast cells, it has been reported that the proportion of 
different mast cell subsets is changed in the synovium of rheumatoid arthritis patients. 
Two main subsets of mast cells exist based on the expression of proteases, divided in 
tryptase-only positive cells (MCT) and tryptase-chymase double-positive cells (MCTC). 
Whereas normal synovium mainly contains MCTC cells, early inflammation in rheumatoid 
arthritis is associated with a selective expansion of MCT, followed by increases of MCTC in 
established or chronic disease (Gotis-Graham and McNeil, 1997; McNeil and Gotis-Graham, 
2000; Olsson et al., 2001). These changes are often correlated with clinical characteristics; 
MCT numbers in early disease associate with inflammation, whereas the MCTC numbers 
in chronic disease associate with tissue remodeling features, which may underlie active 
involvement of both subsets in different pathological processes.
Mast cell mediators in synovial tissue or fluid
Mast cells produce a range of mediators, through three major pathways of secretion. First 
of all, they are characterized by presence of intracellular granules, containing preformed 
mediators such as histamine, proteases, proteoglycans, and heparin, which are rapidly 
released upon degranulation. Certain activation pathways can induce the release of 
lipid-derived mediators, produced from arachidonic acid, such as leukotrienes and 
prostaglandins. Finally, mast cell activation induces gene transcription, leading to de novo 
synthesis of cytokines, chemokines and growth factors, which can be released within 
several hours of activation.
Although most of de novo-produced cytokines are not mast cell-specific, several 
preformed granule proteins are more or less specifically expressed by mast cells, including 
the mast cell specific proteases tryptase and chymase. Both histamine and tryptase are 
elevated in synovial fluid of rheumatoid arthritis patients likely reflecting local mast cell 
activation (Buckley et al., 1997; Frewin et al., 1986; Lavery and Lisse, 1994; Malone et al., 
1986). Furthermore, mast cells have been reported to be the main IL-17-positive cells in 
the inflammatory joint of rheumatoid arthritis and spondyloarthropathy patients (Hueber 
et al., 2010). As discussed below, several of these mediators can contribute significantly to 
inflammation in the joint.
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Mast cell activation pathways in rheumatoid arthritis
Mast cells are most well-known because of their role in IgE-mediated immune responses 
as they express the high affinity FcεRI, and therefore have originally mainly been 
considered for their role in allergic diseases. However, the importance of mast cells in 
IgE-independent responses has been appreciated in the last decades, and has led to 
increased understanding of mast cell function in a variety of immune responses, including 
autoimmune disease. 
Mast cell activation by autoantibodies
Depending on their specific isotype, antibodies can exert immune activation by binding 
to cellular Fc receptors and activation of complement. Because various isotypes of ACPA 
(IgG, IgA, IgM) have been previously demonstrated, ACPA are, in principle, able to activate 
the immune system via both pathways (Verpoort et al., 2006).
The potential of ACPA to activate complement has been shown in vitro. ACPA bound 
to immobilized antigen activated the complement system, via both the classical and 
alternative pathways (Trouw et al., 2009). These pathways can activate mast cells, 
for examples through the cleavage product C5a. It has been shown in mice that C5aR 
activation of synovial mast cells is essential for the induction of arthritis (Nigrovic et 
al., 2010). However, in humans, it is not clear whether this pathway contributes to 
autoantibody-mediated mast cell activation. 
Besides indirect activation of immune cells via complement activation, autoantibodies 
can also directly activate cells upon crosslinking of Fc receptors, in particular Fcγ receptors 
(binding IgG), Fcε receptors (IgE), and Fcα receptors (IgA). As ACPA are mainly present as 
IgM and IgG isotypes, the binding of IgG-ACPA to Fcγ receptors is thought to play a major 
role in autoantibody-mediated pathogenesis.
Activating Fc receptors are predominantly expressed by myeloid immune cells, including 
mast cells. In mice, certain mast cell subsets, including synovial mast cells, express the 
activating FcγRIIIa, (Benhamou et al., 1990; Fang et al., 2013; Latour et al., 1992) the 
receptor involved in arthritis induced by anti-collagen autoantibodies (Díaz de Ståhl et 
al., 2002). Human mast cells have been shown to express FcγRIIA, whereas there is some 
controversy regarding expression of FcγRI (Jonsson et al., 2012; Lee et al., 2013; Suurmond 
et al., 2014a). We have recently shown that human cultured mast cells could be activated 
by ACPA immune complexes in a citrulline-dependent manner (Suurmond et al., 2014a). 
This activation was mediated through crosslinking FcγRIIA. As this receptor was expressed 
by synovial mast cells from all patients analysed, we propose that this receptor is a major 
player in autoantibody-mediated mast cell activation.
Mast cell activation by Toll like receptor ligands
Toll Like receptors (TLRs) are expressed by a variety of immune cells, and are considered 
to act as sentinels of the immune system. As mast cells are thought to play an important 
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role in protection against pathogens, their expression of TLRs has been studied in 
different cell subsets and species. Although some variation is present in expression of 
these receptors, mast cells generally express a wide variety of TLRs, and triggering of TLR 
by pathogen associated molecular patterns induces activation of mast cells (Kulka et al., 
2004; Matsushima et al., 2004; McCurdy et al., 2003; Varadaradjalou et al., 2003). 
Importantly, mast cells also express those TLRs that are thought to mediate responses to 
endogenous ligands released in inflammatory conditions. The main receptors involved in 
such responses are TLR2, TLR4 and endosomal TLRs which sense nucleic acids (Midwood 
et al., 2009; Piccinini and Midwood, 2010). 
We have recently shown that human mast cells indeed respond to HSP70, an endogenous 
ligand for TLR4, which is present in rheumatoid arthritis synovium (Suurmond et al., 
2014a). Another endogenous TLR ligand, the extra domain A of fibronectin, can induce 
joint inflammation in mice in a mast cell- and TLR4-dependent manner, (Gondokaryono et 
al., 2007) suggesting that this pathway of mast cell activation can contribute to pathogenic 
responses in RA.
Mast cell activation by cytokines
As described above, several cytokines or growth factors are involved in survival and 
expansion of mast cells in synovium. In addition, cytokines can activate mast cells directly. 
Such cytokines include IL-3, IL-4, IL-5, and IL-33, each of which are increased in synovial 
tissue or fluid of rheumatoid arthritis patients. However, stimulation of mast cells with 
cytokines alone usually mediates mainly proliferation with only a low level of activation. 
Importantly, the cytokine environment can play an important role in priming of mast cell 
responses to other triggers (Junttila et al., 2013). IL-33 has been shown to enhance arthritis 
in a mast cell-dependent manner, (Xu et al., 2008) suggesting that activation or priming of 
mast cells by cytokines can significantly alter inflammatory responses in the joint.
Mast cell - T cell interactions
The interaction between mast cells and T helper cells has been explored in recent years. 
In both human and mouse, mast cells have been shown to present antigens to CD4+ T 
cells, thereby enhancing T cell responses with the possibility of skewing specific T helper 
subsets as well (Gaudenzio et al., 2013; Kambayashi et al., 2009; Suurmond et al., 2013). 
Besides antigen presentation, mast cell-derived cytokines can also induce T cell activation 
(Nakae et al., 2005). Although we have recently shown that the interaction between T 
helper cells and mast cells does not only activate T cells, but can also change mast cell 
phenotype, the exact influence of T cells on mast cell function has been studied sparsely 
(Baram et al., 2001). Whereas regulatory T cells can inhibit mast cell activation, the effect 
of T cells involved in rheumatoid arthritis, such as Th17 cells, is not known (Gri et al., 2008; 
Kashyap et al., 2008). However, these cell types are likely to interact and it is tempting to 
speculate that such an interaction contributes to pathogenesis of rheumatoid arthritis. A 
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recent study indeed suggested that mast cells can regulate T cell responses in an arthritis 
mouse model, by inducing CD4+ T cell expansion and Th1 and Th17 cytokine secretion 
(Schubert et al., 2014).
Chronic inflammation mediated by a complex interplay of multiple pathways
As rheumatoid arthritis is characterized by the activation of multiple immune pathways, 
these pathways are likely to interact. For example, it has been shown for different types 
of myeloid cells that activation through TLRs synergizes with triggering of Fc receptors 
(Suurmond et al., 2014a; Suurmond et al., 2014b; Vogelpoel et al., 2014). As mast cells 
can be activated by different cytokines, several studies have investigated the interaction 
between cytokine- and FcεRI-mediated activation. These studies have shown increased 
degranulation and cytokine production when mast cells are exposed to combined 
triggers of e.g. IL-3, IL-4 and IL-33 with FcεRI crosslinking (Gebhardt et al., 2002; Lorentz et 
al., 2005; Ochi et al., 2000; Rivellese et al., 2014). Whereas these studies are important for 
understanding of the role of cytokines in allergic responses, Fcγ receptors, as compared to 
FcεRI, are probably more important for mast cell activation in rheumatoid arthritis. 
In this context, IL-33 was shown to enhance immune complex mediated mast cell 
responses through Fc γ receptors (Kashiwakura et al., 2013). In addition, we have studied 
the interaction of Toll Like receptor triggering on Fcγ receptor mediated mast cell 
activation, and shown that this greatly enhanced cytokine production by human mast 
cells (Suurmond et al., 2014a).  Importantly, we also showed this interaction was present 
in an antigen-specific system using ACPA autoantibodies and endogenous TLR ligands 
present in synovium.
Such a synergy between TLR or cytokines and Fc receptor responsiveness likely represents 
a physiological function of the immune system to mount an enhanced response when 
antibodies are produced after the first encounter of a pathogen (Abraham and St John, 
2010). Whereas this is conceivably highly beneficial when a pathogen needs to be 
eliminated, such responses in an autoimmune setting can drive chronic inflammation, 
because it can lead to further release of modified self-antigens and TLR ligands (Fig. 1). 
Therefore, synergy in mast cell responses may contribute to chronicity of rheumatoid 
arthritis.
Mast cell effector functions in rheumatoid arthritis
Mast cells are well-known for their potent and quick effector functions, such as present 
during allergic reactions. However, as tissue-resident cells, their physiological role is 
thought to be protection against pathogens, as well as to contribute to wound healing 
(Abraham and Malaviya, 1997). Therefore, it is not surprising that they also contribute to 
these processes during  autoimmune responses.
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Mast cell-mediated tissue inflammation
During certain bacterial infections, mast cells can orchestrate a local inflammatory 
response by rapidly increasing vascular permeability and releasing chemokines. Thereby 
they contribute to the recruitment of neutrophils and other immune cells, ultimately 
resulting in amplification of the local inflammatory response (Malaviya et al., 1996). 
Rheumatoid arthritis is also characterized by accumulation of immune cells. Whereas 
the synovial lining mainly contains monocytes/macrophages and T cells, synovial 
fluid is the site to which neutrophils are recruited. In humans, it has been shown that 
neutrophil chemoattraction to the synovial fluid is mainly mediated by IL-8, a cytokine 
produced (although not exclusively) by mast cells in response to ACPA autoantibodies 
and TLR ligands (Chen et al., 2001; Koch et al., 1991; Suurmond et al., 2014a). In mice, mast 
cell-derived TNFα and leukotriene B4 can both mediate neutrophil recruitment as well 
(Biedermann et al., 2000; Nigrovic et al., 2007; Zhang et al., 1995; Zhang et al., 1992). In 
addition, histamine can increase vascular permeability, thereby augmenting neutrophil 
recruitment (Fig. 2A) (Binstadt et al., 2006). 
These and other mast cell-derived chemokines can also induce recruitment of T cells 
and monocytes, although evidence indicating that this also occurs in the context of 
autoimmunity is scarce. Growth factors for neutrophils and macrophages, such as GM-
CSF and G-CSF are also produced by mast cells, suggesting that besides inducing cellular 
infiltration, mast cells may also contribute to survival of these cell subsets.
Crosstalk between synovial fibroblasts and mast cells
An important consequence of the chronic tissue inflammation present in rheumatoid 
arthritis is activation of synovial fibroblasts, also called fibroblast-like synoviocytes, the 
main stromal cell type of the synovium. Activation of synoviocytes in rheumatoid arthritis 
leads to their proliferation and reduced apoptosis, secretion of cytokines and chemokines 
and invasiveness, whereby synoviocytes invade the underlying cartilage/collagen tissue 
(Lafyatis et al., 1989).
Synovial fibroblasts can be activated by multiple pathways, including TLR activation, and 
cytokines (Pierer et al., 2004). Cytokines implicated in this process are TNFa, IL-1, and IL-
17 (Granet et al., 2004; Hot et al., 2012). Mast cells can produce each of these cytokines, 
thereby potentially contributing to activation of synovial fibroblasts (Fig. 2B). In addition, 
other mast cell mediators, such as histamine and tryptase have been shown to induce 
activation and inhibition of apoptosis in synovial fibroblasts cells as well (Sawamukai et 
al., 2010; Zenmyo et al., 1995).
Likewise, interaction between synovial fibroblasts can also lead to bi-directional crosstalk, 
whereby fibroblasts recruit and activate mast cells, for example through stem cell factor 
and IL-33 (Xu et al., 2008).
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Tissue remodeling sustained by mast cells
Tissue inflammation and activation of fibroblasts goes hand-in-hand with various tissue 
remodeling processes, characterized by angiogenesis, breakdown of cartilage and bone 
erosion. 
Angiogenesis occurs mainly in the synovial lining of the joint, where rapid-growing 
fibroblasts and infiltrating immune cells require increased amounts of nutrients and 
oxygen supplied through the blood. Angiogenesis is mediated by growth factors such as 
VEGF and FGF, and angiogenic cytokines such as IL-8, TNFα and GM-CSF, but can also be 
mediated by mast cell granule-derived mediators such as heparin, tryptase and chymase 
(Fig. 2C) (Azizkhan et al., 1980; Blair et al., 1997; Muramatsu et al., 2000; Paleolog, 2002). 
Mast cells are often found in close proximity to blood vessels, and their numbers are often 
associated with angiogenesis, especially in the context of tumors and wound healing 
(Ribatti, 2013; Wulff and Wilgus, 2013). Although no functional data are available on the 
direct role of mast cells in synovial angiogenesis, their secretion profile suggests that they 
may contribute this process. 
The two main destructive processes in rheumatoid arthritis are cartilage breakdown 
and bone erosion. Synovial fibroblasts, next to chondrocytes have been implicated in 
cartilage breakdown. Both cell types secrete matrix degrading enzymes such as matrix 
metalloproteinases (MMPs) (Tolboom et al., 2002). These enzymes can break down 
extracellular matrix proteins such as collagen, aggrecan and fibrinogen. An important 
feature of MMPs is their secretion as inactive pro-enzymes which need to be cleaved by 
other MMPs or other proteinases to become activated (Van Wart and Birkedal-Hansen, 
1990). As this cleavage occurs in the extracellular space, the proteases required for 
cleavage can be derived from different cellular origins. In this respect, mast cell tryptase 
could play a prominent role as it is known for its ability to activate MMPs (Gruber et al., 
1988; Magarinos et al., 2013). In doing so, mast cells can contribute to loss of cartilage 
through activation of MMPs via secretion of tryptase (Fig. 2C).  
Osteoclast activation is the main mechanism leading to bone erosions. Although mast 
cells are not known to release RANKL, a major factor involved in osteoclast activation, 
mast cells may contribute to setting the balance in bone homeostasis. For example, 
patients with mastocytosis (systemic mast cell hyperplasia) exhibit features of accelerated 
bone turnover, possibly through a direct effect of histamine on osteoclasts (Nakamura et 
al., 1996; Seitz et al., 2013).
In summary, mast cells can secrete a variety of mediators which are implicated in many of 
the basic pathogenic hallmarks of rheumatoid arthritis.
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Figure 2. Mast cell contribution to pathogenic processes in rheumatoid arthritis.
(A) Activated mast cells can amplify tissue inflammation through several mechanisms. They increase 
vascular permeability through release of histamine, leading to increased recruitment of immune 
cells. In particular, neutrophils are recruited into synovial fluid by chemokines such as IL-8, TNFα, 
and leukotrienes, whereas monocytes and T cells are recruited to the synovial tissue through 
chemokines such as TNFα, CCL2, and CCL5. 
(B) Mast cells in synovium have a bidirectional interaction with fibroblasts, whereby fibroblasts can 
activate mast cells through growth factors and cytokines (SCF, IL-33), and activated mast cells in 
turn can  activate synovial fibroblasts. Mast cell degranulation can induce proliferation of fibroblasts 
by histamine and tryptase, and cytokine production by mast cells (TNFα, IL-1, IL-17) can led to 
activation of synovial fibroblasts. Together, this crosstalk can induce fibroblasts invading into the 
underlying cartilage tissue. 
(C) Mast cell-derived cytokines and proteases can contribute to increased angiogenesis,a process 
required for the increased metabolic demand in inflamed tissue. Furthermore, various mast cell 
proteases can lead to extracellular MMP cleavage, leading to their activation, a crucial process in the 
breakdown of cartilage.
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Mouse models for arthritis and mast cell involvement
Arthritis mouse models
Insight in the contribution of mast cells to pathogenesis of rheumatoid arthritis has also 
been obtained using models of experimental arthritis. 
The first study to show an important role for mast cells in arthritis was performed in mice 
deficient in kit signaling, KitWKitW-v mice. In this study, experimental arthritis, induced by 
K/BxN serum transfer, was completely abolished in the absence of mast cells. Transfer of 
cultured bone marrow derived wild-type mast cells to mast cell deficient mice restored 
the incidence of arthritis after K/BxN serum transfer, indicating a direct effector function 
of mast cells in the development of arthritis (Lee et al., 2002). The critical role of mast cells 
for development of arthritis in this model has boosted the recognition of mast cells as a 
non-redundant cell in the development of autoimmune disease.
However, the findings from this study have been recently challenged in different models 
(Table 1). First of all, KitW-Sh/KitW-Sh mice, another mast cell deficient mouse due to defect 
kit signaling, were able to develop arthritis after passive transfer of anti-collagen type II 
antibodies (Zhou et al., 2007). In addition, KitWKitW-v mice had normal arthritis development 
in the collagen induced arthritis model (Pitman et al., 2011). Unlike neutropenic KitWKitW-v 
mice, KitW−sh/W−sh mice have a baseline pro-inflammatory phenotype, including neutrophilia 
(Michel et al., 2013; Nigrovic et al., 2008). Therefore, these confounding results have 
sometimes been attributed to the neutrophilia in KitW−sh/W−sh mice, which renders them 
insensitive to mast cell-mediated neutrophil recruitment, a critical event in early arthritis 
development (Brown and Hatfield, 2012). 
Of the mast cell deficient mouse models independent of kit,  two models have been used 
to study arthritis. In one study, the Cpa3Cre/+ mice, which are mast cell deficient, were fully 
susceptible to the induction of serum-induced arthritis and clinical scores, histology and 
gene expression analysis were comparable to wild-type mice (Feyerabend et al., 2011). 
Therefore, it was concluded that the role of mast cells in arthritis is limited. Whereas mast 
cell deficiency using Mcpt5-Cre iDTR mice did not affect serum-induced arthritis either, 
these mice experienced reduced arthritis upon immunization with collagen, (Schubert 
et al., 2014) suggesting that further research is needed to increase our understanding of 
these discrepancies.
Despite these contradictory findings using mice with a complete mast cell deficiency, 
additional evidence for mast cell-mediated pathogenesis in arthritis comes from studies 
using mice deficient in mast cell-specific proteases, such as chymase or tryptase. Mice 
deficient in mMCP4, the homologue of human chymase, develop less severe arthritis 
upon collagen induced arthritis (Magnusson et al., 2009). Mice which are deficient in 
either tryptase mMCP6 and/or -7, especially in combination with heparin-deficiency, 
display a reduced severity of adjuvant-induced arthritis and K/BxN induced arthritis (for 
mMCP6 deficiency) (McNeil et al., 2008; Shin et al., 2009). In addition, mast cell-specific 
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(Mcpt5-Cre-mediated) deficiency in A20, a regulatory molecule, leads to increased mast 
cell activation, thereby exacerbating collagen induced arthritis (Heger et al., 2014). 
As most of these mouse models contain a single deficiency in a mast cell-specific mediator, 
and are therefore not associated with any other defects such as the kit mutant mice, 
these studies provide compelling evidence for mast cell involvement in arthritis, despite 
the contrasting data obtained with mast cell deficient mouse models. Therefore, more 
research is needed to increase our understanding of the role of mast cells in rheumatoid 
arthritis.
Pharmacological inhibition of mast cells
As several lines of evidence suggest a role for mast cells in rheumatoid arthritis, intervention 
with mast cell activation could potentially form novel therapies. The drug cromolyn is 
clinically used as a treatment for asthma patients. The exact mechanism of cromolyn in 
not completely understood, but it is described to prevent the release of mast cell specific 
mediators like histamine from rat peritoneal cells (Cox, 1967). Cromolyn is described 
as a mast cell stabilizing agent and is used frequently in mouse studies. The effect of 
cromolyn as a prolactive on CIA was investigated in DBA/1 mice. A lower clinical score and 
radiographic score were observed compared to non-treated mice, when cromolyn was 
administered when first symptoms of clinical arthritis became evident (Kobayashi et al., 
1999). In addition, it was shown that intra-articular treatment of cromolyn or salbutamol 
prevented angiogenesis, pannus formation and joint destruction in mice.(Kneilling et al., 
2007) Recently however, the specificity of cromolyn and the sensitivity of different types 
of mast cells to cromolyn in mice is under debate (Oka et al., 2012). Also, the specificity of 
salbutamol can be questioned since it has also inhibits the secretion of pro-inflammatory 
cytokines by macrophages and T cells (Kneilling et al., 2007). Therefore, development 
of mast cell-specific therapeutics is needed to establish the exact role of mast cells in 
rheumatoid arthritis.
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K/BxN Mast cell deficient mice 
resistant to develop 
arthritis. Restored  with 
systemic or local en-
graftment of BMMCs
Kneilling et al., 
2007; Lee et al., 
2002
CIA No effect of mast cell 
deficiency
Pitman et al., 2011
KitW-Sh/KitW-Sh Mast cell deficient 





No effect of mast cell 
deficiency
Zhou et al., 2007
Cpa3-Cre
(cre-master)
Mast cell deficient 
through Cre-mediat-
ed toxicity
K/BxN No effect of mast cell 
deficiency
Feyerabend et al., 
2011
Mcpt5-Cre iDTR Mast cell deficient 
upon injection of 
DT (only connective 
tissue-like MC)
K/BxN No effect of mast cell 
deficiency
(Schubert et al., 
2014)
CIA Reduced arthritis in 
mast cell deficient mice
Mast cell protease-deficiency







K/BxN Reduced arthritis Shin et al., 2009
NDST-2-/-
& Combinations
mBSA/IL-1β Reduced arthritis McNeil et al., 2008
Mast cell-conditional knockout
A20-deficiency Mcpt5-Cre A20Fl/Fl CIA Exacerbated arthritis Heger et al., 2014
Pharmacological mast cell inhibition
Cromolyn (not mast cell 
specific)
CIA Reduced arthritis Kneilling et al., 
2007; Kobayashi et 
al., 1999
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Table 1. Overview of experimental arthritis in mast cell-deficient or mast cell protease-deficient 
mice
Conclusions
Rheumatoid arthritis is a complex autoimmune disease caused by environmental and 
genetic interactions leading to a chronic activation of many (immune) cells in the synovial 
tissue. The pathology of rheumatoid arthritis involves multiple activation pathways and 
interactions between a variety of cell types with arthritogenic functions leading to the 
progression of joint destruction.
Mast cells can also be found in rheumatoid arthritis tissue, which indicates a possible role 
for this potent cell in the disease pathology. Many in vivo arthritis studies in mice have 
aimed to clarify the precise role of mast cells. However, since mouse models do not fully 
reflect the disease process and as some models for mast cell deficiency have additional 
non-mast cell defects, it is difficult to assess the specific role of mast cells on disease 
pathogenesis in vivo. 
Nevertheless, mast cells have the capacity to respond to a wide range of activating ligands 
in synovium and their effector functions likely reflect their potential role in pathogenesis 
of rheumatoid arthritis.
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Abstract
Background 
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease, which is characterized 
by inflammation of synovial joints leading to the destruction of cartilage and bone. 
Infiltrating mast cells can be found within the inflamed synovial tissue, however their role 
in disease pathogenesis is unclear. Therefore we have studied the role of mast cells during 
different phases of experimental arthritis.
Methods 
We induced Collagen-Induced Arthritis (CIA), the most frequently used animal model of 
arthritis, in an inducible mast cell knock-out mouse and determined the effect of mast cell 
depletion on the development and severity of arthritis.
Results 
Depletion of mast cells in established arthritis did not affect clinical outcome. However, 
depletion of mast cells during the pre-clinical phase resulted in a significant reduction 
in arthritis. This reduction coincided with a decrease in circulating CD4+ T cells and 
inflammatory monocytes but not in the collagen-specific-antibody levels. Mast cell 
depletion resulted in reduced levels of IL-6 and IL-17 in serum. Furthermore, stimulation of 
splenocytes from mast cell depleted mice with collagen type II resulted in reduced levels 
of IL-17 and enhanced production of IL-10. 
Conclusions 
Here we show that mast cells contribute to the pre-clinical phase of CIA. Depletion of 
mast cells before disease onset resulted in an altered collagen specific T cell and cytokine 
response. These data may suggest that mast cells play a role in the regulation of the 
adaptive immune response during the development of arthritis.
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Introduction 
Rheumatoid arthritis (RA) is characterized by progressive inflammation of the synovial 
joints that leads to the breakdown of cartilage and bone, eventually resulting in 
malformation of hands and feet, thereby reducing the quality of life for the patient 
[1]. In the western world, RA affects around 0.5 – 1% of the general population [2]. The 
etiology and pathology of RA are not completely understood and environmental and 
genetic factors are thought to play a role in disease pathogenesis [3,4]. Various types of 
immune cells, such as macrophages, B cells, T cells and mast cells have been described to 
contribute to the initiation and progression of joint destruction [5]. Mast cells are potent 
innate immune effector cells and accumulate in the synovium during RA progression. 
Over time, mast cells can account for up to 5% of all nucleated cells within the inflamed 
synovial tissue [6,7]. Mast cells express a wide range of surface-receptors that allow them 
to be activated by different ligands, such as IgE, cytokines, (endogenous) TLR ligands 
and IgG-immune-complexes [8]. Many of these ligands have been detected within the 
inflamed synovial tissue of RA patients. Depending on the activation route, mast cells can 
release a wide range of preformed mediators such as chymase, tryptase and histamine 
and can also release cytokines and chemokines [9]. The precise role of mast cells in the 
pathogenesis of RA is unknown, but activation of synovial mast cells could potentially 
contribute to the further progression of joint destruction either by the recruitment of 
leukocytes such as neutrophils and monocytes but could also facilitate the breakdown 
of cartilage in the joint by activating osteoclasts via release of mediators like histamine 
[10,11]. To date several mouse studies have been conducted to study the role of mast cells 
in experimental arthritis. Different results were obtained in these studies, which could 
potentially have been caused by the choice of mast cell deficient mouse strain or the 
method of arthritis induction [12–15]. However, most of these studies were performed in 
arthritis models based on the infusion of autoreactive antibodies such as with the K/BxN 
model. The pathogenesis of K/BxN model is based on the transfer of serum containing 
anti-glucose-6-phosphate (GPI) antibodies obtained from K/BxN mice. Infused anti-GPI 
antibodies in recipient mice will home to distal joints were they form immune complexes, 
which activate an inflammatory response via complement receptors, Fc receptors and is 
future depended on production of TNFα and IL-1. Adaptive immune cells such as T cells 
are reported not to be required for disease induction in this model [16,17]. Nonetheless, T 
cells are thought to play a major role in RA, therefore we studied mast cells in the collagen 
induced arthritis (CIA) model where T cells contribute significantly to the initiation of 
the pathogenic immune response [18,19]. For example, in a study conducted by Jansen 
et.al. CD4+ T cells were depleted in CIA mice using either abatacept or a CD4+ depleting 
antibody. This depletion resulted in a significant reduction of collagen specific antibodies, 
which coincided with a lower disease activity [20]. This study confirms the importance of T 
cells in the early phases of CIA in the establishment of a strong humoral immune response 
towards collagen type II. CIA has many similarities with RA, like cartilage degradation, 
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fibrin deposition, mononuclear infiltration, synovial cell hyperplasia, pannus formation, 
periosteal bone formation and eventual ankyloses of one or more joints [18]. Comparable 
to human RA, CIA is composed of a preclinical (prodromal) and a clinical phase. The 
preclinical phase is defined as the period following the initial immunization with collagen 
and preceding the onset of clinical symptoms, and could be considered as a model for the 
prodromal stage of RA in which the underlying auto-immune response is already present 
but there is no visible manifestation of clinical symptoms. The clinical phase of CIA is 
characterised by an irreversible destruction of synovial joints. Recently, it was reported 
that depletion of mast cells in MCPT5-Cre-iDTR mice, before the first immunization with 
collagen type II (CII), could reduce the clinical outcome by altering the T cell subsets in the 
draining lymph nodes [21]. 
Although the role of mast cells in the initial onset of the pathogenic immune response 
is of great scientific importance, information about mast cells in later stages of disease, 
might be more helpful for potential therapeutic intervention. Therefore the aim of this 
current study is to further dissect the role of mast cells in arthritis by depletion of them 
during these later phases of the disease.
To this end, we made use of the red-mast cell basophil (RMB) mouse, which is a novel 
mast cell inducible knock-in mouse strain based on the transgenic expression of the 
simian diphtheria toxin receptor (DTR). Normally, mice are resistant to diphtheria toxin 
(DT) but cells who express the DTR will become highly sensitive to DT, which will cause 
apoptosis after challenges with DT. In the RMB mice, the DTR is expressed under control 
of the promoter from the β-chain of the high affinity receptor for IgE (FcεRI) [22]. In mice, 
mast cells and basophils express a high affinity receptor for IgE (FcεRI) composed of one 
alpha, one beta, and two gamma chains, which is essential for cell surface expression 
[23]. Although it has been reported that other immune cells such as dendritic cells and 
monocytes can express the FcεRI these cells lack the β-chain of the receptor [24,25]. In 
summary, only basophils and mast cells express the β-subunit, which allows a cell specific 
ablation in this current mouse model [22,23,26,27]. As reported previously, basophils are 
depleted only for a short period of time (<12 days) and the depletion of mast cells lasts 
at least above 6 months in the peritoneal cavity [22]. In this study, we employed the RMB 
mouse to determine the contribution of mast cells to the pre-clinical and clinical phase of 
arthritis by depleting mast cells during these stages.
Material and Methods
Mice
All animal work was performed conform national guidelines and experiments were approved by the animal 
welfare committee of the Leiden University Medical Centre. 
The red mast cell and basophil mice (RMB or B6; B6.Ms4a2tm1Mal mice) [22] were backcrossed for one generation 
with wild-type DBA/1 mice (Harlan BV, The Netherlands) in order to obtain mice that are highly susceptible for 
collagen induced arthritis and in which FcεRIβ expressing cells can be depleted by injection of DT.
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Collagen Induced Arthritis and Collagen Antibody Induced Arthritis
Collagen Induced Arthritis (CIA) was induced in 8-10 week old male RMB-DBA/1 mice by injection in the tail 
base with 100 μg of bovine collagen type II (CII) (2mg/mL) (Chondrex Inc. (US) emulsified in Complete Freund’s 
Adjuvant (CFA) (1 mg/mL; Difco (US)). On day 21 the mice received a subcutaneous boost with 100 μg CII in 
incomplete Freund’s adjuvant (Difco) [28]. 
Collagen antibody induced arthritis was induced by intravenous injection of 1 mg anti-collagen antibodies 
(Athrogen 5 Clone 2 Chondrex (US)) intravenously on day 0 [29]. A clinical score was assigned based on a scoring 
protocol in which each swollen or red phalanx was given 0.5 point and 1 point per toe. A red or swollen knuckle 
was given 1 point, a red or swollen footpad was given 1 point and a swollen ankle and/or wrist were given 5 
points. The maximum score for each paw was 15 points, resulting in a maximum possible score of 60 points per 
mouse. For the immunoglobulin levels, mice were bled before immunization, on day 21, and at the end of follow 
up. Blood was centrifuged and serum was harvested and stored at −20°C until use.
In vivo depletion of FcεRIβ+ cells
To systemically deplete all FcεRIβ+ cells mice were injected i.p. for three times with a one day interval with 1 μg 
Diphtheria Toxin (DT) (DT Unnicked, C. diphtheria (Cat #322326), CalBiochem (US), (40 ng/g bodyweight).
To deplete mast cells and basophils in the clinical phase of arthritis, mice received either DT or PBS upon clinical 
manifestation of arthritis. The mice were divided over two groups with a similar clinical score at the day of 
injection. Mast cells and basophils were depleted in one group by i.p. DT injection, while the control group 
received i.p. injections with PBS.
To deplete mast cells in the pre-clinical phase of arthritis, mice were injected with either DT or PBS starting 7 
days after the first immunization. Efficiency of depletion was measured by FACS analysis for circulating basophils 
(CD49b+/FcεRI+/IgE+) three days after last DT injection. At sacrifice mast cells in the joint were visualized by 
staining with a napthol AS-D chloroacetate easterase staining kit (CAE) (Cat# 91C-1KT, Sigma-Aldrich, Germany). 
For a schematic overview of the arthritis experiment, see supplemental figure 1.
Histology
Hind legs of arthritic mice were harvested at end of the study. Tissues were fixed in 4% formalin and decalcified 
in PBS containing 10% EDTA for 14 days before embedding into paraffin. 5 µm thick sections were cut and either 
a toluene blue staining or an enzymatic staining (CAE), was performed to quantify the amount of mast cells.
To analyse the joint inflammation, sections were stained with haematoxylin and eosin (H&E). Histopathological 
changes were scored using the following parameters; 0: No inflammation, 1: hyperplasia of the synovial layer, 
infiltration of leukocytes into the joint 2: Pannus formation 3: Destruction of cartilage 4: Destruction of bone and 
extensive infiltrates. The sample treatment protocol was withheld from the evaluators to prevent bias.
Flow cytometry
At sacrifice, blood was obtained in EDTA tubes and erythrocytes were removed using a specific erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3).
Blood leukocytes were stained extracellularly to determine a) monocytes (NK1.1-/Ly6G-/CD11bhi), inflammatory 
monocytes (NK1.1-/Ly6G-/CD11bhi/Ly6Chi/CCR2+) and neutrophils (NK1.1-/Ly6Ghi/CD11bhi), b) basophils (CD3-/
3
CD4-/CD19-/CD8-/CD49b+/IgE+/CD117-), c) T cells (CD3+/CD4+) and d) B cells (CD19+/B220+). The antibodies used 
(eBiosciences, US) are summarized in table 1. Flow cytometry analysis was performed on the FACSCantoII and 
data were analyzed using FACSDiva software (Becton Dickinson, US).
Table 1: Antibody panels used for flow cytometry analysis.









































At sacrifice, a single cell suspension was prepared from the spleen by using a 70 μm cell strainer (Falcon, US). 
Erythrocytes were removed using a specific erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, 
pH 7.3). 
Regulatory T cell numbers were determined by staining extracellular with eFluor-450 conjugated rat anti mouse 
CD4. Next, cells were fixed and permeabilized according to supplier’s protocol (eBiosciences). Subsequently, 
cells were stained with APC conjugated rat anti-mouse/human FoxP3 or corresponding isotype as a control 
(eBioscience).
To determine inflammatory Th17 T cell phenotype in the spleen, 400.000 splenocytes/well were cultured in 96 
well round-bottom plates (Greiner Bio-One, The Netherlands) and stimulated with anti-CD3 and anti-CD28 (2 
μg/mL each, eBioscience) in complete IMDM, supplemented with 10% heat inactivated fetal calf serum, 100 u/
mL penicillin/streptomycin, 2 mM L-Glutamine (PAA, Austria) and 20 mM β-mercaptoethanol (Sigma-Aldrich). 
After 1 hour, brefeldin A (Sigma-Aldrich) was added up to a concentration of 10 μg/mL to inhibit secretion of 
the cytokines. After an additional 4 hours of incubation, cells were washed twice with FACS Buffer (PBS, 1% BSA, 
2mM EDTA) and stained for T cell surface markers.
Cells were first stained with eFluor-450 conjugated rat anti mouse CD4. Next, cells were fixed and permeabilized 
according to supplier’s protocol (eBiosciences), followed by intracellular staining with PE conjugated rat anti-
mouse IL-17 or corresponding isotype as a control (eBioscience). 
For the determination of the cytokine profile, splenocytes were cultured at 300.000 cells/well in triplicate and 
stimulated with either αCD3/28 (2 μg/mL each) or 50 μg/mL collagen type II for 96 hours, while unstimulated 
cells served as controls. Subsequently, the supernatant was collected for cytokine analysis. 
Serum immunoglobulin detection and cytokine levels
Total IgG1, IgG2a, IgG2c and IgE serum levels were determined by ELISA according to manufacturer’s manual 
(Bethyl, US). Collagen specific IgG1, IgG2a, IgG2c and IgE were determined using an in-house ELISA procedure. 
In short, bovine collagen was coated overnight at a concentration of 10 μg/mL in carbonate-bicarbonate buffer 
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(pH9,6) on NUNC Maxisorp plates. Plates were washed with PBS/0,05% Tween20, and blocked with PBS/10% milk 
for 2 hours. After washing, the plates were incubated with 1/8000 diluted serum in PBS/1% BSA/ 0,05% Tween20 
for 18 hours at 4C°. The different Igs were detected using an HRP-conjugated goat anti-mouse Ig antibody 
(Southern Biotec, US) diluted in PBS/1% BSA/ 0,05% Tween20. HRP enzyme activity was visualized using ABTS. 
As a standard, serial dilutions of a pooled serum sample from mice with CIA were used. Cytokine levels were 
determined using a commercially available ELISA kit (BD: IL-6, TNF, IFNγ, IL-10) and eBiosciences (IL-17A). All 
cytokine ELISA’s were performed according to manufacturer’s protocol.
Statistical analysis
Data are expressed as mean ± SEM. All data presented was tested with the Shapiro-Wilk test for normal 
distribution. An unpaired two-tailed Student T-test was used to compare normally distributed data between two 
groups of animals. Data of two groups with more than one variable were analysed by two-way ANOVA followed 
by Bonferroni post hoc test.
Clinical scores of mice were compared by calculating the area under the curve (AUC) of the clinical score from 
each mouse overtime followed by an unpaired two-tailed Student T-test. Statistical analysis was performed 
using Prism (Graphpad). Probability values of P<0.05 were considered significant.
Results
FcεRIβ+ cell depletion in established arthritis does not reduce clinical score or delay disease 
progression 
Arthritis is characterized by a constant activation and recruitment of immune cells into 
the joint leading to the destruction of cartilage and bone. Mast cells accumulate in the 
inflamed joint and could therefore actively contribute to the disease progression in CIA. 
To investigate the contribution of mast cells to the progression of established CIA in RMB-
DBA/1 mice, FcεRIβ+ cells were depleted in the effector phase of the disease (Suppl. Fig 
1a.). As shown in figure 1a, depletion of FcεRIβ+ cells after clinical manifestation of CIA 
had no effect on the clinical score. In both groups we detected similar levels of specific 
immunoglobulins towards collagen type II (CII) in serum (Fig. 1b). Mast cells were present 
in the joints of saline treated mice, whereas mast cell were completely absent in DT 
treated mice (Fig. 1c). Further analysis of the different blood leukocyte populations by flow 
cytometry showed no differences in percentages basophils, neutrophils, (inflammatory)-
monocytes, CD4+ T cells and B cells (Fig. 1d). Taken together, these data indicate that 
depletion of FcεRI+ cells after the onset of CIA did not affect progression of CIA.
To further study the role of mast cells in the effector phase of arthritis we used the collagen 
antibody-induced arthritis (CAIA) model in RMB-DBA/1 mice [29]. Unlike the CIA model, 
this model does not require an active adaptive immune response towards collagen type 
II. The CAIA model depends on the injected pathogenic anti-collagen antibodies and 
resembles the effector phase of collagen induced arthritis after the adaptive immune 
response has developed. 
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Figure 1. Depletion of FcεRIβ+-cells in clinical phase of CIA does not influence clinical 
outcome in RMB-DBA/1 mice.  
(A) Progression of CIA was monitored by clinical scoring of RMB-DBA/1 mice injected with either 
PBS or DT (n=15/group). (B) Serum levels of IgG1, IgG2a, IgG2c and IgE isotype antibodies directed 
against collagen type II were quantified in serum from PBS or DT injected RMB-DBA/1 mice (n=15/
group). (C) Mast cell numbers were determined in ankle joints of PBS and DT treated mice (n=15/
group). Arrows show mast cells in the joint. (D) FACS analysis for common peripheral leucocytes in 
both groups (***P<0.001). 
A representative example of 2 independent experiments is depicted.
Mast cell deficient or competent RMB-DBA/1 mice were i.v. injected with anti-collagen 
antibodies and scored daily for arthritis development (suppl. Fig. 1b). We did not observe 
a significant difference in clinical score between both groups (Fig. 2a). At sacrifice, a 
total mast cell depletion was confirmed in the joints of DT treated mice (Fig. 2b). Flow 
cytometry analysis of the blood compartment showed no significant differences in blood 
leukocytes subsets (basophils, neutrophils, monocytes, inflammatory monocytes, T cells 
and B cells) as depicted in Figure 2c. These findings suggest that mast cells do not play a 
role in experimental arthritis once arthritis and a fully developed and the anti-collagen 
type II antibody response has been developed. 
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Figure 2. Clinical outcome of collagen antibody induced arthritis (CAIA) is independent of 
FcεRIβ+-cells. 
(A) Progression of CAIA induced arthritis in both mast cell competent and depleted RMB-DBA/1 
mice (n=6/group). (B) Mast cell numbers in the ankle joint of PBS and DT injected RMB-DBA/1 mice 
(n=6/group). (C) FACS analysis for common peripheral leucocytes in both groups (n=6/group). 
3
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Figure 3. Absence of FcεRIβ+-cells during preclinical phase of CIA reduces clinical outcome of 
arthritis in effector phase of disease. 
(A) Progression of CIA was monitored by clinical scoring of RMB-DBA/1 mice, which have been 
injected with either PBS or DT in the preclinical phase of CIA. (n=15/group). (B) Serum levels of IgG1, 
IgG2a, IgG2c and IgE isotype antibodies directed against collagen type II were quantified in serum 
from PBS or DT injected RMB-DBA/1 mice (n=15/group). (C) Mast cell numbers were determined 
in ankle joints of PBS and DT treated mice (n=6/group). Arrows show mast cells in the joint. (D) 
Histological score of joint inflammation in the ankle joint of PBS and DT treated mice (n=15/group). 
Representative H&E stained sections of ankles obtained from PBS and DT treated RMB-DBA/1 mice. 
*P<0.05. A representative example of 2 independent experiments is depicted.
Absence of mast cells in the pre-clinical phase of CIA reduces clinical outcome
Mast cells can secrete various mediators that can regulate the immune response. Therefore 
mast cells could potentially influence the clinical course of arthritis by regulating collagen-
specific B and T cell response required for the development of disease. The CII-specific 
response starts to develop directly after the first immunization, but mice typically do not 
develop arthritis until after the booster injection 3 weeks later. To investigate whether 
mast cells can play an immunoregulatory role during this phase of disease, we depleted 
FcεRIβ+ cells in RMB-DBA/1 mice 7 days after the first immunization as schematically 
shown in supplementary figure 1c.
Absence of FcεRIβ+ cells in the pre-clinical phase of CIA resulted in significantly lower 
clinical score (AUC: PBS 246±16 vs. DT 183±15, p=0.0085) (Fig. 3a). Depletion of FcεRIβ+ 
cells did not affect anti-collagen type II antibody titers (Fig. 3b). Histological analysis 
showed a complete depletion of mast cells in the joints of DT treated mice (Fig. 3c), 
whereas in PBS treated mice mast cells were present in the affected joints. Further analysis 
of the joint inflammation in both groups showed a significant reduction in histological 
score in FcεRIβ+ cell depleted mice (Fig. 3d). 
At the end of follow up (day 45), we detected reduced serum levels of the inflammatory 
cytokines IL-6 (PBS 510±52 vs. DT 339±46 pg/mL, p=0.02) and IL-17 (PBS 521±75 vs. 
DT 326±50 pg/mL, p=0.04) and elevated anti-inflammatory IL-10 (PBS 158±9 vs. DT 
212±18 pg/mL, p=0.02) in the serum of FcεRIβ+ cell depleted mice compared to FcεRIβ+ 
cell competent mice (Fig. 4a). We did not observe any differences of TNFα levels in the 
serum (Fig. 4a) and expression levels of TNFα within the inguinal lymph node (data not 
shown). We performed flow cytometry analysis on the blood compartment for circulating 
basophils, monocytes, neutrophils, T cells and B cells. Since the mice received the last DT 
injection more than 12 days before sacrifice, we detected a complete repopulation of 
basophils in DT treated mice (Fig. 4b). Peripheral blood neutrophil and total monocytes 
(Fig. 4b) were not different between groups. Nonetheless we did observe a reduction 
inflammatory monocytes (CD11b+/Ly6G-/Ly6Chi/CCR2+) in FcεRIβ+ cell depleted mice (Fig. 
4b). Furthermore, CD4+ T cells in FcεRIβ+ cell depleted mice was decreased with 22% (Fig. 
4b), while the percentage of CD8+ T cells (Fig. 4b) and B cells (Fig. 4b) was not affected. 
To further investigate the phenotype of the circulating CD4+ T cells, we stimulated 
splenocytes with α-CD3/28, followed by intracellular flow cytometry staining for different 
T cell subsets. The balance between Th17 and regulatory T cells is thought to influence 
arthritis severity in mice (25,26). As shown in figure 5a,b depletion of FcεRIβ+ cells 
influenced T cell cytokine production, as it resulted in decreased IL-17 producing T cells 
(PBS 1,02±0.15 vs. DT 0,67±0,04 %, p=0.02) and an increase in FoxP3+ regulatory T cells 
(PBS 6,50±0,27 vs. DT 7,80±0,34 %, p=0.01) (Fig 5a,b) compared to non-depleted mice. To 
study the antigen-specific response towards collagen type II, splenocytes were stimulated 
with CII and cytokine production was analysed by ELISA. Mast cell depletion resulted in 
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Figure 4. Preclinical FcεRIβ+-cell depletion influences systemic cytokine profile and peripheral 
leucocytes subsets. 
(A) Serum levels of IL-6, IL-17, IFNg and IL-10 were quantified in serum of PBS and DT treated RMB-
DBA/1 mice.(n=15/group) (B) FACS analysis of the blood compartment for peripheral leucocytes 
(n=15/group). (**P<0,01 ***P<0.001). A representative example of 2 independent experiments is 
depicted.
an increase in collagen specific IL-10 production (PBS 875±225 vs. DT 1912±96 pg/mL, 
p=0.002) and a decrease in collagen specific IL-17 production (PBS 301±73 vs. DT 121±33 
pg/mL, p=0.03) (Fig 5c). This change in the T cell cytokine response was in line with the 
intracellular cytokine staining results for the CD4+ T cells. 
As DT-injections can lead to side effects, we performed additional control experiments 
in which wild-type mice (C57Bl/6-DBA/1) were treated with either PBS or DT in a similar 
experimental set-up as described in supplementary Figure 1c. We did not observe any 
effects of DT on clinical score (Suppl. Fig 2a), serum cytokine profile (Suppl. Fig 2b). and 
blood leukocyte subsets (Suppl. Fig 2c) in wild-type control mice. Aspecific stimulation 
of splenocytes resulted in an increase in IL-17 and TNFα, but no differences in CII specific 
changes in cytokine profile in DT treated compared to PBS treated wild type mice (Suppl. 
Fig. 2d). Intracellular analysis for Th17 and FoxP3+ T cells showed also no differences (Suppl. 
Fig. 2e). 
Taken together these data suggests a regulatory role for mast cells in the early stages 
of CIA, when the immune response is established that precedes the onset of clinical 
symptoms.
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Figure 5. Altered CD4+T-cell phenotype in spleen and enhanced anti-inflammatory response 
towards collagen type II of splenocytes from FcεRIβ+-cell depleted mice. 
(A) Splenocytes from PBS and DT injected RMB-DBA/1 mice were stained intracellular for IL-17 after 
stimulation with anti-CD3/28 (n=15/group). (B) Splenocytes from PBS and DT injected RMB-DBA/1 
mice were stained intracellular for FoxP3. (n=15/group). (C) Cytokine release of splenocytes from 
PBS or DT injected RMB-DBA/1 mice after re-stimulation with either αCD3/28 or collagen type II 
(n=15/group). (*P<0.05). A representative example of 2 independent experiments is depicted.
3
Discussion
Mast cells are well known for their contribution to allergies and hypersensitivity [32]. 
They have also been implicated in autoimmune diseases such as RA. Increased mast cell 
numbers in the synovium were observed, as well as elevated levels of mast cell activation 
markers, such as tryptase and chymase, in synovial fluid [33]. 
Both in RA as well as in experimental arthritis models the possible pathogenic role of mast 
cells is still under debate. Several studies have been performed in mice with mutations 
in the gene encoding for the c-Kit receptor causing mast cell deficiency. C-kit signaling 
however is not only essential in mast cell development and survival but also affects many 
other hematopoietic lineages like stem cells, innate lymphoid cells, neutrophils and non-
hematopoietic cells such as melanocytes and germ cells [34]. To circumvent the side-
effects of cKit mutations, mice have been generated with a normal Kit signalling pathway, 
in which mast cell deficiency is more selective. Induction of arthritis by K/BxN serum 
transfer in for example Cpa3-cre mice induced clinical arthritis, which was comparable 
to mast cell competent mice [15]. Similarly, pharmacological stabilization of mast cells in 
the clinical phase of CIA with the drug Nedocromil was unable to reduce the clinical score 
of DBA/1 mice compared to placebo treated mice [35]. In contrast, it was shown that the 
mast cell inducible knock-out Mcpt5-cre iDTr mouse developed reduced levels of collagen 
induced arthritis, when mast cells were depleted before induction of arthritis (i.e. before 
the first immunization with CII) [21]. This depletion reduced both the number of immune 
cells in the draining lymph nodes and the amount of secreted inflammatory cytokines in 
response to collagen II. DT treatment of these Mcpt5-Cre iDTR mice results however in 
a reduction in the number of connective tissue type mast cells (CTMC) only , not that of 
mucosal mast cells (MMC) [36]. Interestingly, it is reported that mast cells in the inflamed 
synovium express less Mcpt5 compared to perivascular mast cells [37], indicating a micro-
environmental regulation of the mast cell phenotype inside the synovium. 
In the current study, we sought to investigate the contribution of mast cells to the different 
stages of collagen induced arthritis, when the first immunization was done in a mast cell 
competent mouse to exclude the possibility that the absence of mast cells affected the 
immunization efficiency. We have crossed the RMB mouse on a C57BL/6 background [22] 
with the DBA/1 mouse, thus generating the RMB-DBA/1 mouse, in which mast cells can be 
selectively depleted while being highly susceptible to the induction of CIA. We observed 
an >90% incidence of CIA in these RMB-DBA/1 mice, which is comparable to the incidence 
in homozygous DBA/1 mice [20,28], rendering this a valuable mouse model to study mast 
cells in CIA. Using this model, we were able to deplete fully FcεRIβ+ cells (mast cells and 
basophils) at any phase of disease. Activated mast cells secrete a wide range of proteases 
and lipid mediators, but also of a number of cytokines and chemokines, such as IL-6, IL-8 
and CCL2. These cytokines are described to influence both the adaptive immune response 
and attraction of leukocytes to the side of inflammation [38]. Activated basophils are well-
known for their capacity to secrete cytokines such as IL-4, IL-13,which influence the T cell 
skewing towards a Th2 response [39]. The repopulation kinetics of mast cells and basophils 
after the last DT injection differs. While a complete recovery of basophils is observed within 
12 days after the last DT injection, mast cells depletion lasts for the entire duration of the 
experiment. Therefore, it is highly likely that the majority of the observed effects in this 
study are due to mast cell depletion rather than the absence of basophils. Nonetheless, 
we cannot exclude that basophils do contribute to the immune response in this relatively 
short period. 
Our data suggest that mast cells are involved during the initiation of arthritis and that 
their role is limited after the first appearance of clinical symptoms, at least in the CIA 
model. During the preclinical phase of CIA, we and other have detected mast cell specific 
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activators like collagen specific IgE antibodies [40]. IgE-mediated activation leads to the 
degranulation of mast cells resulting in the release of immune modulating mediators. 
Furthermore, a peak of degranulated (activated) mast cells in the knee and digits was 
recently shown around the booster injection in the CIA model [35]. This may suggests that 
mast cells contribute to the early development of an immune response in experimental 
arthritis. For example, it has been shown that mast cells can contribute to T cell priming 
through the release of TNFα in the draining lymph nodes leading to expansion of the 
tissue [41]. Our ex vivo experiments indicated that mast cell depletion in the preclinical 
phase resulted in an altered T cell skewing, as we detected a marked reduction in IL-17 and 
an increase in IL-10 production by splenocytes of mast cell depleted mice after stimulation 
with collagen type II.
IL-6 is a key cytokine for the development and maintenance of Th17 cells in mice [42]. 
This cytokine can be produced by various innate immune cells including mast cells. IgE 
mediated mast cell activation results in high secretion of both IL-6, which is a potent 
promoter of Th17-cell induction, and TNFα, which can drive the hypertrophy of the draining 
lymph nodes and the recruitment of naïve CD4+ T cells into the lymph node [41,43]. In the 
current study, we detected collagen type II specific IgE antibodies, indicating the presence 
of a CIA specific mast cell activator. Mast cell derived cytokines such as IL-6 may influence 
T cell skewing or other cellular interactions in the lymph node. The importance of IL-6 in 
CIA has been demonstrated by blocking IL-6, which reduces the severity of arthritis [44]. 
Clinical trials in human RA with anti-IL6R (Tocilizumab) have demonstrated that blockade 
of IL-6 has therapeutic efficacy in (early) RA patients [45]. In this study we observed lower 
levels of serum IL-6 in mast cell depleted mice. This reduction of IL-6 coincided with an 
altered T cell skewing towards a more anti-inflammatory T-cell phenotype.
Th17 cells have been implicated to play a role in CIA by driving arthritis progression through 
e.g. osteoclast activation [44,46]. Furthermore, it was shown that anti-IL-17 treatment 
significantly reduced arthritis development and severity in mice [46,47]. Also in human 
RA, IL-17 and IL-17+ cells have been reported to contribute to RA progression. For example, 
elevated levels of IL-17A can be detected in serum and synovial fluid of RA patients [48], 
and IL-17+ cells can be present in synovial tissue from RA patients. Interestingly, the most 
abundant IL-17+ cell type in RA synovium were mast cells [49]. Flow cytometry analysis of 
stimulated splenocytes from mast cell depleted mice showed a decrease in CD4+ IL-17+ T 
cells and an increase in regulatory CD4+ FoxP3+ T cells. Furthermore, we detected elevated 
levels of IL-10 in the supernatant of splenocytes after stimulation with collagen II. In CIA, 
the protective role of IL-10 has been previously been shown by both systemic treatment 
of IL-10 and in mice deficient for IL-10 [50–52]. 
Whether mast cells play a role in the established phase of RA is not known. However, it 
is known that they can represent an abundant cell type in the inflamed synovium [6,7]. 
Likewise, it has been shown that the auto immune response coinciding with sero-positive 
RA, represents features of an active ongoing immune response [53]. This could also 
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include the mast cell which might play a role in the modulation of this response either in 
the inflamed synovial tissue or in the draining lymph node by the secretion of cytokines 
[54]. Whether mast cells also mediate other effects in RA is not known. However, the 
presence of mast cells in both human RA and mouse experimental arthritis suggests a 
contributing part. Although CIA shows many similarities with human RA it also differs in 
terms of progression of arthritis. Since human RA is less progressive and shows also flares 
of arthritis it could be that mast cells here do play a role.
The role of mast cells has also been investigated in other models of auto-immune 
diseases, such as experimental autoimmune encephalomyelitis (EAE). Similar to the results 
obtained from experimental arthritis studies, also data from EAE studies vary depending 
on the mast cell -deficient mouse strain used [55]. As circulating IL-6 and IL-17 levels were 
reduced in this study, it would be of interest to determine mast cell dependent effects on 
EAE with our RMB mouse, since it has been shown that IL-6 and IL-17 are important in EAE 
development [56]. Taken together, the selective absence of mast cells can have different 
consequences in different diseases, depending on the time of mast cell depletion, the 
mouse strain used and/or the experimental conditions used. As disease manifestation 
varies between individual patients, it is conceivable that the contribution of mast cells 
to disease development can vary between individuals, between disease stages as well as 
between different diseases.
Conclusions
In conclusion, we show that depletion of mast cells during the initiation of experimental 
arthritis decreases disease severity, while depletion of mast cells in established disease 
had no effect. Depletion of mast cells in the pre-clinical phase of CIA is associated with a 
more anti-inflammatory T cell response, suggesting that mast cells could play a role in the 
regulation of the adaptive immune response in early arthritis.
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Supplementary figure 1. Study outline of performed arthritis experiments in RMB-DBA/1 
mice.
(A) Mast cell depletion in clinical phase of CIA. (B) Collagen antibody induced arthritis in mast cell 
depleted RMB-DBA/1 mice. (C) Mast cell depletion in pre-clinical phase. (CFA: Complete Freund’s 
Adjuvant, CII: Collagen type II, IFA: incomplete Freund’s Adjuvant, DT: diphtheria toxin)
3
Supplementary figures 
Supplementary figure 2. DT treatment in wild-type control animals.
(A) Progression of CIA was monitored by clinical scoring of C57Bl/6-DBA/1 mice injected with 
either PBS or DT. (B) Serum levels of IL-6, IL-17, IFNγ and IL-10 were quantified in serum of PBS 
and DT treated C57Bl/6-DBA/1 mice. (C) FACS analysis of the blood compartment for peripheral 
leucocytes in PBS and DT treated C57Bl/6-DBA/1 mice. (D) Cytokine release of splenocytes from 
PBS or DT injected C57Bl/6-DBA/1 mice after re-stimulation with either αCD3/28 or collagen type II 
or unstimulated medium control (n=15/group). (E) Splenocytes from PBS and DT injected C57Bl/6-
DBA/1 mice were stained intracellular for IL-17 after stimulation with anti-CD3/28 (n=15/group). 
Splenocytes from PBS and DT injected C57Bl/6-DBA/1 mice were stained intracellular for FoxP3. 
(**P<0,01, ****P<0,001) All graphs n=15/group). 
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Presence of anti-citrullinated protein antibodies in sera of 
non-rheumatic cardiovascular patients is associated with 
long-term mortality. 
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Cardiovascular (CV) mortality is higher in patients with rheumatoid arthritis (RA), in 
particular when anti-citrullinated protein antibodies (ACPA) are present. Recently, ACPA 
have also been described in CV patients without RA.
In this study, we aimed to confirm the presence of ACPA in the serum of non-rheumatic 
CV patients. In addition, we aimed to assess the relation between ACPA with clinical 
parameters, plaque phenotype and long-term mortality.
Methods 
Sera of CV patients who were included into either the AtheroExpress, Circulating Cells 
or MISSION! study were analyzed for presence of ACPA. After exclusion of patients with 
known rheumatic diseases, we analyzed the associations between ACPA positivity and 
clinical characteristics in all three cohorts. Furthermore, we aimed to associate ACPA 
with either vulnerable plaque characteristics in the AtheroExpress cohort or long-term 
mortality in the MISSION! study.
Results 
Compared to sera from healthy controls, we detected a significantly higher percentage 
of ACPA positivity in the sera of patients in all three study cohorts. Clinical analysis of 
these ACPA negative and positive CV patients showed that presence of ACPA did not 
associate with general characteristics such as lipid profile, BMI or other known risk factors. 
Plaque phenotype did not differ between ACPA negative and positive CV patients in the 
AtheroExpress study. However, we observed an increased cumulative cardiac mortality in 
ACPA positive CV patients compared to ACPA negative CV patients in the MISSION! cohort. 
Corrected for age, ACPA positivity was independently associated with long-term mortality.
Conclusion 
This study confirms that ACPA is present in a subpopulation of non-rheumatic CV patients. 
Clinical analysis showed that long-term mortality in STEMI patients without RA was 
independently associated with the presence of ACPA. Therefore, ACPA in patients without 
RA might act as a cardiovascular factor. 
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of the synovial 
tissue, which affects around 1% of the world population. The persistent synovitis leads 
to the breakdown of cartilage and bone that ultimately results in joint disability [1]. The 
generation of autoantibodies is a key characteristic of the majority of RA patients and 
especially anti-citrullinated protein antibodies (ACPA) are frequently found in the sera 
and synovial fluid of RA patients [2]. Citrullination or peptidylarginine deimination is a 
physiological process catalyzed by a family of enzymes called peptidyl arginine deiminases 
(PAD-1-4) [3]. These enzymes convert the positively charged amino acid arginine to an 
uncharged amino acid citrulline in the presence of relatively high calcium concentrations 
[3]. Clinically, ACPA is an important marker for a more progressive RA compared to ACPA-
negative RA patients [4]. Additionally, ACPA positivity in RA patients is associated with a 
higher cardiovascular mortality [5].
The major underlying pathology of many acute cardiovascular diseases is the process 
of atherosclerosis. Atherosclerosis is the sub-endothelial accumulation of lipids and 
inflammatory cells in the arterial wall, resulting in the development an atherosclerotic 
plaque, generally composed of a lipid core covered by a fibrous cap. Thrombosis after 
rupture or erosion of such a fibrous cap can lead to occlusive vascular diseases such as 
myocardial infarction or stroke [6]. Citrullination of proteins is not restricted to the synovial 
tissue and is reported to also occur in other tissues, for example within the myocardium 
and inside the atherosclerotic lesion [7, 8]. In addition, PAD enzymes have been detected 
in high levels in atherosclerotic lesions of non-RA patients with cardiovascular disease 
[8]. Low levels of circulating ACPA have been reported in a small proportion of patients 
with acute cardiovascular syndromes in the absence of rheumatic diseases [9]. Formation 
of immune complexes composed of ACPA and citrullinated proteins can activate the 
complement cascade as well as Fc-receptor mediated activation of local leukocytes, 
thereby fuelling the ongoing inflammatory response. Therefore, the presence of ACPA in 
cardiovascular patients could potentially contribute to atherosclerotic lesion growth in 
the vessel wall, however up to date a causal relation between ACPA and cardiovascular 
diseases such as atherosclerosis has not been established.
In the current study, we aimed to determine whether ACPA is detectable in CV patients 
without reported RA. In addition, we aimed to associate ACPA positivity with clinical 
characteristics, plaque phenotype and long-term mortality in these patient cohorts.
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Methods
Study population and design
Athero-Express
A total of 135 patients of the Athero-Express were included in this study. The Athero-express biobank 
involves patients that underwent carotid endarterectomy (CEA) in two Dutch teaching hospitals in Utrecht 
and Nieuwegein, the Netherlands [10]. The criteria to perform carotid endarterectomy were based on the 
recommendations by the Asymptomatic Carotid Atherosclerosis Study (ACAS study) for asymptomatic patients 
and the North American Symptomatic Carotid Endarterectomy Trial and the European Carotid Surgery Trial 
(NASCET study) for symptomatic patients [11–15]. The local medical ethical boards of both participating 
hospitals approved this study. The participating patients signed a written informed consent prior to inclusion. 
The patient’s baseline characteristics and medical history were obtained via questionnaires and the patient 
medical records.
Circulating Cells
The study cohort consists of a total of 443 patients, these patients form a subgroup of the Centre for Translational 
Molecular Medicine (CTMM) – Circulating Cells study cohort [16]. In brief, Circulating Cells is a multi-centre study 
in which CAD patients scheduled for coronary angiography were included. Exclusion criteria were age <18 
years, inability to give informed consent, suspected drug or alcohol abuse, serious concomitant disease and 
serious recent infectious disease in the last 6 weeks or suspected elevated state of the immune system, and non-
cooperativeness. The Circulating Cells protocol was approved by the review board or ethics committee of each 
participating centre. Nine months after inclusion, patients were contacted and any major adverse cardiovascular 
events (MACE) that occurred in the preceding months were recorded. MACE is the primary endpoint of this 
study and is defined as cardiovascular disease related death, myocardial infarction, percutaneous coronary 
intervention, coronary artery bypass grafting and cardiovascular accident.
Mission
Data for this study were used from 300 patients with ST-segment elevation myocardial infarction (STEMI), who 
were initially included in the MISSION! Intervention Trial. STEMI was defined as ongoing chest pain (>30 minutes), 
accompanied with ST-elevation (≥0.2 mV in ≥2 leads in V1-V3 or ≥0.1 mV in other leads) or presumed new left 
bundle branch block (LBBB) and a typical rise and fall of cardiac biomarkers. In case of out-of-hospital cardiac 
arrest, only patients with return of spontaneous circulation at the moment of arrival at the catheterization 
laboratory were included. Patients with prior myocardial infarction (n=11) or prior revascularization (n=6) 
were excluded. In addition, patients with evidence for rheumatic disease (n=8) were excluded for analysis. The 
MISSION! Intervention Trial was conducted from February 2004 to October 2006. Clinical and angiographic 
results in patients with STEMI treated with either Bare Metal Stents (BMS) or Sirolimus Eluting Stents (SES) during 
primary percutaneous coronary intervention (PCI) was evaluated [17].
Information on all-cause mortality was obtained from the Dutch Municipality Records registry. Cause of death 
was retrieved from general practitioners. Clinical follow-up data was collected during the 30 days, 3, 6 and 
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12 months outpatient clinic visits. Follow-up data on serious adverse events including myocardial infarction, 
revascularisation and stroke was obtained by telephone interviews at 2, 5 and 10 years after admission. The 
study protocol was approved by the institutional ethical committee. Written informed consent was obtained 
from all patients before enrolment in the study. In the current study, baseline blood samples derived from the 
patients before primary PCI were used for anti–citrullinated protein antibodies (ACPA) determination.
SYNTAX Scoring
To assess the complexity of coronary artery disease, coronary angiographic primary PCI images were used to 
calculate the SYNTAX score [18]. This was performed by an experienced interventional cardiologist.
Anti–citrullinated protein antibodies measurement
ACPA positivity was determined based on reactivity of sera against a third generation cyclic citrullinated peptide 
(CCP3) in a commercially available ELISA system (Quanta LiteTM CCP3.1 IgG/IgA Cat# 704550, INOVA Diagnostics 
Inc., US). According to supplier’s manual, values above 20 aU/mL were considered CCP3.1 positive.
Statistical analysis
Normally distributed continuous variables were reported as mean and standard deviation, and compared with 
Student’s t-test. Skewed distributed continuous variables were reported as median and interquartile range, 
and compared with Mann-Whitney U test. Categorical variables were reported as number and percentage, 
and compared with Pearson’s chi-square test. Event-free survival was analyzed with Kaplan-Meijer estimates 
and compared between groups with the log-rank test. Cox regression was performed to assess the association 
between the ACPA positivity and primary and secondary outcome measures. All statistical tests were performed 
with SPSS software (Version 22.0, SPSS IBM Corp., Armonk, New York). P-values <0.05 assessed by two-sided tests 
were considered to be statistically significant.
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Results
Presence of ACPA was determined by screening sera, obtained from CV patients included 
in the AtheroExpress, Circulating Cells and MISSION! cohorts, for reactivity towards a cyclic 
citrullinated peptide (CCP3).
Baseline characteristics
The baseline characteristics of patients included in the AtheroExpress are summarized in 
table 1. In brief, the cohort has a mean age of 67 and a male prevalence (71%), which 
reflects a relatively typical population of patients with vascular occlusive diseases. The 
majority of patients was symptomatic (74%) as illustrated by the incidence of amaurosis 
fugax, a TIA or a stroke, was hypertensive (86%) and used statins (69%).
Table 1: Baseline patient characteristics of AtheroExpress
Characteristic Median (±SD) 
Age, mean years (SD) 67 (9) 
BMI, mean kg/m2 (SD) 27 (4) 
   n (%) of patients
Male  96/135 (71%) 
Smoker 55/134 (41%)
Diabetes mellitus 25/135 (19%) 
Statin use 93/135 (69%) 
Hypertension 116/135 (86%)
Hypersensitive 27/132 (20%) 
History VI 4/135 (40%)
History MI 30/134 (22%) 
Clinical presentation  
Asymptomatic 35/135 (26%)
 Symptomatic 100/135 (74%)
 Amaurosis fugax 22/135 (16%)
TIA 51/135 (38%) 
Stroke  27/135 (20%)
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The circulating cells cohort consist of a total of 443 patients with a mean age of 63 and a 
male prevalence of 71%. The majority of the patients were diagnosed with stable coronary 
artery disease (CAD) (81%), whereas the remaining patients suffered from unstable CAD 
(non-ST elevation myocardial infarction/unstable angina) (19%). Table 2 summarizes the 
baseline characteristics of this patient cohort.
Table 2: Baseline patient characteristics of Circulating Cells
Characteristic Median (±SD)
Age, mean years (SD) 63 (10)
BMI, mean kg/m2 (SD) 27 (4)
Men (%) 314/443 (71%)
Median (IQR)
SBP (mm Hg) 136 (122-145)
DBP (mm Hg) 78 (70-85)
Glucose (mmol/L) 6,55 (5,40-6,90)
HB (mmol/L) 8,70 (8,30-9,20)
LDL-C (mmol/L) 2,51 (1,87-3,01)
HDL-C (mmol/L) 1,08 (1,24-0,89)
Triglycerides (mmol/L) 1,57 (0,99-1,90)
hsCRP (ng/mL) 7919 (1685-7235)
WBC (x1000 cells/μL) 7,3 (5,9-8,5)
n (%) of patients
Current smoker 97/443 (22%)





Vitamin K antagonist 47/443 (11%)
Statin 351/443 (79%)
The MISSION! cohort consists of a total of 275 patients with a mean age of 59 and a male 
prevalence of 76%. Baseline characteristics are summarized in table 3.
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Table 3: Baseline patient characteristics of Circulating Cells
Characteristic n= 246
Patient characteristics
Age, mean (SD), y 58,9 (11,5)
Woman 65 (275)
Body mass index, mean (SD), kg/m2 26,6 (4,5)
Risk factors
Treated hypertension 76 (28)
Diabetes 25 (9)
Treated hyperlipidemia 48 (17)
Current smoker 152 (55)
Family history of CVD 122 (44)
Clinical characteristics
Out of hospital cardiac arrest 7 (3)
Cardiogenic shock 5 (2)
Anterior infarction 145 (53)
Infarct size, median (IQR), g/m2 9,1 (4,4 – 15,7)
Troponine max, median (IQR) 5.8 (2,4 – 10)
CK max, median (IQR) 1985 (966 – 3633)
Troponine max (log) 0,62 (0,55)
CK max (log) 3,3 (0,5)
Number of vessels diseased (>50%) 1 154 (56)
 2 107 (39)
 3 12 (4)
Complete revascularization 275 (100)
Culprit vessel RCA 82 (30)
 LAD 150 (55)
 LCX 43 (16)
Proximal lesion 138 (50)
TIMI flow before intervention 0 189 (69)
Drug-eluting stent 135 (49)
Irreversible ischemia myoview 198 (72)
Irreversible ischemia myoview 107 (39)
Syntax score before pPCI (IQR) 14,5 (8,8 – 20,4)
Syntax score after pPCI (IQR) 8,9 (6,7 – 13,2)
CRP, median (IQR) 0,5 (0,0 – 6,3)
CRP (log) 4,6 (5,5)
CRP >3mg/L 108 (39)
Clinical endpoints
Re-infarct 36 (13)
Cardiac death 13 (5)
Death 35 (13)
Re-infarct or death  65 (24)
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CCP3-reactivity in the sera of CV patients
CCP3-positivity in the tested cohorts as well as a group of age matched healthy controls is 
depicted in figure 1. We observed that 1,9% (3/160) of the healthy controls, 8,1 % (11/135) 
of the Athero- Express patients, 5,3% (23/430) of the Circulating Cells patients and 10,0% 
(30/292) of the Mission! patient cohort showed reactivity for the CCP3 peptide. Statistical 
analysis showed that the percentages of CCP3 reactive antibodies in all the cohorts are 
significantly elevated compared to healthy controls.
Clinical characteristics
AtheroExpress
Next, we aimed to correlate ACPA positivity with clinical observations within the 
AtheroExpress database. We did not observe associations between ACPA positivity and 
any of the following plaque characteristics: fat deposition, collagen, smooth muscle 
cells, macrophages, microvessel density. In addition, clinical presentation (asymptomatic 
(n=35) or symptomatic (n=100) patients) was not associated with ACPA positivity. 
Furthermore, analysis of the symptomatic patients did not show any association with 
clinical presentation (data not shown).
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Figure 1. Presence of ACPA by determination of CCP3 reactive antibodies in the sera of age-matched 
healthy controls and three cohorts of cardiovascular patients. Dashed line indicates the cut-off val-
ue, which was set on 20 aU/mL. **** P=0.0001
Circulating Cells
Clinical analysis of ACPA positivity in the circulating cells cohort showed no significant 
differences in clinical characteristics between CCP3 negative and positive patients as 
shown in table 3. However, the majority of the CCP3 positive patients were diagnosed 
with stable CAD (90%).
Table 4: Characteristics of CCP3 negative and positive CV patients in the Circulating Cells cohort
Characteristic CCP3 Negative CCP3 Positive P value
Age, mean years (SD) 62 (10) 67 (10) 0,174
BMI, mean kg/m2 (SD) 26,9 (4,4) 26 (3) 0,453
Men 301/421 (71%) 13/22 (59%) 0,212
SBP (mm Hg) (IQR) 134 (121-145) 143 (128-158) 0,174
DBP (mm Hg) (IQR) 80 (70-85) 77 (73-82) 0,944
Glucose (mmol/L) (IQR) 6,0 (5,4-6,9) 6,0 (5,6-6,7) 0,687
HB (mmol/L) (IQR) 887 (8,3-9,2) 8,6 (8,4-9,1) 0,742
LDL-C (mmol/L) (IQR) 2,39 (1,88-3,02) 2,20 (1,81-2,63) 0,350
HDL-C (mmol/L) (IQR) 1,04 (0,89-,1,23) 1,03 (0,94-1,37) 0,730
Triglycerides (mmol/L) (IQR) 1,32 (1,00-1,91) 1,05 (0,84-1,62) 0,080
hsCRP (ng/mL) (IQR) 2954 (1672-7281) 3997 (2033-7134) 0,381
WBC (x1000 cells/μL) (IQR) 7,1 (5,9-8,5) 7,3 (6,2-8,9) 0,549
Current smoker 92/421 (22%) 5/22 (23%) 0,928
Diabetes Mellitus 86/421 (21%) 4/22 (18%) 0,790
Hypertension 265/421 (65%) 16/22 (73%) 0,360
Beta-Blocker 317/421 (75%) 19/22 (86%) 0,237
Ca-antagonist 123/421 (29%) 7/22 (32%) 0,794
Aspirin 353/421 (84%) 16/22 (73%) 0,173
Vitamin K antagonist 44/421 (10%) 3/22 (14%) 0,636
Statin 334/421 (79%) 17/22 (77%) 0,816
MISSION!
CCP3 positivity did not associate with clinical parameters within the MISSION! as shown 
in table 2. 
Table 5: Characteristics of CCP3 negative and positive CV patients in the MISSION! cohort
Characteristic CCP3 Negative CCP3 Positive P value
  n= 246 N = 29
Patient characteristics
Age, mean (SD), y 58,4 (11,6) 62,7 (10,4) 0,056
Woman 55 (22) 10 (34) 0,146
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Characteristic CCP3 Negative CCP3 Positive P value
Body mass index, mean (SD), 
kg/m2
26,5 (4,1) 27,0 (5,5) 0,586
Risk factors
Treated hypertension 70 (28) 6 (21) 0,376
Diabetes 23 (9) 2 (7) 0,664
Treated hyperlipidemia 44 (18) 4 (14) 0,583
Current smoker 136 (55) 16 (55) 0,991
Family history of CVD 108 (44) 14 (48) 0,667
Clinical characteristics   
Out of hospital cardiac arrest 7 (3) 0 (0) 0,355
Cardiogenic shock 5 (2) 0 (0) 0,445
Anterior infarction 128 (55) 17 (63) 0,413
Infarct size, median (IQR), g/m2 8,6 (4,4-15,4) 13,1 (4,7-18,7) 0,250
Troponine max, median (IQR) 5,5 (2,4-9,5) 8,6 (2,4-14,1) 0,126
CK max, median (IQR) 1948 (957-3512) 2297 (1045-4657) 0,258
Troponine max (log) 0,60 (0,55) 0,78 (0,52) 0,129
CK max (log) 3,2 (0,5) 3,3 (0,5) 0,264
Number of vessels diseased 
(>50%)
1 141 (58) 13 (45) 0,183
 2 92 (38) 15 (52) 0,144
 3 11 (5) 1 (3) 0,792
Complete revascularization 244 (100) 29 (100) ~
Culprit vessel RCA 74 (30) 8 (28) 0,781
 LAD 133 (54) 17 (59) 0,641
 LCX 39 (16) 4 (14) 0,773
Proximal lesion 126 (51) 12 (41) 0,316
TIMI flow before intervention 0 169 (69) 20 (71) 0,814
Drug-eluting stent 124 (50) 11 (38) 0,204
Irreversible ischemia myoview 178 (78) 20 (80) 0,824
Irreversible ischemia myoview 96 (43) 11 (46) 0,780
Syntax score before pPCI (IQR) 14,5 (9,0-20,5) 14,3 (7,3-19,9) 0,418
Syntax score after pPCI (IQR) 9,0 (7,0-13,0) 8,0 (4,3-14,5) 0,389
CRP, median (IQR) 0,0 (0,0-6,0) 5,0 (0,0-9,0) 0,122
CRP (log) (-)4,8 (5,5) (-)3,1 (5,4) 0,124
CRP >3mg/L 92 (43) 15 (60) 0,110
Clinical endpoints
Re-infarct 32 (13) 4 (14) 0,906
Cardiac death 9 (4) 4 (14) 0,031
Death 27 (11) 8 (28) 0,011
Re-infarct or death  54 (22) 11 (38) 0,055
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Using the MISSION! cohort we were able to investigate whether CCP3 positivity correlated 
with long term mortality, which is of interest, as it is known from RA patient studies that 
ACPA positivity increases the overall mortality rate. As shown in figure 2 there was an 
association between ACPA positivity and mortality rate after 10 years of follow-up. One 
possibility could be that the atherosclerotic lesion complexity, location and number of 
affected coronary arteries is dependent on ACPA levels. These parameters are used to 
calculate the SYNTAX score. We determined the SYNTAX score of all included patients in 
the MISSION! cohort. We did not observe a correlation between ACPA levels and SYNTAX 
score (data not shown).
Discussion
The pathogenesis of RA is characterized by the development of different autoreactive 
antibodies such as rheumatoid factor (RF), anti-carbamylated proteins antibodies 
(a-CarP) and anti-citrullinated protein antibodies (ACPA) [2, 19, 20]. Especially ACPA is 
an important clinical biomarker, which is strongly associated with a more progressive 
disease course, response to treatment and degree of joint destruction [2]. In addition, the 
presence of ACPA in RA patients is associated with increased incidence of cardiovascular 
disease and mortality [21]. Products of persistent inflammation in RA, e.g. cytokines and 
108 | CHAPTER 4
Figure 2. Increased cumulative cardiac mortality was observed in ACPA positive patients compared 
to ACPA negative patients. Corrected for age, ACPA positivity was independently associated with 
long-term mortality [HR 2.4 (CI 1.1-5.4) p-Value= 0.025].











































antibodies, are thought to directly influence the progression of atherosclerosis [22]. Both 
RA and atherosclerosis share similar immunological pathways and therefore, presence 
of ACPA may also affect the vascular inflammation. For example, innate immune cells 
(macrophages, neutrophils and mast cells) with ACPA bound to their Fcγ receptors can get 
further activated upon interaction of cell-surface bound ACPA with citrullinated antigens 
[23–25]. To date, several studies have shown the presence of citrullinated proteins inside 
atherosclerotic lesions and within the myocardial tissue of RA as well as non-RA patients 
[7, 26]. In addition, enzymes that drive the citrullination process, PAD enzymes, are also 
known to be present inside the plaque [8]. Taken together, ACPA mediated activation of 
local intraplaque immune cells could lead to the release of pro-inflammatory mediators 
such as cytokines, chemokines and proteases. In turn, this will further enhance the lipid 
accumulation and destabilization of the atherosclerotic lesion.
In this study, we showed that ACPA can be detected in the serum of a subpopulation 
of CV patients, who had no history of rheumatic diseases. We screened three cohorts; 
AtheroExpress, Circulating Cells and MISSION! for the presence of ACPA. In all three 
tested cohorts we found that a significant proportion (5-10%) of the CV patients showed 
reactivity towards citrullinated peptides (CCP3) compared to 1% positivity in healthy 
age-matched controls. This observation is in line with a previous study, which reported 
presence of ACPA in 10,4% of the cases in a cohort of coronary heart disease patients 
compared to 3,8% in controls [9]. These data indicate that an humoral immune response 
towards citrullinated proteins can not only develop in RA, but also in a chronic systemic 
inflammatory diseases such as atherosclerosis.
In contrast to RA, the pathogenic contribution of autoreactive antibodies in cardiovascular 
diseases is still a subject of debate. On one hand, IgM producing B1 B cells have shown 
to be atheroprotective, while on the other hand IgG producing B2 B cells are reported to 
aggravate atherosclerosis [27]. Next to antibodies, B cells produce a variety of mediators 
and are able to present antigens to T cells. This underscores that B cells and their products 
can significantly contribute to the pathogenesis of atherosclerosis and RA. Indeed, B cell 
depleting therapies, such as the use of rituximab, in RA have been shown to be effective 
and these studies have also shown beneficial effects on the progression of atherosclerosis. 
Treatment of RA patients with rituximab for a period of 4 months showed an improvement 
in lipid profiles and a reduction in carotid intima- media thickness [28]. In addition, 
improvements in endothelial function as determined by flow- mediated vasodilation and 
in systemic inflammation as indicated by serum levels of hsCRP were reported in another 
clinical study, in which RA patients were treated with rituximab [29]. These studies 
underline a significant role for B cells in vascular inflammation in active RA patients, which 
is mediated by the secretion of cytokines and antigen presentation and/or the production 
of auto- reactive antibodies.
Association analyses of ACPA positivity in cardiovascular patients with parameters such as 
lipid profile, inflammatory markers and medication use did not reveal any associations in 
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all three analyzed cohorts. We compared plaque phenotype of ACPA positive CV patients 
of the AtheroExpress cohort, which did not reveal any differences in vulnerable plaque 
characteristics between ACPA positive and negative patients. In RA, the presence of ACPA is 
associated with increased mortality [30, 31]. Also in non-rheumatic cardiovascular patients 
of the MISSION! cohort we observed a significant association between ACPA positivity and 
long term mortality. We did not investigate the causal mechanism in this current study 
but one possibility could be the accelerated atherosclerosis in ACPA positive patients. We 
further analyzed this by characterizing the complexity of the coronary arteries disease 
by SYNTAX scoring the patients in the MISSION! cohort. However, this analysis did not 
reveal an association between SYNTAX score and ACPA positivity. Further research could 
focus on investigating the systemic inflammatory status of these patients by determining 
circulating proatherogenic mediators. In addition, the intraplaque citrullination could be 
different between APCA negative and positive patients, which could also influence the 
plaque stability.
There are several limitations to our study. The reported APCA titers in the presented 
cohorts are relatively low compared to the levels in established RA patients. This could 
indicate that there is a difference in the development of ACPA producing B cells and/or 
the inflammatory milieu in cardiovascular versus RA patients. Further research should 
focus on the comparison of cardiovascular ACPA with RA ACPA in terms of glycosylation, 
fine specificity and avidity as well as isotype class. In addition, we used a commercially 
available kit to determine ACPA levels. Although this assay is a highly sensitive and 
reproducible method, we were unable to control for citrulline specificity by including 
an arginine control. Finally, although we excluded all patients with known rheumatic 
diseases, we cannot exclude that these ACPA positive CV patients will develop symptoms 
of RA in the future.
In conclusion, here we confirm the presence of ACPA in serum of a subpopulation of CV 
patients. Analysis showed an association between ACPA positivity and long-term mortality. 
Further research should focus on characterizing the phenotype of cardiovascular ACPA 
compared to rheumatic ACPA in terms of isotype, glycosylation and affinity towards 
citrullinated proteins.
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Abstract
Background
Recently, we have shown that intraplaque mast cell numbers are associated with 
atherosclerotic plaque vulnerability and with future cardiovascular events, which 
renders inhibition of mast cell activation of interest for future therapeutic interventions. 
However, the endogenous triggers that activate mast cells during the progression and 
destabilization of atherosclerotic lesions remain unidentified. Mast cells can be activated 
by immunoglobulins and in the present study, we aimed to establish whether specific 
immunoglobulins in plasma of patients scheduled for carotid endarterectomy were related 
to (activated) intraplaque mast cell numbers and plasma tryptase levels. In addition, the 
levels were related to other vulnerable plaque characteristics and baseline clinical data. 
Methods and results
OxLDL-IgG, total IgG and total IgE levels were measured in 135 patients who underwent 
carotid endarterectomy. No associations were observed between the tested plasma 
immunoglobulin levels and total mast cell numbers in atherosclerotic plaques. 
Furthermore, no associations were found between IgG levels and the following plaque 
characteristics: lipid core size, degree of calcification, number of macrophages or smooth 
muscle cells, amount of collagen and number of microvessels. Interestingly, statin use was 
negatively associated with plasma IgE and oxLDL-IgG levels. 
Conclusions
In patients suffering from carotid artery disease, total IgE, total IgG and oxLDL-IgG levels do 
not associate with plaque mast cell numbers or other vulnerable plaque histopathological 
characteristics. This study thus does not provide evidence that the immunoglobulins tested 
in our cohort play a role in intraplaque mast cell activation or grade of atherosclerosis. 
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Introduction
The incidence of atherosclerotic disease is increasing by the aging population and the 
life style in the Western world. The mast cell, a prominent inflammatory cell type and 
a major effector cell in allergy and asthma, has been shown to accumulate both in the 
rupture-prone shoulder region of human atheromas (1,2) and in the perivascular tissue 
during atherosclerotic lesion progression (3). Recently, we have shown that intraplaque 
mast cell numbers are associated with plaque vulnerability and interestingly, with future 
cardiovascular events (4). In that study, mast cells numbers associated with vulnerable 
plaque characteristics such as lipid core size, intraplaque haemorrhage, microvessel 
density and inflammatory cell accumulation, suggesting that mast cells actively 
contribute to atherosclerotic plaque progression and destabilization. Inhibition of mast 
cell activation may therefore be of interest for future therapeutic interventions. However, 
the mechanism of mast cell activation during the development of atherosclerosis remains 
up to date unresolved. Previously, we and others have established that mast cells in the 
vessel wall can be activated by for example neuropeptides (5), complement factors (6) 
and lipid mediators (7) in animal models of atherosclerosis. Furthermore, the mast cell 
expresses the high-affinity IgE receptor (FcεR1) and the IgG receptor (FcγR) (8,9). Mast 
cells can be activated via IgE mediated crosslinking of the FcεR, after which mast cells 
release granules into the surrounding area. IgE levels have been shown to be elevated in 
patients with unstable angina pectoris (10) and intriguingly, also higher in dyslipidemic 
men as compared to control subjects (11). Furthermore, Lappalainen et al demonstrated 
that specific oxLDL-IgG immune complexes were able to induce mast cell activation (12). 
Circulating specific IgE and IgG antibodies or lipid-immunoglobulin immune complexes, 
which exert their effects through the FcεR and FcγRs, are known to play a role in several 
immune responses (9) and may thus also be involved in mast cell activation within the 
atherosclerotic plaque, thereby affecting plaque stability. Based on these observations, 
we hypothesize that circulating immunoglobulins may be involved in or be reflective 
of mast cell activation and thereby accelerate the destabilization of the atherosclerotic 
plaque. This study was designed to assess the presence of associations between 
immunoglobulin expression and mast cell numbers in plaques from patients with carotid 
stenosis. Hence, we assessed total and ox-LDL specific IgG and total IgE plasma levels and 
related their numbers to several mast cell parameters and established vulnerable plaque 
characteristics. In additions, immunoglobulin levels were related to clinical characteristics. 
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Materials and Methods
Study population and design
A total of 135 patients of the Athero-Express were included in this study. The Athero-express biobank 
involves patients that underwent carotid endarterectomy (CEA) in two Dutch teaching hospitals in Utrecht 
and Nieuwegein the Netherlands (13). The criteria to perform carotid endarterectomy were based on the 
recommendations by the Asymptomatic Carotid Atherosclerosis Study (ACAS study) for asymptomatic patients 
and the North American Symptomatic Carotid Endarterectomy Trial and the European Carotid Surgery Trial 
(NASCET study) for symptomatic patients (14-18). Patients were operated between March 2002 and August 2008 
of which intraplaque mast cell numbers were available (4). In that study, patients were selected who remained 
healthy and patients who suffered from an event during follow-up in a 2:1 ratio. Of 135 patients blood plasma 
samples were available. Total mast cell numbers and baseline characteristics did not differ between the patients 
of which plasma was and was not available. The local medical ethical boards of both participating hospitals 
approved this study. The participating patients signed a written informed consent prior to inclusion. The patient’s 
baseline characteristics and medical history were obtained via questionnaires and the patient medical records. 
Materials 
The carotid plaques used in this study were processed as described previously (13). In short, after surgical 
dissection the plaque was cut into segments of 5 mm. The segment with the largest plaque area was fixed in 
formalin and embedded in paraffin for histology. The two adjacent sections were frozen in liquid nitrogen and 
used for protein isolation. In addition, blood was drawn prior to CEA procedure and plasma was stored at -80 °C. 
Quantification of immunoglobulin and MC tryptase levels in patient plasma
Plasma total IgE and IgG levels were measured using a human IgG and IgE ELISA according to manufacturer’s 
protocol (Bethyl Laboratories, Montgomery, TX). Plasma IgG-oxLDL levels were measured by coating cupper 
oxidized human LDL in PBS (pH=9,0) on MaxiSorp 96-well plates (Nunc, Roskilde, Denmark) overnight at 4˚C. 
Diluted Samples and standards (Biomedica, Wien) were added and incubated for 2 hours at 37˚C. Supernatants 
were discarded and plates were washed thoroughly. Anti-human IgG-HRP (Bethyl Laboratories, Montgomery, 
TX) was added as detection antibody for 1 hour at 37˚C. Bound oxLDL-IgG was visualized by using 2,2’-azinobis 
3-ethylbenzthiazoline-6-sulfonic acid (ABTS, Sigma). Colour was measured at an optical density of 415 nm using 
a conventional ELISA reader. Between each ELISA step plates were washed with PBS containing 0.05% Tween20.
MC tryptase levels were determined in plasma samples using an ImmunoCAP® 250 tryptase assay (Phadia AB, 
Uppsala, Sweden)
Immunohistochemistry
Sections were stained for mast cell tryptase (mast cells), CD68 (macrophages), smooth muscle cells (alpha actin), 
and CD34 (endothelial cells) as previously described (4). Total mast cell numbers were determined by counting 
all (degranulating) mast cells present in a plaque cross-section at x40 magnification (4). A degranulating mast 
cell was defined by a group of mast cell tryptase positive extracellular granules in close proximity of each other 
or in close proximity of a mast cell. The total plaque area (mm2) was measured using the analySIS 2.8 software 
(Olympus Soft Imaging Solutions GmbH, Münster, Germany) to determine the distribution density of mast cells 
expressed as numbers of mast cells/mm2. Image-analyzing software was used to determine positive macrophage 
and smooth muscle cell staining expressed as a percentage of covered plaque area (13). Microvessels were 
counted in three hot-spots and were expressed as average microvessel density per hotspots (19). Collagen 
content (picrosirius red) was scored semi-quantitatively. The size of the extracellular lipid core (atheroma) was 
assessed by the H&E and picrosirius red stain (13). 
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Statistics and data analysis
IBM SPSS statistics version 20 was used for all analyses (IBM corporation, Armonk, NY, USA). Immunoglobulin 
levels are not normally distributed; non-parametrical testing was used to determine differences. The Mann-
Whitney U test was used to study immunoglobulin levels as a continuous variable for all risk factors. The 
Spearman correlation coefficient was calculated to assess associations between immunoglobulin levels and all 
continuous variables in this study. Differences were considered significant with a p-value of below 0.05.
Results
Baseline patient characteristics
Total IgE, total IgG and oxLDL-IgG plasma levels were measured in a total of 135 patients 
that underwent carotid endarterectomy. Baseline clinical characteristics of the 135 patients 
are provided in Table 1. The studied patient population with a mean age of 67 and a male 
prevalence (71%) reflects a relatively typical population of patients with vascular occlusive 
diseases. The majority of patients was symptomatic (74%) as illustrated by the incidence 
of amaurosis fugax, a TIA or a stroke, was hypertensive (86%) and used statins (69%).
Table 1. Baseline characteristics of patients in relation to immunoglobulin plasma levels
Total IgG p-value oxLDL-IgG p-value Total IgE p-value
Age, mean years (sd) 67 (9) r = -0.082 0.347 r = 0.031 0.724 r = 0.097 0.265
BMI, mean kg/m2 (sd) 27 (4) r = -0.115 0.19 r = 0.001 0.995 r = -0.126 0.15
Gender
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Table 1. Baseline characteristics of patients in relation to immunoglobulin plasma levels. (continued)
Data are presented as No. (%) and median [IQR] unless otherwise indicated; r = Spearman’s rank 
correlation coefficient; sd = standard deviation; IQR = interquartile range; BMI = body mass index; TIA 
= transient ischemic attack; *p-value represents statistical analysis for asymptomatic patients versus 
symptomatic patients (composed of amaurosis fugax, TIA an stroke).
Plasma immunoglobulin levels and mast cell parameters
A correlation with borderline significance was found between total IgE and oxLDL-IgG 
(r=0.169, p=0.051). Total IgG did not correlate with either total IgE or oxLDL-IgG. No 
association was found between total IgE, total IgG and oxLDL-IgG plasma levels and 
total mast cell numbers or total degranulating mast cells (Table 2). In addition we did not 
observe any association between the three immunoglobulins and tryptase plasma levels. 
Table 2. Immunoglobulin plasma levels with respect to mast cell parameters
Total IgG p-value oxLDL-IgG p-value Total IgE p-value
Total mast cells r = -0.038 0.664 r = 0.137 0.114 r = -0.038 0.664
Mast cells/mm2 r = -0.104 0.230 r = 0.115 0.186 r = -0.014 0.872
Degranulating 
mast cells/mm2
r = -0.074 0.519 r = 0.008 0.946 r = -0.076 0.506
Plasma tryptase r = -0.076 0.378 r = 0.040 0.643 r = 0.064 0.457
Data are presented as Spearman’s rank correlation coefficient (r)
Plasma immunoglobulin levels and vulnerable plaque characteristics
As depicted in Figure 1, no consistent associations were found between immunoglobulin 
levels and measures of vulnerable plaque phenotype. There was no association between 
immunoglobulin levels and any of the following plaque characteristics: fat deposition, 
collagen, smooth muscle cells, macrophages, microvessel density. 
Plasma immunoglobulin levels and clinically relevant characteristics
Table 1 provides an overview of the associations between the three immunoglobulin 
expression levels and relevant clinical characteristics. A negative association was 
observed between statin use and total IgE (97.5 [43.1-276.8] vs. 157.3 [75.2-545.4] ng/mL, 
p=0.012) and oxLDL-IgG (288 [224-406] vs. 399 [282-584] mU/mL, p=0.004). Higher total 
IgE levels were observed in smokers compared to non-smokers (91.8 [62.3-145.0] vs. 76.7 
[47.1-111.2] ng/mL, p=0.002). Clinical presentation was not associated immunoglobulin 
levels: no differences were observed in expression levels for any of the immunoglobulins 
between asymptomatic patients (n=35) and symptomatic (n=100) patients. Furthermore, 
we did not detect any differences in any of the circulating immunoglobulin levels between 
the subgroups of symptomatic patients (i.e. patients suffering from amaurosis fugax, TIA 
or stroke). Additionally, no association was found between immunoglobulin levels and 
the delay between surgery and presentation of symptoms. 
Plasma Igs Do Not Associate with Plaque Mast Cells | 121
5
Figure 1. No association were found between IgE (left graphs), IgG (middle graphs) and oxLDL-IgG 
(right graphs) levels and any of the plaque characteristics: fat deposition, collagen, smooth muscle 
cells, macrophages and microvessel density.
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Discussion
Progression of an atherosclerotic plaque is often characterized by measures of plaque 
vulnerability. A vulnerable plaque is prone to rupture resulting in severe cardiovascular 
complications. Experimental studies have shown that mast cell activation results in pro-
gression and destabilization of the atherosclerotic plaque (20,21). In addition, in human 
plaques, mast cells correlated with vulnerable plaque characteristics and appeared associ-
ated with future combined cardiovascular events (4). It has been suggested that activated 
mast cells induce intraplaque neoangiogenesis thereby making the plaque more suscep-
tible for rupture. For therapeutic intervention, identification of the endogenous mast cell 
activators during the progression and destabilization is of great value. In allergy and asth-
ma, IgE is the main trigger for mast cell degranulation via crosslinking of the FcεR, while 
specific IgG immune complexes can exert mast cell activation resulting in cytokine release 
via binding to various Fcγ receptors. Previous studies have demonstrated that plasma IgE 
levels may be linked to the presence of cardiovascular diseases (11) and mice lacking the 
FcεR displayed reduced atherogenesis (22). Furthermore, oxLDL specific IgG molecules 
that can form immune complexes with oxLDL have been detected in human and rabbit 
atherosclerotic plaques (23) and these immune complexes were able to induce TNFα and 
IL-8 release from human mast cells (12). Taken together, these data suggest that IgE and 
specific IgGs may be important mast cell activators in cardiovascular disease. 
It is however still unknown whether circulating immonuglobulins are capable of activat-
ing mast cells in human atherosclerotic plaques. Here we show that circulating IgG, IgE 
and oxLDL-IgG are not associated with mast cell determinants in a patient cohort with 
severe carotid stenosis that underwent an endarterectomy. No association was observed 
between any of the three immunoglobulins measured in this study and total plaque mast 
cell numbers or mast cell tryptase plasma levels. In addition, we did not observe any cor-
relation with intraplaque degranulating mast cell numbers. Our results do not provide 
supportive evidence that increased immunoglobulin levels induce activation of mast cells 
in advanced human atherosclerotic plaques. 
Previously, IgE was shown an independent marker for cardiovascular disease in men (24). 
Therefore we explored the possibility of an association between the three immunoglobu-
lins had any future adverse events in patients with established cardiovascular disease. We 
did not find any association between immunoglobulin levels and future cardiovascular 
events, however, we were underpowered for analysing risk prediction for the immuno-
globulins in our cohort. Nevertheless, no association was found with histological markers 
of plaque vulnerability, one of the most important determinants for future cardiovascular 
complications.
Serum oxLDL specific IgG antibodies have previously been linked to the presence and 
destabilization of the atherosclerotic plaque (25). As mentioned above, specific IgGs have 
been observed within the atherosclerotic plaque. In the current study, we did not detect 
any correlation between plasma oxLDL-IgG levels and mast cell activation or plaque phe-
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notype. However, systemic oxLDL-IgG levels may not reflect the local oxLDL-IgG immune 
complexes that may actually activate the mast cell within the atherosclerotic plaque. His-
tological analysis of immune complexes, and with that also local IgE content, and colo-
calization with mast cells within the plaque may provide more information on the mecha-
nisms of mast cell activation in atherosclerosis. 
Interestingly, lower IgE and oxLDL-IgG levels were observed in patients that used statins. 
When we differentiated between the patients on statins and the patients not on statins 
it does not affect the outcome of the associations observed between immunoglobulin 
levels and mast cell parameters or plaque vulnerability (data not shown). The inhibitory 
effects of statin use on oxLDL-IgG antibody levels have been previously described (25), 
however reduced levels of IgE after statin treatment has to our knowledge not been re-
ported before in patients with atherosclerosis. These data thus identify a novel effect of 
statin treatment, in addition to lipid-lowering, possibly by affecting antibody production 
of B cells.
The results of our study may be limited by the relative small number of patients. We have 
previously established that plasma tryptase levels of these patients correlate with plaque 
mast cell number and activation status, thus being reflective of mast cell activation. How-
ever, using these patients we were unable to detect a relation between any of the meas-
ured circulating immunoglobulin levels and intraplaque mast cell numbers or its activa-
tion, which may be improved by using a larger patient cohort. In addition, we measured 
plasma immunoglobulin levels at a single time-point that is at time of carotid endarterec-
tomy, which is most reflective of the mast cell status within the plaque at that time point. 
Measuring plasma immunoglobulin levels at multiple time-points, for example at follow-
up, may provide more information on the variation in circulating immunoglobulin levels 
together with disease progression.
In conclusion, no associations were found for total IgE, total IgG and oxLDL-IgG and the 
presence of total mast cell numbers or the number of degranulating mast cells in ath-
erosclerotic plaques. Furthermore, the immunoglobulins were not related to most of the 
established characteristics of the rupture-prone atherosclerotic plaques. Taken together, 
this study does not provide supportive evidence that the three investigated circulating 
immunoglobulins activate mast cells during the progression of atherosclerotic disease. 
We can however not exclude that the mast cells may be activated by other specific im-
munoglobulins, or that local factors within the vessel wall are more predominant deter-
minants of mast cell activation in the atherosclerotic plaque. Future research on the local 
environmental specific IgE and IgG levels within the plaque may thus shed more light on 
mechanism of mast cell activation in atherosclerosis.
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Abstract
Objective
Atherosclerosis can be considered as a lipid-driven chronic inflammatory disease of the 
large- and medium sized arteries. Innate mast cells accumulate in the atherosclerotic 
lesion during its development and can take up to 6% of all nucleated cells in rupture 
prone lesions. In the past years, a number of experimental atherosclerosis studies have 
been performed in mice to unravel the contribution of mast cells and their mediators to 
atherogenesis. Frequently, mice have been used with alterations in the stem cell signaling 
pathway like the KitW-sh/W-sh mice, which results in mast cell deficiency. However, it became 
evident that KitW-sh/W-sh mice suffer from bystander defects such as neutrophilia. To study the 
development of atherosclerosis without these side effects, we used a mast cell inducible 
knockout mouse, the Red Mast cell Basophil (RMB) mouse, in which mast cell deficiency is 
independent of stem cell signaling.
Methods and Results
RMB mice were crossed with apoE deficient mice to obtain RMB-apoE-/- mice. In these mice, 
mast cells were depleted by intraperitoneal Diphtheria Toxin (DT) injection or PBS injection 
as a control. Directly after mast cell depletion, mice were placed on a western type diet to 
induce lesion development. Two weeks after the start of the diet, semi-constrictive collars 
were placed around the carotids followed by 4 additional weeks of WTD. At sacrifice, we 
did not detect any differences in body weight, total cholesterol levels or total leukocyte 
counts between mast cell depleted and competent groups. Histological analysis of the 
carotids showed a consistent depletion of mast cells after DT treatment, which coincided 
with a reduction in both lesion size and necrotic core area and an increased collagen 
content. Furthermore, we detected reduced levels of circulating IL-6 and TNFα in mast cell 
depleted mice. 
Conclusions
In this current study we confirmed in a novel mouse model that mast cells contribute to 
the initiation phase of atherosclerotic lesion development.
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Introduction
Mast cells are innate immune cells which are located throughout the body in peripheral 
tissues as skin, gut and within the vascular system [1]. Close to the external environment 
they are one of the first immune cells able to respond to invading pathogens. Mast cells 
are equipped with a variety of receptors that enables them to react within seconds to a 
number of stimuli. IgE-mediated activation is by far the most powerful activation pathway 
of mast cells, which results in the release of preformed mediators such as tryptase, chymase 
and histamine stored within the granules of the cell. The acute release of mediators is 
followed by the secretion of newly synthesized mediators including chemokines and 
cytokines [2]. The role of mast cells in allergy and hypersensitivity is well known, but more 
recent, also the contribution of mast cells to  immune driven disorders such as rheumatoid 
arthritis and atherosclerosis has been identified [3–5]. 
Mast cells accumulate within atherosclerotic lesions at sites of plaque rupture, where 
they can be up to 6% of all nucleated cells [6]. The lesion contains a number of different 
stimuli such as endogenous toll like receptor (TLR) ligands and immune complexes that 
could potentially activate mast cells. For example, oxLDL-immune complexes are able to 
activate mast cells via FcγRs to release tumor necrosis factor (TNFα), interleukin 8 (IL-8) 
and monocyte chemotactic protein 1 (MCP-1), which may enhance the inflammatory 
response within the lesion [7]. Upon activation, mast cells can release proteases like 
chymase and tryptase that are able to degrade collagen as well as HDL and induce 
apoptosis of smooth muscle cells, which will induce and accelerate lesion destabilization 
[8–10]. Likewise, systemic mast cell activation leads to plaque growth and destabilization, 
which can be rescued by the administration of the mast cell stabilizer cromolyn [11]. 
Moreover, atherosclerosis-prone mice deficient for mast cells (LDLr-/-KitW-sh/W-sh) develop 
smaller and more stable lesions compared to control LDLr-/- mice [12]. Although these 
studies demonstrate that mast cells contribute to atherosclerotic lesion development 
and destabilization, the use of KitW-sh/W-sh mice is limited due to the fact that these mice 
with a defect in c-kit signaling suffer from several complications such as neutrophilia 
and expansion of splenic myeloid-derived suppressor cells [13–15]. To circumvent these 
undesired effects, mice have been developed in which mast cell deficiency is induced 
independently of SCF signaling, for example the carboxypeptidase A(Cpa3)-Cre; Mcl-1fl/
fl mice, the mast cell protease 5 (Mcpt5)-Cre+iDTR+ mice and the Red-Mast cell-Basophil 
(RMB) mice [16–19]. Cpa3-Cre; Mcl-1fl/fl mice express Cre recombinase under control of 
Cpa3 promoter, which is combined with a floxed allele of the antiapoptotic factor. This 
combination results in deficiency in mast cells and a marked reduction in basophils. 
Recently, mice have been developed were mast cells can be depleted upon injection 
with diphtheria toxin (DT). Examples are the Mcpt5-Cre+iDTR+ mice and RMB mice that 
co-express the simian DT receptor together with proteins highly expressed by mast cells, 
which are for these two mouse models  Mcpt5 and FcεRIβ, respectively. Administration of 
DT to these mice will causes apoptosis of all cells that express the DT receptor. 
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In the current study we used the RMB mouse model to study the role of mast cells in 
atherosclerosis. In this mouse model, the repopulation kinetics of basophils and mast cells 
after depletion with DT is shown to different. Basophils are depleted relatively shortly (<12 
days), whereas systemic mast cell depletion is maintained for up to 2 months after the 
last DT injection [19]. We crossed these RMB mice with apoE-/- mice to create an inducible 
mast cell knockout on an atherosclerotic-prone background, creating the RMB-apoE-/-. In 




All animal work was performed conform the guidelines from the Directive 2010/63/EU of the European 
Parliament. Experiments were approved by the Leiden University Animal Welfare committee. The red mast cell 
and basophil mouse strain (RMB mice, official name: B6.Ms4a2tm1Mal) was provided by the laboratory of dr. P. 
Launay INSERM U1149, Paris, France [19]. These mice express the simian diphtheria toxin receptor under control 
of the promoter of the FcεRIβ gene. Injection of diphtheria toxin induces apoptosis of all FcεRIβ expressing cells, 
which are in mice only basophils and mast cells [20]. The RMB mice were crossed with apoE-/- mice to obtain 
atherosclerosis-prone RMB-apoE-/- mice. 
To systemically deplete all FcεRIβ+ cells, RMB-apoE-/- mice were injected i.p. on day 1, 3 and 8 with 25 ng/g 
bodyweight DT (Diphtheria Toxin Unnicked, C. diphtheriae (Cat #322326, CalBiochem)). Two weeks before the 
start of the experiment, mice received either DT injections as described above to deplete FcεRIβ+ cells or PBS 
as a control.  The efficiency of DT treatment to deplete mast cells was determined by both FACS analysis for 
circulating basophils (CD49b+/FcεRI+/IgE+) three days after last DT injection and by a mast cell staining in the 
carotids and hearts (CAE, Sigma) at end of the study.
At week 0 mice were fed a Western type diet (0.25% cholesterol and 15% cacao butter, SDS, Sussex, UK) for 
total 6 weeks. Two weeks after the start of Western type diet (WTD), perivascular collars were placed around 
both left and right carotid artery, which causes low shear stress and disturbed blood flow at the proximal side 
of the collar that results in endothelial activation, increased endothelial adhesion molecule expression and 
atherosclerotic lesion formation [21]. In short, mice were anaesthetized by subcutaneous injection of ketamine 
(60 mg/kg, Eurovet Animal Health, Bladel, The Netherlands), fentanyl citrate and fluanisone (1.26 mg/kg and 2 
mg/kg respectively, Janssen Animal Health, Sauderton, UK) and a semi-constrictive collar was placed.
At sacrifice, mice were anaesthetized as described above and sacrificed via orbital exsanguination. Fixation 
through the left cardiac chamber was performed with phosphate-buffered saline (PBS). Subsequently, both 
common carotid arteries and the heart were excised and stored in 3.7% neutral-buffered formalin (Formal-fixx; 
Shandon Scientific Ltd, UK) for histological analysis. Serum was obtained for determination of cytokine and 
immunoglobulin levels. Splenocytes, blood and heart lymph nodes were isolated for FACS analysis of leukocytes.
Histology and morphometry
Carotid arteries and hearts were embedded in Tissue-Tek® O.C.T.™ compound (Sakura BV, The Netherlands) after 
which cryosections were prepared. Section of the carotid arteries were stained with hematoxylin-eosin (H&E) to 
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determine lesion size and necrotic core area (in µm2) at the side of maximal stenosis. Lesions in the aortic root 
were quantified in Oil Red-O-stained sections. Mean lesion area (in µm2) was calculated from 6 serial sections, 
starting at the appearance of the tricuspid valves. 
Collagen content was determined by staining with picrosirius red and an enzymatic staining (CAE, Sigma-
Aldrich, Germany) was used for the visualization of mast cells. Perivascular mast cells were counted manually by 
a blinded independent operator. The necrotic core size was defined as the a-cellular, debris-rich plaque area as 
percentage of the total plaque area. The atherosclerotic lesion areas and histological stainings of both carotids 
and aortic root were quantified using the Leica image analysis system, consisting of a Leica DMRE microscope 
coupled to a video camera and Leica Qwin Imaging analysis system (Leica Ltd, UK).
Flow cytometry
At sacrifice, blood was obtained in EDTA tubes and white blood cell (WBC), red blood cell (RBC) and platelets (PLT) 
were determined using an automated Sysmex XT-2000iV veterinary haematology analyzer (Sysmex orporation, 
Kobe, Japan). For flow cytometry analysis, erythrocytes were removed using a specific erythrocyte lysis buffer 
(0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). 
Blood leukocytes were stained extracellular with four different stains to determine a) monocytes (NK1.1-/
Ly6G-/CD11bhi), inflammatory monocytes (NK1.1-/Ly6G-/CD11bhi/Ly6Chi/CCR2+) and neutrophils (NK1.1-/Ly6Ghi/
CD11bhi), b) basophils (CD3-/CD4-/CD19-/CD8-/CD49b+/IgE+/CD117-), c) T cells (CD3+/CD4+), d) B-cells (CD19+/
B220+). The different used antibodies are summarized in table 1. Antibodies were obtained from (eBiosciences, 
US). Flow cytometry analysis was performed on the FACSCantoII and obtained data was analyzed using FACSDiva 
software (BD Biosciences, US).
Table 1: Antibody panels used for flow cytometry analysis









































Serum cytokine and immunoglobulin levels were determined using a commercially available ELISA kit (BD, US, 
Bethyl laboratories, US). All procedures were according to manufacturer’s protocol.
Serum concentrations of total cholesterol was determined by enzymatic colorimetric assay according to protocol 
of supplier (Roche Diagnostics, US). Precipath (Standardized serum Roche Diagnostics, US) was used as internal 
standard.
Statistical analysis
Data are expressed as mean ±SEM. A 2-tailed Student’s t-test was used to compare individual groups in the in 
vivo studies. A level of P<0.05 was considered significant. 
6
A new mast cell knockout mouse model in atherosclerosis |133 
Results
No effect of FcεRIβ+-cell depletion on body weight, total cholesterol and leukocyte counts in 
RMB-apoE-/- mice
A schematic overview of the current study is depicted in figure 1a. In short, FcεRIβ+ cells 
were depleted in RMB-apoE-/- mice before induction of atherosclerosis by western type 
diet feeding. DT efficiency was determined by flow cytometry analysis for circulating blood 
basophils. At 3 days after the last DT injection, we observed a population of basophils in 
PBS treated mice and absence of basophils in the DT treated group (Fig. 1b). Subsequently, 
mice were fed a western type diet for a total of 6 weeks, two weeks after start of diet 
mice received perivascular collars to accelerate lesion development. At sacrifice, we did 
not observe weight differences between the PBS and the DT treated group (Fig. 1c). Total 
serum cholesterol level (Fig. 1d), total leukocyte and red blood cell numbers, as well as 
platelet counts (Fig. 1e) did not differ between the mast cell depleted and control treated 
group. 
Figure 1. The effect of FcεRIβ+-cell depletion on body weight, total cholesterol and leukocyte 
counts in RMB-apoE-/- mice
(A) Flow-chart of the in vivo experimental set-up. (B) Gating stratagy of blood basophils and 
summary of all PBS and DT treated mice. (C) Body weight was monitored during the experiment 
in PBS- or DT-treated RMB-apoE-/- (n=15/group). (D) Total serum cholesterol levels were determine 
in PBS- or DT treated RMB-apoE-/- mice at the end of the experiment (n=15/group). (E) Total white 
blood cell (WBC), red blood cell count (RBC) and platelet count was determined in PBS or DT-treated 
RMB-apoE-/- mice at sacrifice (n=15/group). ***P<0.001.
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Depletion of FcεRIβ+ cells reduces lesion size and increases lesion stability in carotid arteries.
Atherosclerotic lesion size and composition in the carotid arteries was analyzed after 4 
weeks of lesion development. Mast cells are the only tissue resident cells that express the 
β-chain of the FcεRI [20]. DT treated RMB-apoE-/- mice showed a complete absence of mast 
cells, while mast cells were present in PBS-treated RMB-apoE-/- mice (Fig. 2a). Quantification 
of the atherosclerotic lesion size in the carotid artery showed that depletion of FcεRIβ+ 
cells led to a 28% reduction in mean lesion size compared to PBS-treated mice (DT: 78.6 
± 7.9*103 μm2 versus PBS: 109.1 ± 8.3*103 μm2, p=0.02, Fig. 2b). Additionally, we analyzed 
the collagen content using a Sirius Red staining and the percentage of necrotic area as a 
measure for plaque stability. Depletion of FcεRIβ+ cells resulted in an increased collagen 
content in the lesions of DT-treated mice compared to PBS-treated animals (DT: 10.7 ± 
1.1% versus PBS: 4.7 ± 0.7%, p=0.0003, figure 2c) and a reduction in the relative necrotic 
core area  (DT: 32.3 ± 4.3% versus PBS: 44.9 ± 4.3%, p=0.02, Fig. 2d).
Figure 2. Depletion of FcεRIβ+ cells reduces lesion size and increases lesion stability in carotid 
arteries.
(A) An efficient depletion of perivascular mast cells was observed in DT-, but not in PBS treated 
RMB-apoE-/- mice (n=15/group). Magnification insert shows mast cells. (B) DT treatment resulted in 
a reduction in lesion size compared to non-depleted mice (n=15/group). The depletion of FcεRIβ+-
cells prior to induction of lesion development coincided with an increase in collagen content (C) 
and a reduction in necrotic core area (D) compared to non-mast cell-depleted mice (n=15/group). 
(D: dotted lines indicate necrotic core). *P<0.05, ***P<0.001.
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FcεRIβ+ cell depletion does not influence lesion size but increases collagen content in aortic 
root.
Similarly as in the carotid arteries, we observed a complete depletion of perivascular mast 
cells in the aortic root of DT-treated mice (Fig. 3a). Analysis of the lesion size in the aortic 
root of PBS and DT treated mice did not reveal any difference in Oil-Red-O positive area 
(DT: 4.7 ± 0.5*105 μm2 versus PBS: 4.1 ± 0.2*105 μm2, p=NS, Fig. 3b). The collagen content in 
the lesions of FcεRIβ+ cell depleted mice was increased compared to mast cell competent 
mice (DT: 16.6 ± 1.6% versus PBS: 9.1 ± 1.6% p=0.006, Figure 3c). We observed a trend 
towards a reduction in necrotic core area in FcεRIβ+ cell depleted mice (Fig. 3d).
Figure 3. FcεRIβ+ cell depletion does not influence lesion size but increases collagen content 
in aortic root. 
(A) An efficient depletion of adventitial mast cells was observed in DT injected RMB-apoE-/- mice 
(n=15/group) Arrows indicate mast cells. (B) Despite the efficient FceRIβ+-cell depletion, no effect 
was observed on lesion size between both groups. (C) Collagen content was significantly increased 
whereas the necrotic core area. (D) was slightly decreased in FceRIβ+-cell deleted mice compared to 
non-depleted mice. **P<0.01 ****P<0.0001.
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Figure 4. Depletion of FcεRIβ+ cells had no effect on circulating leukocytes in the blood.
(A) Circulating innate basophils (CD49b+/IgE+/CD3-/CD19-), Neutrophils (CD11b/Ly6G), Monocytes 
(CD11bhigh/Ly6G-/NK1.1-), Inflammatory monocytes (CD11bhigh/CCR2+/Ly6C+/Ly6G-/NK1.1-) and (B) 
adaptive CD4+ T cells, CD8+ T cells and B-cells (CD19+) in both PBS and DT treated RMB-apoE-/- mice 
(n=15/group).
At sacrifice, flow cytometry was performed on the WBC population to determine the 
numbers of circulating innate immune cells such as basophils, neutrophils, (inflammatory) 
monocytes (Fig. 4a) and adaptive immune cells such as CD4+ T cells, CD8+ T cells and B cells 
(Fig. 4b). As depicted, we did not detect any difference in the analyzed leukocyte subsets 
between PBS and DT treated mice.
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Depletion of FcεRIβ+ cells decreases levels of pro-atherogenic cytokines and increases total IgE 
levels.
In the serum we determined pro-atherogenic mediators such as IL-6, TNFα and MCP-1 
and as well as total IgG and IgE levels. Circulating IL-6 levels were reduced upon depletion 
of mast cells (DT: 218.9 ± 22.7 pg/mL versus PBS: 409.2 ± 40.8 pg/mL, p=0.006), and also 
TNFα levels were reduced (DT: 69.0 ± 5.9 pg/mL versus PBS: 91.9 ± 6.9 pg/mL, p=0.02). 
No differences in circulating MCP-1 were detected between groups. Total IgG levels in 
serum did not differ between FcεRIβ+ cell competent and FcεRIβ+ cell depleted mice. 
However, we did observe an elevated concentration of total IgE in the serum of FcεRIβ+ 
cell depletedmice (DT: 1024.0 ± 28.5 pg/mL versus PBS: 840.8 ± 80.2 pg/mL, p=0.04).
Figure 5. Depletion of FcεRIβ+ cells decreases levels of pro-atherogenic cytokines and 
increases total IgE levels. 
(A) Serum levels of IL-6, TNFα and MCP-1 were quantified in serum of PBS and DT treated RMB-apoE-/- 
mice (n=15/group). (B) Serum levels of total immunoglobulin G (IgG) and immunoglobulin E (IgE) 
(n=15/group). *P<0.05, ***P<0.001.
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Discussion
Mast cells are tissue resident cells located at sites that are in close proximity with the 
external world like the skin or within the gut [1]. Furthermore, mast cells are located 
around blood vessels and can influence vascular homeostasis by the release of several 
mediators, such as proteases, chemokines and cytokines. [4]. Already 60 years ago, mast 
cells have been implicated in cardiovascular diseases among which atherosclerosis [22]. 
Many experimental studies have been performed to unravel the contribution of the mast 
cell and its mediators to plaque initiation, progression and destabilization [11, 12, 23–25]. 
However, these studies were generally performed in mice with mutations in the stem cell 
factor signaling (SCF) pathway, like the KitW-sh/W-sh mice, in which a chromosomal inversion 
causes a disruption of the c-kit (SCF receptor) gene thereby blocking kit expression [13]. 
Since mast cells need SCF signaling for their maturation, proliferation and survival, these 
mice lack mast cells [26]. However, it became evident that SCF is also essential for other 
(non)-immune cells and, as a consequence, these mice suffer from side-effects such 
as neutrophilia [15]. In the current study we used the recently generated red-mast cell 
basophil (RMB) mouse strain, which is independent of c-kit [19]. These mice express the DT 
receptor under control of the promoter of the FcεRIβ-gene, which is expressed exclusively 
by basophils and mast cells. Nonetheless, there is a marked difference in the repopulation 
kinetics reported of these cells after depletion.
At sacrifice, we confirmed this difference in repopulation kinetics as blood basophils were 
completely repopulated while a complete depletion of tissue resident mast cells was still 
observed in DT treated animals at 6 weeks after depletion of FcεRIβ+ cells. Moreover, the 
contribution of basophils to atherogenesis is still largely unknown. Basophils have up to 
now not been demonstrated to be present within the atherosclerotic lesion, which could 
be caused by their limited lifespan due to early apoptosis outside the bloodstream [27]. 
Furthermore, we started the FcεRIβ+ cell depletion 14 days before start of western-type 
diet, and thus the induction of atherosclerotic lesion development, and 4 weeks before 
perivascular collar placement around the carotids. Therefore, we can conclude that the 
observed effects of FcεRIβ+ cell depletion on atherogenesis in this study are most likely 
due to the depletion of tissue-resident mast cells rather than the relative short absence of 
circulating basophils.
A stable atherosclerotic plaque is characterized by the presence of a relatively small 
necrotic core, which is covered by a thick layer of smooth muscle cells that produce 
extracellular matrix molecules such as collagen. In the current study depletion of mast 
cells had no effect on body weight, total cholesterol and total leukocyte count as it 
was comparable to PBS control mice. However, we did observe that mast cell depletion 
resulted in a significant reduction in lesion size and an increase in collagen content in both 
carotid artery and aortic root lesions. Furthermore, the necrotic core area was significantly 
reduced in the carotid arteries and a similar trend was observed in the aortic root in mast 
cell depleted mice. These observations are in line with a previous study that showed that 
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in LDLr-/-KitW-sh/W-sh mice lesions are smaller with a higher collagen content after 12 weeks 
of diet [12]. Mast cell derived IL-6 and IFNγ have been identified to be the key mediators 
in lesion development that study. In addition, we have previously shown that inhibition of 
chymase, one of the mast cell specific proteases, was able to reduce plaque progression 
in apoE-/- mice, which coincided with enhanced collagen content and decreased necrotic 
core size [28]
In our current study we detected a reduction in serum IL-6 in mast cell depleted mice. IL-6 
promotes endothelial dysfunction, SMC proliferation and migration as well as recruitment 
and activation of inflammatory cells, thereby accelerating vascular inflammation [29]. 
Additionally, it was previously demonstrated that IL-6 affects the expression of scavenger 
receptors SR-A and CD36, which are involved in the uptake of oxLDL and thus promotes the 
formation of foam cells, a hallmark of early atherosclerotic lesion formation [30]. However, 
in vivo data discussing IL-6 in atherogenesis are rather contradictory. On one hand it 
was shown that administration of recombinant IL-6 to apoE-/- mice results in accelerated 
atherosclerosis, which coincided with an increase in inflammatory cytokines [31]. On the 
other hand, apoE-/- mice deficient for IL-6 developed larger lesions compared to apoE-/- 
controls. These studies indicate that IL-6 has both pro- and anti-inflammatory functions 
in atherosclerosis and that these functions are tightly balanced, which is essential for the 
immune response outcome during lesion development.
Furthermore, TNFα is an important acute phase cytokine that is implicated in many 
autoimmune disease such as rheumatoid arthritis and also in atherosclerosis. TNFα is 
expressed predominantly by activated macrophages but also by many other local (immune) 
cells like foam cells, smooth muscle cells and mast cells [32–34]. Since macrophages and 
mast cells have either transmembrane bound TNFα or preformed TNFα in their granules 
these cells are able to rapidly release TNFα upon stimulation [34–36]. Therefore, mast cells 
can be a source of TNFα in acute phase reactions [34]. TNFα stimulates both macrophages 
and smooth muscle cells to synthesize matrix proteases resulting in degradation of the 
fibrous cap [37, 38]. Moreover, TNFα is capable of decreasing the suppressive capacity of 
Tregs [39] and mast cell derived TNFα was shown to drive both the hypertrophy of the 
draining lymph nodes and recruitment T cells to the site of infection [40]. In our study, the 
depletion of mast cells coincided with a significant reduction in serum TNFα. Sun et al. 
described that mast cell derived TNFα did not affect atherogenesis [12]. However, TNFα-
/- bone marrow derived mast cells used in that particular study produced relatively higher 
amounts of both IL-6 and IFNγ, i.e. 50 and 30% respectively, compared to wild-type bone 
marrow derived mast cells. Therefore it cannot be excluded that the observed effects on 
lesion size are due to enhanced secretion of these proatherogenic cytokines. Furthermore, 
it has been shown that mice deficient for both apoE-/- and TNFα developed a marked 
reduction in lesion size, which indicates an active involvement of TNFα in atherogenesis 
[41].
Taken together, this study establishes that absence of mast cell before the induction of 
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atherosclerosis is beneficial for both lesion growth and stability as well as for the systemic 
inflammatory milieu. Our data are correspond with previous experimental atherosclerosis 
studies demonstrating a critical role for mast cells in atherogenesis, without effects on 
other hematopoietic cells and shows that the RMB-apoE-/- mouse model can be of great 
value to study the role of mast cells in atherosclerosis. 
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Abstract
Objective 
Mast cells are potent immune effector cells that are known to contribute to the initiation 
of atherosclerosis, and are implicated in the destabilization of atherosclerotic lesions 
matrix degradation via the release of proteases. Furthermore, mast cells can influence T 
cell skewing via the release of cytokines and cell-cell contact. To study the effects of mast 
cells on progression of atherosclerosis we used an inducible mast cell knockout mouse, 
the red mast cell basophil (RMB) mouse, that lacks the LDLr (RMB-LDLr-/-). In this novel 
mouse model mast cells can be depleted after the development of atherosclerotic lesions, 
which enables us to investigate its effects on atherosclerotic lesion progression.
Methods and Results
We induced atherosclerosis in RMB-LDLr-/- mice by western type diet feeding for 10 weeks. 
After 10 weeks, a baseline group was sacrificed, while the other groups received either 
DT to deplete all FcεRIβ+ cells or PBS as a control. After successful depletion of the mast 
cells, mice received diet feeding for an additional 6 weeks. No differences were observed 
in atherosclerotic lesion size between the groups, but a significant increase in collagen 
content and a reduction in macrophage content and necrotic core area was observed 
in mast cell depleted mice compared to non-depleted mice. Furthermore, mast cell 
depletion coincided with a marked reduction in serum IL-6 levels and an increase in IL-10 
levels compared to mast cell competent mice. In addition, an increase in regulatory T cells 
was observed in both the spleen and the heart lymph nodes of mast cell depleted mice.
Conclusions
Mast cell depletion in the progression phase of atherosclerosis improved the lesion 
stability and reduced systemic inflammation. Besides the well-established role of mast 
cells in the initial phases of lesion development, this study shows that mast cells also 
actively contribute to the progression and destabilization of atherosclerosis plaques.
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Introduction
Atherosclerosis is a chronic lipid-driven inflammatory disease of the large- and medium 
sized arteries that involves complex immunologic mechanisms such as accelerated 
inflammation and reduced tolerance [1]. Next to its involvement in early atherogenesis, 
the immune system actively contributes to the progression and destabilization of an 
atherosclerotic plaque. Factors released by activated inflammatory leukocytes such as 
neutrophils, lipid-laden macrophages, T cells and mast cells result in the loss of matrix 
components such as collagen and apoptosis of smooth muscle cells, which accelerate the 
process of plaque destabilization  [2]. Frequently, the process of plaque destabilization 
induces plaque rupture, which leads to acute atherothrombotic occlusion and clinical 
manifestations such as myocardial infarction and stroke [3]. Activated immune cells, 
among which mast cells, accumulate in the shoulder region of advanced atherosclerotic 
lesions, which can trigger matrix degradation by the release of specific proteases [4]. 
Especially mediators such as tryptase, chymase and histamine that are stored inside the 
granules of the mast cells are major contributors to plaque destabilization [5]. Circulating 
tryptase and chymase levels are increased in serum of cardiovascular patients suffering 
from acute myocardial infarction or unstable angina pectoris compared to patients with 
stable angina pectoris or healthy controls [6, 7]. 
To date, a number of experimental atherosclerosis studies have been performed to 
unravel the contribution of mast cells to atherogenesis and plaque destabilization [8–
13]. The mast cell deficient KitW-sh/W-sh mouse strain has been crossed with LDL receptor 
(LDLr) or ApoE deficient mice and these mice develop smaller and more stable lesions 
compared to mast cell competent LDLr or ApoE deficient mice [9, 12]. Likewise, systemic 
mast cell activation by dinitrophenyl (DNP) or compound 48/80 in murine experimental 
atherosclerosis results in enhanced plaque growth accompanied by features of plaque 
destabilization such as an increase in intraplaque hemorrhage, macrophage apoptosis 
and serum tryptase activity, which could be prevented by the mast cell stabilizing drug 
cromolyn [8, 10]. Specific inhibition of chymase by the use of a protease inhibitor in 
murine experimental atherosclerosis improves the lesion stability as shown by an increase 
in collagen content and a decrease in necrotic core area [11]. Although these studies 
establish the contribution of mast cells to atherogenesis, these studies were performed in 
KitW-sh/W-sh mice, which are constitutively mast cell deficient and this limits the possibility to 
study the specific contribution of mast cells to more advanced stages of atherosclerosis. 
Patients with unstable angina usually have advanced unstable lesions, which underlines 
the importance to study immune cells such as mast cells in advanced atherosclerotic 
plaques.
To that aim, we obtained a novel mouse model, the red-basophil-mast cell (RMB) mouse, 
in which we can study mast cell biology in vivo. In these RMB mice we can efficiently 
deplete FcεRIβ+-cells (i.e. mast cells and basophils) by injection with diphtheria toxin (DT). 
Basophils are quite short depleted (<12 days), while a systemic depletion of mast cells 
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is maintained for up to 6 months after the last DT injection [14]. In the current study we 
induced atherosclerosis in RMB-LDLr-/- mice by western type diet feeding. After lesion 
induction, the mice received DT to deplete all FcεRIβ+-cells followed by an additional 
period of diet feeding. At sacrifice, we analyzed lesion size and composition within the 
aortic root and analyzed systemic parameters such as circulating cytokine levels and 
blood leukocyte numbers, thereby establishing that mast cells actively contribute to 
plaque destabilization during the progressive phase of atherosclerosis. 
Materials & Methods
Mice
All animal work was performed conform the guidelines from the Directive 2010/63/EU of the European 
Parliament. Experiments were approved by the Leiden University Animal Ethics committee. The red mast cell 
and basophil mouse strain (RMB mice, official name: B6.Ms4a2tm1Mal) was provided by the laboratory of dr. P. 
Launay, INSERM U1149, Paris, France [14]. These mice express the simian diphtheria toxin receptor under control 
of the promoter of the FcεRIβ gene. Injection of diphtheria toxin will therefore induce apoptosis of all FcεRIβ 
expressing cells (mast cells and basophils). RMB mice were crossed with LDLr-/- mice (The Jackson Laboratory, 
USA) to obtain atherosclerosis-prone RMB-LDLr-/- mice. LDLr-/- mice were included in the study as a control for 
DT-mediated side effects [15, 16].
To study the effects of mast cell depletion on established atherosclerosis (Figure 1a), RMB-LDLr-/- mice (7-10 
weeks old) were fed a Western type diet (0.25% cholesterol and 15% cacao butter, SDS, Sussex, UK) for 10 weeks 
to induce atherosclerosis. At week 10, a subset of mice was sacrificed as baseline control, while the remaining 
mice received either DT injections to deplete FcεRIβ+ cells or PBS as a control. To systemically deplete all FcεRIβ+ 
cells, mice were injected i.p. for three times every other day with 25 ng/g bodyweight DT (Diphtheria Toxin 
Unnicked, C. diphtheriae (Cat #322326), CalBiochem, US). Efficiency of DT treatment was determined by both 
FACS analysis for circulating basophils (CD49b+/FcεRI+/IgE+) three days after the last DT injection and by a mast 
cell staining (chloro-acetate esterase (CAE), Sigma-Aldrich, US) of the aortic root at the end of the study. At 
sacrifice, mice were anaesthetized and sacrificed via orbital exsanguination. Fixation through the left cardiac 
chamber was performed with phosphate-buffered saline (PBS). Subsequently, the heart was excised and stored 
in 3.7% neutral-buffered formalin (Formal-fixx; Shandon Scientific Ltd, UK) for 18 hours at 4°C for histological 
analysis. Serum was collected to determine circulating cytokine levels. Splenocytes, EDTA-blood and heart 
lymph nodes were isolated for flow cytometry analysis of common leukocyte populations.
Histology and morphometry
After fixation, hearts were embedded in Tissue-Tek® O.C.T.™ compound (Sakura BV, The Netherlands) after which 
10 μm cryosections were prepared using a Leica CM3050S cryostat and stained with Oil-Red-O (Sigma-Aldrich, 
US).
Oil-Red-O-stained sections were used to determine lesion size (in µm2) in the aortic root. Mean lesion area 
(in µm2) was calculated from 6 consecutive sections, starting at the appearance of the tricuspid valves. A 
CAE staining was performed to visualize mast cells, which were in a blinded manner counted manually by an 
independent operator. Collagen content was determined in corresponding sections by staining with Masson’s 
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Trichrome staining (Sigma-Aldrich, US). Macrophages were visualized with an immunohistochemical staining 
using a primary rat anti-mouse macrophages/monocytes antibody (Clone moma-2, isotype IgG2b, 1:1000, Cat# 
MCA519G, AbD Serotec, Germany), while a goat anti-rat alkaline phosphatase (1:500, Cat# A8438 Sigma Aldrich, 
US) was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as 
enzyme substrates.
The atherosclerotic lesion areas and histological stainings of the aortic root cryosections were quantified using 
the Leica image analysis system, consisting of a Leica DMRE microscope coupled to a video camera and Leica 
Qwin Imaging analysis system (Leica Ltd, UK). The percentage of collagen and macrophages in the lesions was 
determined by dividing the collagen- or MOMA-2 positive area by the total lesion surface area. The necrotic core 
size was defined as the a-cellular, debris-rich plaque area and represented as percentage of the total plaque area 
and measured in collagen stained sections.
Serum analysis
Serum concentrations of total cholesterol was determined by enzymatic colorimetric assay according to protocol 
of supplier (Roche Diagnostics, Switzerland). Precipath (Standardized serum Roche Diagnostics, US) was used as 
internal standard. Cytokine levels in serum were determined using a commercially available ELISA kit (Becton 
Dickinson, US). All procedures were according to manufacturer’s protocol.
Flow cytometry
At sacrifice, blood was obtained in EDTA tubes and erythrocytes were removed using a specific erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). 
Blood leukocytes were stained extracellularly to determine a) monocytes (NK1.1-/Ly6G-/CD11bhi), inflammatory 
monocytes (NK1.1-/Ly6G-/CD11bhi/Ly6Chi/CCR2+) and neutrophils (NK1.1-/Ly6Ghi/CD11bhi), b) basophils (CD3-/
CD4-/CD19-/CD8-/CD49b+/IgE+/CD117-), c) T cells (CD3+/CD4+) and d) B cells (CD19+/B220+). The antibodies used 
(eBiosciences, US) are summarized in table 1. Flow cytometry analysis was performed on the FACSCantoII and 
data were analyzed using FACSDiva software (Becton Dickinson, US).
Table 1: Antibody panels used for flow cytometry analysis








































Stimulation of splenocytes and heart lymph nodes
At sacrifice, single cell suspensions were prepared from the spleen and heart lymph nodes by using a 70 μm cell 
strainer (Falcon, US). Erythrocytes were removed using a specific erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM 
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NaHCO3, 0.1 mM EDTA, pH 7.3). 
Regulatory T cell numbers were determined by staining with with eFluor-450 conjugated rat anti mouse CD4. 
Next, cells were fixed and permeabilized according to supplier’s protocol (eBiosciences, US). Subsequently, 
cells were stained with APC conjugated rat anti-mouse/human FoxP3 or corresponding isotype as a control 
(eBioscience, US). 
To determine inflammatory T cell phenotypes in spleen or lymph nodes, 400.000 cells/well were cultured in 96 
well round-bottom plates (Greiner Bio-One, The Netherlands) and stimulated with anti-CD3 and anti-CD28 (2 μg/
mL each, eBioscience, US) in complete IMDM, supplemented with 10% hiFCS, 100 u/mL penicillin/streptomycin, 
2 mM L-Glutamine (PAA, Austria) and 20 mM β-mercaptoethanol (Sigma-Aldrich, US). After 1 hour, brefeldin A 
(Sigma-Aldrich, US) was added up to a concentration of 10 μg/mL to inhibit protein transport to the outside 
of the cell. After an additional 4 hours of culture, cells were washed twice with FACS Buffer (PBS, 1% BSA, 2mM 
EDTA) and stained for T cell surface markers.
Cells were first stained with eFluor-450 conjugated rat anti mouse CD4. Next, cells were fixed and permeabilized 
according to supplier’s protocol (eBiosciences, The Netherlands), followed by intracellular staining with FITC 
conjugated rat anti-mouse IFNγ, PE conjugated rat anti-mouse IL-17 and APC conjugated rat anti-mouse IL-10 
or corresponding isotypes as a control (eBioscience, The Netherlands). Flow cytometry analysis was performed 
as described above.
Statistical analysis
Values are expressed as mean ± SEM. Data of three groups were analyzed using a one-way ANOVA. Statistical 
analysis was performed using Graphpad Prism. Probability values of P<0.05 were considered significant.  
Results
Body weight, total cholesterol and mast cell depletion 
To study the contribution of mast cells to plaque progression, we induced atherosclerosis 
in RMB-LDLr-/- mice by feeding a western-type diet for 10 weeks, after which we depleted 
FcεRIβ+-cells using DT (Fig. 1a). Three days after the last DT injection, we performed 
FACS analysis on blood samples for basophils as a control for depletion efficiency of 
DT. We detected basophils in both the PBS treated RMB-LDLr-/-, whereas basophils were 
completely absent in the DT treated RMB-LDLr-/- group (Fig. 1b). After depletion of FcεRIβ+-
cells, all mice received an additional diet feeding for 6 weeks. At sacrifice, we observed 
a difference in body weight gain between the DT and PBS treated mice (Suppl. Fig. 1a), 
caused by the DT treatment as the DT treated LDLr-/- controls showed a similar weight 
curve as DT treated RMB-LDLr-/- mice. Further analysis showed no differences in total 
plasma cholesterol levels (Suppl. Fig. 1b) and total lesion size in the aortic root between DT 
treated LDLr-/- controls or RMB-LDLr-/- mice (Suppl. Fig. 1c). In addition, DT treatment did 
not result in differences in total leukocyte count and percentage of different circulating 
leukocytes (Suppl. Fig. 1d). Mast cells were detected in the aortic root of PBS treated RMB-
LDLr-/-, while significant depletion of mast cells was observed in DT treated mice (Fig. 1d). 
We also observed a complete depletion of mast cells in the skin upon DT treatment of 
RMB-LDLr-/- mice (data not shown).
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Histological analysis of the aortic root
Next, we performed histological analysis of the aortic root to determine atherosclerotic 
lesion size and composition. Quantification of the lesion size in Oil-Red-O stained sections 
showed that the mean lesion size increased in both PBS and DT treated RMB-LDLr-/- mice, 
with 82% and 118% respectively, compared to baseline values (Fig. 2a). We did not detect 
any differences in mean lesion size between PBS and DT treated mice as depicted in 
figure 2a. The collagen content was significantly elevated in FcεRIβ+-cell depleted mice 
compared to both the baseline value (DT: 25.4 ± 1.2 % versus Baseline: 13.5 ± 1.0 %, p < 
0.0001) and the value in PBS treated mice (DT: 25.4 ± 1.2 % versus PBS: 15.6 ± 1.2 %, p < 
0.0001, Fig. 2b). Furthermore, we observed a significant reduction in macrophage positive 
area (DT: 22.2 ± 1.1 % versus PBS: 29.7 ± 1.8 %, p < 0.001) and percentage of necrotic core 
area (DT: 14.5 ± 4.6 % versus PBS: 28.2 ± 9.7 %, p < 0.001) in FcεRIβ+-cell depleted RMB-
LDLr-/- mice compared to non FcεRIβ+-cell depleted RMB-LDLr-/- mice (Fig. 2c-d).
Figure 1. Study outline and basic characteristics in RMB-LDLr-/- and LDLr-/- mice.
(A) Flow-chart of the in vivo experimental set-up. (B) Representative FACS plots of basophil gating in 
PBS and DT treated mice and summary of all mice. (C) Serum total cholesterol levels from all groups 
(n=15/group). (D) Perivascular mast cell count in the aortic root of PBS or DT injected RMB-LDLr-/- 
and LDLr-/- mice (n=15/group). Arrows in magnification point to perivascular mast cells. 
**P<0.01 ****P<0.0001. 7
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Figure 2. Depletion of FcεRIβ+ cells in RMB-LDLr-/- mice does not influence plaque progres-
sion but increases lesion stability in the aortic root.
(A) Depletion of FceRIβ+ cells did not influenced the plaque size in DT injected RMB-LDLr-/- mice 
compared to PBS treated. Compared to non-depleted mice, depletion of FcεRIβ+-cells during lesion 
progression coincided with an increase in collagen content as determined with Masson’s Trichrome 
staining (B) as well as a reduction in macrophage content as determined by MOMA-2 staining (C) 
and a reduction in necrotic core (D) as percentage total lesion size (n=15/group). Representative 
cross-sections stained with Oil-Red-O and haematoxylin, Masson’s Trichrome staining and MOMA-2 
are shown. **P<0.01, ****P<0.0001.
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Systemic cytokine profile in RMB-LDLr-/- mice
We analyzed the serum for proatherogenic cytokines such as IL-6, MCP-1, TNFα, IFNγ, IL-
17 and the atheroprotective cytokine IL-10. As depicted in figure 3, no differences were 
detected in TNFα, IFNγ and IL-17 levels. Interestingly, we observed a significant increase in 
the chemokine MCP-1 level in the non-FcεRIβ+-cell depleted mice compared to baseline 
values which was not observed in the FcεRIβ+-cell depleted group. Furthermore, a 
significant increase in serum IL-10 was detected in FcεRIβ+-cell depleted mice compared 
to baseline values (DT: 512.2 ± 51.3 versus Baseline: 275.7 ± 19.6 pg/mL, p=0.0005) and 
non-depleted mice (DT: 512.2 ± 51.3 versus PBS: 357.4 ± 40.2 pg/mL, p=0.02) (Fig. 3). 
In addition, we observed a marked reduction in circulating IL-6 in FcεRIβ+-cell depleted 
mice compared to baseline values (DT: 124.5 ± 13.8 versus Baseline: 234.3 ± 12.8 pg/
mL, p=0.0005) and non-depleted mice (DT: 124.5 ± 13.8 versus PBS 210.7 ± 20.3 pg/mL, 
p=0.005) (Fig. 3). DT injection in LDLr-/- mice did not influence cytokine levels (Suppl. Fig 
1e).
Figure 3. Increased levels of atheroprotective IL-10 and decreased levels of atherogenic 
MCP-1 and IL-6 after depletion of FcεRIβ+ cells in RMB-LDLr-/- mice.
Serum levels of IL-6, MCP-1, TNFα, IFNγ, IL-17 and IL-10 were quantified in serum of all groups (n=15/
group). *P<0.05, ***P<0.001. 
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Flow cytometry analysis
At sacrifice, flow cytometry analysis of the blood for leukocyte populations showed a 
complete repopulation of basophils in DT treated RMB-LDLr-/- mice (Fig. 4). Although we 
did not observe a difference in the percentage of total monocyte levels between groups, 
the percentage of inflammatory monocytes were significantly reduced in DT treated 
mice. No differences were observed between groups for other leukocyte subsets such as 
neutrophils, T cells and B cells.
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Figure 4. Flow cytometry analysis of circulating blood leukocytes showed a reduction in in-
flammatory monocytes in FcεRIβ+ cell depleted mice. 
No differences were detected in circulating blood basophils, monocytes, neutrophils, CD4+ T cells 
and B cells. The percentage of inflammatory monocytes in FcεRIβ+-cell depleted mice was reduced 
compared to non-depleted mice. *P<0.05.
In both the spleen and the lymph nodes draining from the heart we performed flow 
cytometry analysis to determine the percentages of T cell subsets. As depicted in figure 
5a, we did not observe any difference in total CD4+ T cells or proatherogenic phenotypes 
such as IL-17+ (Th17) and IFNγ+ CD4+ (Th1) T cells in the both spleen and heart lymph nodes. 
Atheroprotective regulatory T cells were measured in spleen and heart lymph node. 
Analysis showed a significant increase in CD4+/FoxP3+ regulatory T cell levels in both the 
spleen (DT 10.0 ± 0.4 % versus PBS 7.6 ± 0.3 %, p=0.0002) and heart lymph nodes (DT: 9.9 
± 0.7 % versus PBS: 7.8 ± 0.5 %, p=0.02) of FcεRIβ+-cell depleted mice compared to non-
depleted mice (Fig. 5b). In addition, we did not observe any differences in T cell subsets in 
DT treated LDLr-/- mice (Suppl. Fig. 1f, g). Figure 5c shows representative FACS plots of the 
FoxP3 staining within the CD4+ population of the heart lymph nodes.
Figure 5. T cell phenotype in spleen and heart lymph nodes showed an increase in regulatory 
T cells in FcεRIβ+ cells depleted mice.
(A) Analysis of both stimulated splenocytes and heart lymph node cells showed no differences in 
atherogenic T cell phenotypes. (B) A slight but significant increase in regulatory T cell was detected 
in splenocytes and heart lymph node cells of depleted mice compared to non-depleted mice. (C) 
Representative FACS plots are shown for all groups. *P<0.05.
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Discussion
The major underlying cause of an acute cardiovascular syndrome (ACS) is the rupture of 
an unstable atherosclerotic lesion, which leads to ischemia in the distal tissue resulting 
in clinical symptoms such as a myocardial infarction or a stroke. Plaque destabilization is 
an important phase that precedes plaque rupture and mast cells can actively contribute 
to that process by the release of proteases such as tryptase, chymase and matrix 
metalloproteinases (MMPs), which induce apoptosis of collagen producing smooth 
muscle cells and degrade the extracellular matrix of the lesion. Indeed, in a number of 
studies elevated levels of the mast cell specific proteases tryptase and chymase have 
been reported in the serum of ACS patients compared to non-ACS patients and have been 
shown to correlate with plaque vulnerability and clinical outcome [17–19]. Additionally, 
in a recent study by Willems et al. the number of intraplaque mast cells was determined 
in lesions obtained from patients undergoing carotid endarterectomy. The number of 
lesional mast cells and serum tryptase levels was significantly higher in patients that had 
a secondary cardiovascular event compared to patients that remained asymptomatic 
during follow-up of the study [20]. These data indicate that mast cell numbers in the lesion 
are associated with future cardiovascular events and one suggest that mast cells indeed 
contribute to lesion destabilization that can lead to plaque rupture. To further study the 
effects of mast cells in the progressive phase of atherosclerosis, we made use of a mast cell 
inducible knockout mouse model on an atherosclerotic prone background (RMB-LDLr-/- 
mouse). This model enables us to study the contributions of mast cells beyond their role 
in the initial phases of atherosclerosis. 
Our current study shows that absence of mast cells during lesion progression did not 
affect lesion size, but did result in an increased plaque stability and a reduction in the 
systemic inflammatory response. Our data are in line with a recent study from Wang et 
al., where pharmacological stabilization of mast cells in established atherosclerosis in 
LDLr-/- mice by the use of the drug cromolyn results in a reduced inflammatory plaque 
phenotype [13]. Similar to our data, mast cell stabilization reduces plaque macrophage 
content, but unlike their study we did not observe a reduction in plaque size and plasma 
cholesterol levels in mast cell depleted compared to non-depleted mice. One explanation 
could be the specificity of cromolyn in mice, which is subject of debate [21]. Cromolyn has 
been reported to interact with ubiquitous proteins such as G-protein-coupled receptor 
35 (GPR35), which are highly expressed in different (non)-immune cells and tissues as in 
the colon, spleen, monocytes, T cells, neutrophils and dendritic cells [22, 23]. Therefore, 
one could speculate that cromolyn is able to influence more cellular processes besides 
the stabilizing effect on mast cells, which could have been contributed to the observed 
effects on lesion size in cromolyn treated mice [24]. Nonetheless, it can be concluded 
that mast cell depletion or stabilization increases lesion stability, which can be caused 
by a reduced release of mediators that induce plaque destabilization. For example, in 
the atherosclerotic lesion the majority of mast cells expresses the extracellular matrix 
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degrading enzyme chymase [25]. Activation of mast cells leads to the release of mediators 
such as chymase, which results in the breakdown of collagen, degradation of HDL and in 
apoptosis of smooth muscle cells [26].
Mast cells secrete chemokines and cytokines that can attract other immune cells into 
the lesion and MCP-1 is an important chemokine in the recruitment of inflammatory 
monocytes into the atherosclerotic lesion [27, 28]. Compared to baseline values, PBS 
treated RMB-LDLr-/- mice but not mast cell depleted RMB-LDLr-/- mice showed a significant 
increase in serum MCP-1 concentrations after six weeks of additional diet. Furthermore, 
we detected a significant reduction in circulating inflammatory monocytes in mast cell 
depleted RMB-LDLr-/- mice. Together with the reduction of the chemokine MCP-1 levels 
this could this explain, to a certain extent, the reduction in macrophage positive area 
observed in mast cell depleted mice. 
Pathogenic (Th1 and Th17) and protective regulatory T cells (Tregs) are tightly balanced 
during immune responses. This balance is controlled by cytokines, e.g. IL-12, IL-4 and IL-
6, and cell-cell interactions via co-stimulatory molecules like CD80/86, ICOSL, CD40 and 
OX40L, which are expressed by antigen-presenting cells such as dendritic cells. Mast 
cells are efficient effector immune cells that upon activation by various ligands actively 
secrete potent mediators, such as IL-8, TNFa and IL-6, and on top of that also express co-
stimulatory molecules such as CD80/86 and OX40L that are able to directly interact with 
T cells thereby enhancing the proliferation and function of T cells [29–33]. In our current 
study we were unable to detect any differences in atherogenic T cell phenotypes such as 
Th1 and Th17 T cells between the groups. This could be due to the fact that in established 
lesions the adaptive immune response has already fully developed and therefore mast cell 
depletion is unable to significantly alter this established atherogenic T cell phenotypes. In 
contrast, mast cell depletion coincided with an increase in Tregs in both the spleen and 
the draining heart lymph nodes and elevated serum levels of IL-10. Tregs are essential in 
the dampening of immune responses in inflammatory conditions during atherosclerosis 
by the secretion of anti-inflammatory TGFβ and IL-10 [34]. Mast cells have been shown to 
directly inhibit Tregs functions via the co-stimulatory molecule OX40-OX40L, the release 
of histamine and secretion of IL-6 [33, 35, 36].
The acute phase cytokine IL-6 is a key cytokine in the skewing of naïve T cells towards 
Th17 cells and inhibition of Treg development [37–39]. Under inflammatory conditions, 
IL-6 producing mast cells co-localize with Tregs and Th17 cells in the draining lymph node 
of immunized mice in an experimental model of multiple sclerosis and appear to play an 
important role in the promotion of Th17 cell differentiation and inhibiting Treg suppression 
[35]. Especially the interaction of the co-stimulatory molecules OX40L and OX40  between 
mast cells and Tregs, respectively, has been shown to block the function of Tregs and 
promote Th17 cell differentiation [35]. Th17 cells have been implicated in the pathogenesis 
of murine and human atherosclerosis [40]. In our current study, we observed a reduction 
of IL-6 and an increase in IL-10 in the serum of mast cell depleted mice compared to 
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non-depleted mice. Most likely, this reduction in IL-6 positively influenced the T cell 
homeostasis in favor of IL-10 producing Tregs.
In conclusion, here we show that a systemic mast cell depletion in RMB-LDLr-/- mice with 
established atherosclerotic lesions locally affects plaque phenotype but also systemically 
alters cytokine profile and T cell phenotype. Together with observation that intraplaque 
mast cell numbers correlate with clinical outcome, these data indicate that mast cell 
stabilization in cardiovascular patients with unstable atherosclerotic lesions could be 
beneficial in preventing lesion destabilization.
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Supplemental figure 1: DT treatment of LDLr-/- mice as control for DT off-target effects
(A) Body weight of RMB-LDLr-/- and LDLr-/- mice injected with either PBS or DT (n=15/group). Total 
plasma cholesterol levels (B), total lesion size (C), total WBC and leukocyte subsets (D), cytokine lev-
els (E), T cell subsets in hLN (F) and T cell subsets in spleen (G) of PBS and DT treated RMB-LDLr-/- and 
DT treated LDLr-/- mice (n=15/group). *P<0.05, **P<0.01, ***P<0.001.
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Chapter 8
General summary and perspectives
Introduction
The immune system is a highly specialized component of the human body, which is 
essential in the host defense against invading pathogens. Complex interactions between 
cellular and non-cellular components of the innate and adaptive immunity result in 
efficient clearance of these pathogens and the development of a lifelong immunological 
memory towards antigens. These potent immune reactions are tightly balanced by 
regulatory immune cells that induce tolerance towards harmless antigens and dampen 
the ongoing immune response by the secretion of regulatory mediators. Imbalance 
of these activating and regulatory pathways can result in either unresponsiveness or 
hypersensitivity of the immune system towards a certain antigen. Nowadays, there is a 
high prevalence of hypersensitive immune reactions, e.g. allergies and immune driven 
disorders. Rheumatoid arthritis (RA) and atherosclerosis are considered as such immune 
driven disorders with high frequencies in the industrialized world [1,2]. Environmental 
factors such as smoking, sedentary life style, stress and a high fat diet as well as genetic 
risk factors have been described to be major risk factors for both diseases. Although 
the pathology and etiology of RA and atherosclerosis are not completely understood 
yet, it is nowadays widely accepted that the immune system plays an important role 
in the continuous process of joint destruction and vascular occlusion. Central in the 
pathogenesis of both diseases is the loss of tolerance towards harmless self-antigens and 
modified self-antigens such as citrullinated proteins or oxidized lipoproteins. This will lead 
to activation of local immune cells, thereby initiating an inflammatory immune response. 
Insufficient dampening of this early immune response results in an adaptive immune 
response, which is composed of T helper cells and antibody-producing B cells. These cells 
actively secrete mediators such as cytokines and immunoglobulins, which will further 
activate and recruit other immune cells like macrophages, osteoclasts, neutrophils and 
mast cells into the inflamed tissue. Mast cells are innate immune cells located in tissues, 
which are in close proximity to the external world such as skin, gut and lung [3]. Mast 
cells have been reported to be located inside the joints below the synovial membrane 
and within vascular tissues. Mast cell activation in RA and atherosclerosis could amplify 
the ongoing immune response, which actively contributes to the breakdown of cartilage 
and bone or the occlusion of a blood vessel. In this thesis, the contribution of mast cells to 
experimental arthritis and atherosclerosis was studied.
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Mast cells in (experimental) arthritis
Mast cells are, besides known for their function in host defense responses, implicated in 
hypersensitivity reactions such as allergies and asthma, but also in the pathogenesis of 
other immune driven disorders. In the past decades, a number of studies have shown that 
mast cells accumulate in the synovial tissue and can take up to 6% of all nucleated cells 
[4,5]. In addition, mast cell specific proteases such as tryptase have been detected in the 
synovial fluid of RA patients. These data suggest that activated mast cells can affect the 
ongoing immune response, leading to more persistent joint destruction. 
In Chapter 2 we review the current literature describing mast cells and their potential 
interactions with other immune cells in rheumatic diseases. This review also summarizes 
the existing data describing a number of potential ligands present in human RA as well as 
murine experimental models that can activate mast cells locally in the joint. 
The pathogenesis of RA can roughly be divided into a pre-clinical and clinical phase. The 
pre-clinical phase is defined as the phase were the patient has developed subclinical 
characteristics of RA, i.e. the generation of autoantibodies and mild symptoms of joint 
swelling. In the clinical phase, an RA patient displays a high disease activity score (DAS28) 
will show the presence of autoantibodies in the serum and synovial fluid, and suffers from 
active breakdown of cartilage and bone in the joints. Collagen induced arthritis (CIA) 
is a mouse arthritis model that shares several clinical, serological and immunological 
characteristics with human RA [6]. Comparable to human RA, CIA can also be divided 
into a pre-clinical and clinical phase and in Chapter 3 we sought to investigate the 
contribution of mast cells to these phases of collagen induced arthritis in the inducible 
mast cell knockout mouse, the red-mast cell basophil mouse (RMB) [7]. Our results show 
that depletion of mast cells in the pre-clinical phase of collagen induced arthritis, but 
not the clinical phase, significantly reduced the clinical disease score. We confirmed the 
independence of mast cells in clinical phase of arthritis by showing similar results in a 
mouse model of antibody induced arthritis. This indicates that mast cells predominantly 
influence the early pre-clinical phase of experimental arthritis that precedes the clinical 
manifestations. Pre-clinical depletion of mast cells resulted in a reduced inflammatory 
cytokine profile of splenocytes after re-stimulation with collagen type II. Arthritogenic 
cytokines such as IL-17 and IL-6 were significantly reduced, while protective IL-10 was 
elevated in mast cell depleted mice. The anti-inflammatory cytokine profile coincided with 
a decrease in inflammatory Th17 T cell and an increase in regulatory FoxP3+ T cells. Taken 
together, this study shows that the role of mast cells is limited once clinical manifestation 
of arthritis have manifested and that mast cells are modulating the early immune response 
in experimental arthritis.
Although mast cell depletion in clinically evident arthritis in mice was unable to reduce 
the clinical score, we cannot exclude that mast cells in human RA do contribute to the 
progression of the disease, and further research should aim to identify RA specific mast 
cell activators. 
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Mast cell activation via immunoglobulins
The majority of RA and cardiovascular patients develops a strong humoral response, which 
is characterized by high titers of immunoglobulins that target (modified) self-antigens 
such as collagen, citrullinated proteins or modified lipoproteins [8,9]. In a high number of 
RA patients, anti-citrullinated protein antibodies (ACPAs) can be detected and serve as a 
biomarker for a more progressive RA phenotype compared to seronegative RA patients 
[10]. Citrullination or deimination is a post-translational conformation of an arginine 
residue within a protein to a citrulline by peptidylarginine deiminases (PADs) [11]. PAD 
enzymes are present in a variety of cell types, including macrophages and neutrophils. 
Upon necrosis of these cells, PAD enzymes are released in the environment, which cause 
the citrullination of proteins in the extracellular matrix. ACPAs target these proteins and 
can thereby accelerate the process of joint destruction. Recently, it has been shown that 
citrullination can also occur outside the joint in for example the myocardium and within 
atherosclerotic lesions [12–14]. Like in RA, in the atherosclerotic plaque macrophages 
express PAD enzymes, which can drive the local citrullination. In Chapter 4 we tested 
whether ACPAs were present in the sera of cardiovascular patients without RA diagnosis. 
Intriguingly, we found that in cardiovascular cohorts “MISSION!” and “Circulating Cells”, a 
significant proportion of non-RA patients displayed reactivity towards CCP3, and were 
thus positive for ACPAs. Further clinical analysis of the data showed that the survival rate 
of ACPA-positive CVD patients within the MISSION cohort is significantly lower compared 
to ACPA negative CVD patients. Taken together, these preliminary data show that the 
presence of ACPA in non-RA cardiovascular patients may be of predictive value for future 
cardiovascular events.
In the sera of cardiovascular patients immunoglobulins recognizing modified lipoproteins 
such as oxidized LDL (oxLDL) can be detected. Recently, intraplaque mast cell numbers 
were shown to be associated with atherosclerotic plaque progression and with the 
incidence of future cardiovascular events [15]. Hallmark of mast cells is the expression 
of various receptors that can bind a number of ligands present inside the plaque, which 
may result in mast cell activation. For example, activating immunoglobulin receptors such 
as the FcεR (IgE) and the FcγR (IgG) are present on both human and murine mast cells 
[16]. In Chapter 5 we determined whether specific immunoglobulins in sera of patients 
scheduled for carotid endarterectomy were related to intraplaque mast cell numbers and 
plasma tryptase levels. Total IgG, total IgE and oxLDL-IgG were determined the sera of 
135 patients. In this study, we did not observe any associations between the measured 
immunoglobulin levels and mast cell numbers inside the atherosclerotic lesion or other 
plaque characteristics like lipid core size, degree of calcification, number of macrophages 
or smooth muscle cells, amount of collagen and number of microvessels. These data 
indicate that mast cell activation inside the lesion may occur via other receptors than 
immunoglobulin receptors or that systemic immunoglobulin levels do not reflect 
localintraplaque mast cell activation status.
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Mast cells in experimental atherosclerosis
As mentioned before, mast cells contain many proteases pre-stored inside their granules, 
which can be released within seconds upon stimulation [17]. Proteases such as tryptase, 
chymase and matrix metalloproteinases can reduce lesion stability by the breakdown of 
collagen fibers of the fibrous cap, by degradation of HDL but also by inducing apoptosis of 
smooth muscle and endothelial cells [18,19]. Furthermore, mast cells can accelerate lesion 
growth by the recruitment of leukocytes into the lesion by the secretion of cytokines and 
chemokines. The contribution of mast cells to atherosclerosis has up to now mainly been 
studied in mast cell deficient mice, which limits the opportunities to study mast cells 
beyond the initial phase. Furthermore, these mast cell deficient mice such as the KitW-sh/W-
sh mice also suffer from side-effects due to the mutation in c-Kit signaling. Therefore, we 
obtained a novel mouse model, which is inducible knockout for mast cells independent of 
c-Kit signaling alterations. This model enables us to study mast cells also in the progressive 
phase of atherosclerosis. We characterize this novel mouse model in Chapter 6 by first 
depleting all mast cells and subsequently inducing atherosclerosis by western-type diet 
feeding and carotid artery collar placement. This study confirmed previous data, showing 
that mast cells contribute to the initial phase of lesion development. In line with the study 
from Sun et al. we observed a reduction in lesion size and increased lesion stability as 
demonstrated by an increase in collagen staining and a reduction in necrotic core size 
upon mast cell depletion [20]. Furthermore, we observed a reduction in the inflammatory 
cytokines IL-6 and TNFα in plasma, which may be indicative of a reduction in the 
inflammatory response.
In Chapter 7 we aimed to further study mast cell-dependent effects in the progressive 
phase of atherosclerosis. To this aim, we first induced advanced lesions in RMB-LDLr-/- 
mice by western type diet feeding for 10 weeks. Next, we depleted mast cells and 
continued western-type diet feeding for 6 weeks. Histological analysis of the aortic root 
showed that depletion of mast cells was unable to affect the lesion size but did improve 
lesion stability. We observed elevated levels of collagen and a significant decrease in 
both macrophage and necrotic core area in mast cell depleted mice. In addition to the 
histological phenotype, mast cell depletion also coincided with a reduction in the systemic 
inflammatory response. Serum analysis revealed a reduction in the atherogenic cytokines 
IL-6 and MCP-1, and an increase in the atheroprotective IL-10. In addition, we performed 
flow cytometry analysis for T cell phenotypes in the draining lymph node of the heart and 
in the spleen. Mast cell depletion was unable to alter pathogenic Th1 and Th17 phenotypes 
but did result in a marked increase in regulatory FoxP3+ T cells. Together with the reported 
clinical observations in cardiovascular patients, this study confirms that mast cells have a 
major impact on the plaque stability and is able to modulate the systemic cytokine profile 
thereby influencing T cell skewing.
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Further perspectives
The pathogenesis of RA and atherosclerosis is characterized by an active immune 
involvement, which amplifies the process of joint destruction and vascular occlusion. 
Furthermore, both diseases share similar immunological pathways such as development of 
autoantibodies and infiltration of leukocytes in the affected tissues. Compared to healthy 
non-RA individuals, there is an increased risk for RA patients to develop cardiovascular 
diseases, which cannot be explained by traditional risk factors alone [21]. For example, RA 
is often accompanied by accelerated progression of atherosclerosis and a more unstable 
rupture-prone plaque phenotype compared to RA negative subjects [22,23]. In addition, 
vascular inflammation is increased in active RA patients compared to healthy controls, 
which can improved by anti-inflammatory therapy, e.g. anti-TNFα. [24]. Currently, RA 
and cardiovascular patients are treated with drugs that dampen the ongoing immune 
response. In RA, DMARDs often in combination with biologicals such as anti-TNFα are 
highly effective in slowing down the progression of joint destruction and frequently 
induce remission of the inflammatory response in the joint. In addition, this treatment 
regimen can have beneficial effects on the inflammatory response in the vasculature 
system. A reported meta-analysis of observational studies showed that methotrexate 
use, but not use of other DMARDs, in RA patients is associated with a 21% reduction in 
CVD risk compared to patient that do not use methotrexate [25,26]. Although anti-TNF 
was shown to affect lipid levels (increase in HDL, triglycerides and total cholesterol), there 
was a significantly reduction in CVD risk in RA patients [27–30]. Cardiovascular patients 
are usually treated with hydroxymethylglutaryl-coenzyme A reductase inhibitors, or 
‘statins’, to lower circulating cholesterol levels. The majority of RA patients is reported to 
have dyslipidemia and in active disease there is a more atherogenic LDL:HDL ratio [31,32]. 
Statin treatment has been shown to be beneficial in RA patients, probably due to both 
its lipid-lowering as its anti-inflammatory effects [33]. In the TARA (Trial of Atorvastatin in 
Rheumatoid Arthritis) trial, disease activity score and lipid profile were reported to decline 
significantly in the statin-treated group compared to the placebo-treated RA patients [34]. 
Recently, another study by Schoenfeld et.al. showed that statin use in RA patients was 
associated with a 21% lower risk of all-cause mortality [35]. However, despite the fact that 
the use of statins has been shown to be effective in RA and CVD patients, a number of 
patients do not respond to the medication or have serious side effects, which renders new 
therapeutic targets highly necessary. 
In this thesis, we showed that mast cells contribute to the early phase of experimental 
arthritis. To date however, it is unknown if mast cell stabilization in active human RA is 
beneficial as a therapeutic treatment despite the high number of mast cells in the synovium 
and the many reported mast cell activation pathways in RA. In experimental arthritis, 
mast cell stabilization by cromolyn was shown to be effective in mice as measured by 
improvement of the radiographic score and histological analysis [36,37]. Taken together, 
mast cell targeting therapy in RA could be of interest as a new additional treatment next 
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to the use of DMARDs and biologicals. 
Comparable to RA, the development of atherosclerotic lesions is also composed of 
different phases and many studies have implicated mast cells in these phases. Our data 
also indicate that mast cell stabilization may have therapeutic potential in patients with 
cardiovascular diseases. At present, one patent has been issued for the use of cromolyn in 
cardiovascular patients as a novel treatment [38]. However, no study results are reported 
yet. Recently, the JUPITER trial demonstrated that statin therapy can significantly reduce 
the risk of a future heart attack or a stroke in patients with low levels of LDL-cholesterol 
but who have increased vascular risk due to high levels of c-reactive protein (CRP), which 
is a biomarker of inflammation [39]. Two large clinical placebo controlled trials (CIRT 
and CANTOS) are now ongoing to investigate whether inhibition of the inflammatory 
response can reduce CVD risk. In the CIRT trial, CVD patients are treated with a low dose 
methotrexate, also prescribed to treat RA patients, to study the effect of inhibition of 
inflammation on vascular event rates. The CANTOS trial targets the inflammatory IL-1β 
in cardiovascular patients by use of neutralizing canakinumab, which already has shown 
to improve clinical outcome in RA patients [40,41]. In the near future, the outcome of 
these trials will address whether anti-inflammatory medication is able to reduce the 
incidence of cardiovascular events among patients who remain at risk due to a persistent 
inflammatory response.
In conclusion, the research performed in this thesis shows that mast cells have immune 
modulating functions in experimental models of immune driven disorders and future 
research will establish whether mast cell stabilization in auto-immune diseases is of 
therapeutic interest.
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Het immuunsysteem is een essentieel onderdeel van het menselijk lichaam in de 
verdediging tegen pathogene micro-organismen. Het immuunsysteem kan grofweg 
worden opgedeeld in twee onderdelen: het aangeboren (“innate”) en het specifieke, 
verworven (“adaptive”) immuunsysteem. Kenmerkend voor een aangeboren afweerreactie 
is een snelle reactie van zowel cellulaire als niet-cellulaire componenten gericht tegen een 
pathogeen. Verworven immuniteit is vaak een tragere, maar hoog specifieke reactie op 
een infectie, die resulteert in een levenslange bescherming.
Mestcellen zijn onderdeel van het innate immuunsysteem en zijn strategisch gelegen in 
verschillende weefsels, die in contact staan met de buitenwereld. Evolutionair gezien zijn 
mestcellen essentieel in de afweerreactie tegen parasieten zoals wormen en protozoa. De 
interactie van mestcellen met deze pathogenen zorgt ervoor dat binnen enkele seconden 
voorgevormde mediatoren zoals signaalstoffen en enzymen worden uitgescheiden in het 
omliggende weefsel. Dit proces staat bekend als degranulatie, en is een fenomeen dat 
bij mestcellen, basofielen en neutrofielen voorkomt. Door deze activatie worden andere 
typen ontstekingscellen aangetrokken naar de plaats van infectie, wat bijdraagt aan een 
snelle eliminatie van de pathogeen. 
Echter, in de huidige westerse samenleving zijn parasitaire infecties zeldzaam en worden 
mestcellen vaker in verband gebracht met overgevoeligheidsreacties zoals allergie en 
astma. Onderzoek van de laatste jaren heeft duidelijk gemaakt dat mestcellen ook een 
rol kunnen spelen in de pathogenese van ontstekingsziektes zoals reumatoïde artritis 
en aderverkalking. In deze ziektes reageren mestcellen zeer snel op (endogene) stoffen 
met het uitscheiden van signaalstoffen en enzymen. Hierdoor hebben mestcellen nu 
een negatieve reputatie zowel in allergieën en auto-immuniteiten. Het onderzoek naar 
de effecten van remming van de activiteit van de mestcel in deze ziektes kan mogelijk 
tot een nieuwe therapeutische benadering kunnen komen. Om het effect van één 
celtype te bestuderen in complexe ziektes zoals reumatoïde artritis of atherosclerose 
zijn dierexperimentele modellen van belang. Deze modellen maken het mogelijk om 
specifiek één bepaalde cel te verwijderen, en zo het effect hiervan op het ziekteverloop 
te bestuderen.
In dit proefschrift hebben wij de invloed van mestcellen in dierexperimentele modellen 
voor reumatoïde artritis en aderverkalking bestudeerd met een focus op de rol van 
mestcellen in de (sub)-klinische fases van het ziekteproces, waarin er een actieve 
immuunrespons ontwikkeld was. Ook hebben wij de aanwezigheid van verschillende 
soorten antistoffen in het serum van cardiovasculaire patiënten onderzocht. Wij hebben 
de niveaus van antilichamen gecorreleerd aan klinische observaties zoals body mass 
index (BMI), lipidenprofiel, klinische diagnose van vaatlijden, samenstelling van de 
atherosclerotische plaque en de uitkomst van de ziekte. 
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Mestcellen en (experimentele) reumatoïde artritis
Reumatoïde artritis (RA) is de meest voorkomende vorm van gewrichtsontsteking (artritis) 
en heeft een prevalentie van 0,5 – 1% van de wereldbevolking en naarmate de leeftijd 
hoger wordt hebben meer mensen RA. Het ziekteproces wordt gekenmerkt door de 
chronische ontsteking van met name de kleine hand- en voetgewrichten. De ontsporing 
van het immuunsysteem speelt een belangrijke rol in het proces van gewrichtsdestructie, 
en de huidige behandelmethoden zijn sterk gericht op het remmen van de chronische 
ontsteking en het remmen van specifieke inflammatoire eiwitten. Dankzij het op de markt 
verschijnen van verschillende zogenaamde biologicals zoals tumor necrosis factor (TNF)-
blokkers is het mogelijk geworden in veel patiënten een verlaging van ziekteactiviteit of 
zelfs remissie te bereiken.
In het reumatische gewricht, in het synovium en in het synoviale vocht zijn een aantal typen 
ontstekingscellen aanwezig. Grote aantallen geactiveerde neutrofielen, macrofagen, 
T cellen en antistoffen producerende plasmacellen dragen bij aan de activatie van 
osteoclasten, die actief kraakbeen en botweefsel afbreken. Naast deze ontstekingscellen 
accumuleren ook mestcellen in het synoviale weefsel, en ze kunnen ongeveer 5% van alle 
cellen in het reumatische gewricht vormen. In het synoviale vocht van RA-patiënten zijn 
ook hoge concentraties van door mestcellen geproduceerde enzymen gevonden zoals 
chymase en tryptase. Deze enzymen kunnen direct zorgen voor gewrichtsafbraak, maar 
ook via de activatie van osteoclasten kunnen mestcellen bijdragen aan de pathogenese. 
Bovendien kunnen mestcellen grote hoeveelheden interleukines en chemokines 
uitscheiden, die niet alleen de infiltratie van nieuwe afweercellen in het gewricht kunnen 
bewerkstelligen, maar ook systemisch de cellulaire adaptieve afweerreactie kunnen 
moduleren. Dit maakt duidelijk dat de mestcel een belangrijke speler zou kunnen zijn in 
de pathogenese van RA.
De chronische ontsteking in RA is een belangrijke schakel in het proces van kraakbeen en 
bot afbraak. Hoofdstuk 2 geeft een overzicht van de huidige literatuur over de rol van 
mestcellen in het proces van gewrichtsafbraak in RA en de huidige kennis opgedaan in 
dierexperimentele modellen van RA. In dit hoofdstuk is samengevat dat in RA endogene 
liganden aanwezig zijn die o.a. mestcellen kunnen activeren via Toll-Like Receptoren 
en receptoren voor IgG antistoffen (FcγR). Ondanks het feit dat er meer mestcellen 
aanwezig zijn in het ontstoken synoviale weefsel, is de bijdrage van mestcellen aan de 
pathogenese van RA nog onduidelijk. De afgelopen decennia zijn er door verschillende 
onderzoeksgroepen studies gedaan om de rol van mestcellen in RA te onderzoeken. 
Echter, door het gebruik van zowel verschillende artritismodellen als verschillende 
muismodellen voor mestcel deficiënte is er nog geen eenduidig beeld of mestcellen 
bijdragen aan reumatoïde artritis. In experimentele artritis modellen die gebaseerd zijn 
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op het toedienen van pathogene antistoffen lijkt het effect van mestcellen marginaal. 
Deze modellen worden gekarakteriseerd door de afwezigheid van een adaptieve immuun 
response en zijn volledig gebaseerd op lokale complement activatie in het gewricht. 
Een artritis model waarin wel een sterke adaptieve reactie wordt ontwikkeld is het 
zogenaamde “collagen-induced-arthritis (CIA)” model, dat qua ziekteverloop vergelijkbaar 
is met humane RA. Wanneer in mestcel deficiënte muizen CIA wordt geïnduceerd, is de 
klinische score en ontstekingsreactie lager dan in wildtype dieren. Dit duidt erop dat 
mestcellen een bijdrage leveren aan de pathogenese van artritis via modulatie van de 
adaptieve immuun response.
De pathogenese van RA wordt gekenmerkt door een preklinische fase en een klinische 
fase. In de preklinische fase wordt de patiënt met een genetisch risico blootgesteld aan 
omgevingsfactoren en dit kan leiden tot een subklinische immuunreactie in de gewrichten. 
In de klinische fase van RA worden de gewrichtszwellingen zichtbaar en circuleren er ook 
RA specifieke antistoffen zoals reumafactor (RF) en anti-citrullinated protein antilichamen 
(ACPA). Het hierboven genoemde CIA model voor experimentele artritis wordt eveneens 
gekenmerkt door een preklinische en een klinische fase en mestcellen kunnen in beide fases 
mogelijk bijdragen aan het ziekteproces. Omdat de eerder genoemde dierexperimenten 
uitgevoerd zijn in mestcel-deficiënte muizen, is het onmogelijk de bijdrage van mestcellen 
in de latere fases van artritis te onderscheiden van een initieel effect. Met behulp van 
een nieuw muismodel, waarin het mogelijk is mestcellen te depleteren, hebben we in 
hoofdstuk 3 gekeken naar het effect van mestcel depletie tijdens beide fases van artritis. 
Het verwijderen van mestcellen in de preklinische fase van artritis heeft een positief effect 
op de uitkomst van RA, terwijl het verwijderen van mestcellen in de klinische fase van 
artritis geen significant effect heeft op de artritis. Mestcel depletie in de initiële fase van 
RA leidt tot een lagere klinische score van artritis, wat overeenkomt met een verminderde 
schade in de gewrichten van de enkels. Immunologische analyse van de dieren laat 
zien dat afwezigheid van mestcellen samenvalt met een kleinere populatie pathogene 
Th17 cellen en een grotere populatie immuun-dempende, regulatoire T cellen. In het 
plasma is de concentratie van de inflammatoire interleukines (IL)-6 en IL-17 verlaagd in 
vergelijking tot mestcel competente dieren. In dit hoofdstuk hebben wij laten zien dat de 
rol van mestcellen in de klinische fase van CIA gelimiteerd is, maar dat mestcellen in de 
preklinische fase een bijdrage leveren aan de ontwikkeling van de artritis via hun effect of 
de pathogene, adaptieve immuunrespons.
176 | CHAPTER 9
Circulerende immunoglobulines in cardiovasculaire patiënten en associaties met 
klinische parameters
Naast de chronische ontsteking van gewrichten hebben RA patiënten ook vaak 
systemische klachten zoals algehele malaise, koorts, Sjögren syndroom en aanwezigheid 
van zogenaamde reumatische noduli: knobbels ontstekingsweefsel, die vaak in de 
buurt van de gewrichten te vinden zijn. Het meest karakteristieke extra-articulaire 
effect in het ziekteverloop van RA is een tot op heden niet begrepen verhoogd risico 
op cardiovasculair lijden. Onderzoek heeft aangetoond, dat RA patiënten een verhoogd 
risico hebben voortijdig te sterven aan een hartaanval of beroerte. Atherosclerose is 
vaak de onderliggende pathologie van deze cardiovasculaire syndromen. Het proces 
wordt gekenmerkt door een lipiden-gemedieerde inflammatie van de vaatwand op 
plekken met een hoge ‘shear stress’. De ontsteking zorgt voor de ophoping van vetten en 
ontstekingscellen in de vaatwand, de atherosclerotische plaque of laesie genoemd, wat 
resulteert in een lokale vernauwing. Veel kenmerkende immunologische aspecten van 
RA komen overeen met het proces van atherosclerose, zoals de ontwikkeling van auto-
antilichamen gericht tegen gemodificeerde endogene eiwitten. De meerderheid van RA 
patiënten ontwikkelt een sterke antilichaamrespons tegen bijvoorbeeld gecitrullineerde 
eiwitten. Klinisch onderzoek heeft aangetoond dat er een relatie bestaat tussen de 
aanwezigheid van reuma specifieke antistoffen zoals reumafactor of “anti-citrullinated 
protein” antilichamen (ACPA) en de ziekte uitkomst en verloop in RA patiënten. Met 
name ACPA is in de kliniek een belangrijke klinische biomarker voor de effectiviteit 
van de behandeling, het bereiken van remissie en verhoogde mortaliteit. Recentelijk is 
aangetoond dat gecitrullineerde eiwitten ook aanwezig zijn in het myocardium en in 
de atherosclerotische plaque van zowel RA als niet-RA patiënten, en dat ACPA mogelijk 
pathogene effecten kan bewerkstelligen buiten het gewricht. In hoofdstuk 4 beschrijven 
wij dat ACPA gedetecteerd kan worden in het serum van een deel van een cohort 
cardiovasculaire patiënten in afwezigheid van reumatische klachten. Met behulp van 
een test voor de detectie van ACPA door middel van cyclic citrullinated peptides (CCP3) 
vonden wij reactiviteit tegen dit peptide in 6 – 11% van de patiënten. Klinische analyses 
lieten echter geen correlatie zien tussen bekende cardiovasculaire risicofactoren zoals 
het lipidenprofiel, BMI of inflammatoire markers en ACPA-positieve cardiovasculaire 
patiënten. Wel vonden wij een associatie tussen ACPA positiviteit en lange-termijn 
mortaliteit over 10 jaar na inclusie. De aanwezigheid van ACPA correleerde significant met 
sterfte. In deze studie laten wij zien dat cardiovasculaire patiënten zonder reumatische 
(voor)geschiedenis een antistof reactie kunnen ontwikkelen tegen gecitrullineerde 
eiwitten, die bijdraagt aan voortijdige sterfte. 
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Circulerende antistoffen kunnen een negatieve invloed hebben op de ontsteking in een 
gewricht of vaatwand door antigenen te binden en zo immuuncomplexen te vormen. 
Deze immuuncomplexen binden vervolgens aan zogenaamde Fc-receptoren op 
ontstekingscellen. Na binding van een immuuncomplex aan deze Fc-receptoren volgt de 
activatie van de cel, en zal de ontsteking verder worden versterkt door de secretie van 
signaaleiwitten door de ontstekingscel. Ook mestcellen brengen deze receptoren tot 
expressie, en binding van een ligand aan deze receptoren vormt ook een zeer potente 
manier van mestcel activatie. Eerder werk heeft aangetoond dat het aantal mestcellen 
in een atherosclerotische plaque voorspellend is voor toekomstig cardiovasculair lijden. 
In hoofdstuk 5 onderzochten wij of in patiënten met hart en vaatziekten circulerende 
immunoglobulines correleerden met het fenotype van de plaque, zoals de grootte van 
de necrotische kern, de mate van calcificatie, het aantal macrofagen en spiercellen, 
hoeveelheid collageen en het aantal bloedvaatjes. Verder hebben we de antilichaam 
niveaus gekoppeld aan klinische kenmerken van de patiënt, zoals body mass index 
(BMI), lipidenprofiel, wel of niet roker, bloeddruk en de mate van cardiovasculair lijden 
(symptomatisch of asymptomatisch). Wij vonden geen associatie tussen de types 
immunoglobulines (IgG, IgE en oxLDL-IgG) en genoemde parameters. Mogelijk zijn andere 
liganden verantwoordelijk voor de activatie van mestcellen in de atherosclerotische 
plaque, of verschilt de lokale concentratie van immunoglobulines met de circulerende 
concentratie. 
Mestcellen in experimentele atherosclerose
De vorming van atherosclerotische plaques begint al op adolescente leeftijd en ontwikkelt 
zich asymptomatisch gedurende een groot deel van het leven. Het immuunsysteem 
speelt in de fase van de groei van de atherosclerotische plaque een belangrijke rol en 
draagt bij aan de destabilisatie van de plaque. De destabilisatie van de laesie als gevolg 
van vermindering van de hoeveelheid extracellulaire matrix en celdood is een belangrijk 
proces, dat vaak een scheuring van de plaque (ruptuur) tot gevolg heeft. Door een ruptuur 
komt de inhoud van de plaque in de bloedbaan, wat kan leiden tot de vorming van een 
stolsel, dat ischemie veroorzaakt in het onderliggende weefsel, en kan leiden tot een 
beroerte of hartaanval. De huidige therapie voor cardiovasculaire patiënten is gebaseerd 
op het verlagen van het LDL-cholesterol door het gebruik van cholesterolverlagende 
geneesmiddelen (statines) en door het operatief verwijderen van plaques. Omdat 
het immuunsysteem een significante rol speelt in het proces van atherogenese, kan 
de modulatie van de immuunresponse nieuwe therapeutische aangrijpingspunten 
opleveren. Naast leukocyten zoals macrofagen, zijn ook mestcellen waargenomen in de 
atherosclerotische laesies, en de hoogste aantallen mestcellen zijn gevonden in instabiele 
en geruptureerde plaques. Ook mestcel specifieke mediatoren zijn verhoogd aanwezig in 
het serum van cardiovasculaire patiënten. 
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Dierexperimenteel onderzoek heeft aangetoond dat systemische activatie van mestcellen 
resulteert in plaquegroei en destabilisatie. Muizen, die deficiënt zijn voor mestcellen, 
ontwikkelen kleinere plaques in vergelijking met mestcel competente muizen. Deze 
studies hebben aangetoond dat mestcellen in de vroege fase van atherosclerose een 
belangrijke rol spelen. In hoofdstuk 6 karakteriseerden wij een nieuw muismodel, waarin 
het mogelijk is mestcellen te verwijderen of depleteren op elk gewenst moment door 
het toedienen van het eiwit difterie toxine. Dit muismodel is gekruist met een muis, die 
atherosclerose ontwikkelt, waardoor het mogelijk is om mestcellen te depleteren in 
latere fases van atherosclerose. In deze studie hebben wij na depletie van mestcellen 
atherosclerose geïnduceerd door het voeren van een hoog vet dieet en het operatief 
plaatsen van een collar om de halsslagaders. Analyse van de plaques liet zien dat depletie 
van mestcellen leidde tot kleinere en stabielere laesies. In het bloed vonden we een daling 
van het aantal inflammatoire monocyten, en een reductie van de pro-inflammatoire 
eiwitten IL-6 en MCP-1 in mestcel gedepleteerde muizen. Deze data sluiten goed aan bij 
eerdere studies in mestcel deficiënte muizen, waar ook kleinere, stabielere laesies werden 
gevonden. Het voordeel van het huidige muismodel is dat wij nu in staat zijn om de rol 
van mestcellen in latere fases van atherosclerose te onderzoeken.
Mestcellen kunnen door de uitscheiding van mediatoren zoals histamine, chymase, 
tryptase en cytokines ook bijdragen aan de progressie van atherosclerose. Deze 
mediatoren beïnvloeden verschillende processen en induceren bijvoorbeeld de 
dood van spiercellen en de afbraak van extracellulaire matrix zoals collageen, wat kan 
resulteren in plaque destabilisatie. De studie beschreven in hoofdstuk 7 laat het effect 
zien van mestcel depletie op reeds ontwikkelde atherosclerotische plaques. Analyse 
van de atherosclerotische plaques toonde aan dat depletie van de mestcellen niet de 
grootte maar wel de stabiliteit van de laesie gunstig beïnvloedde. De plaquestabiliteit 
was significant verbeterd: een verhoogd collageengehalte, een kleinere necrotische kern 
en minder macrofagen in mestcel gedepleteerde muizen ten opzichte van competente 
muizen. Mestcel depletie leidde tot een toename in het aantal regulatoire T cellen in de 
milt en drainerende lymfeknopen van het hart. In het plasma van mestcel gedepleteerde 
muizen vonden we een significante daling in het niveau van het pro-atherogene cytokine 
IL-6 en een toename van IL-10. Samenvattend laat deze studie zien dat mestcellen in 
belangrijke mate bijdragen aan de destabilisatie van de plaque, maar ook direct of indirect 
bijdragen aan de inductie van regulatoire T cellen. 
Concluderend, dit proefschrift laat zien dat mestcellen in experimentele modellen voor 
reumatoïde artritis en atherosclerose significant bijdragen aan de pathogenese van deze 
ziektes. De depletie van mestcellen heeft zowel op lokaal als systemisch niveau een positief 
effect op het ziekteproces. Daarnaast hebben wij aangetoond dat bepaalde circulerende 
antilichamen voorspellend zijn voor het voortijdige sterfte aan hart- en vaatziekten. 
Deze studies suggereren dat de remming van mestcelactivatie in chronische immuun-
gemedieerde ziektes wellicht een nieuw therapeutische aangrijpingspunt kan zijn. 
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